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ABSTRACT 
Huntington’s Disease is a progressive, adult onset, neurodegenerative disease.   It is 
inherited in an autosomal dominant fashion and is caused by a trinucleotide repeat 
expansion in huntingtin, which encodes the protein huntingtin.  The length of the 
expanded trinucleotide repeats accounts for some, but not all of the age of onset of the 
condition.  Despite the monogenic basis of Huntington’s disease, the clinical features 
display marked variability within families and between those who carry the same length 
expansion.   The variability in age of onset and in clinical features is likely to be due to 
a number of environmental and other genetic factors.  Identification of these factors may 
lead to novel therapeutic approaches.   
 
A number of potential disease modifying agents have been elucidated and are 
approaching clinical trials.   Robust ‘biomarkers’ of disease onset and progression are 
essential for developing a framework for future clinical trials that have the ability to 
judge the efficacy of any therapeutic intervention.  In this thesis I will present work 
arising from TRACK-HD, an international observational biomarker study of 
Huntington’s Disease which has identified a panel of biomarkers for use in future 
clinical trials.   
 
A number of subs-studies arising from TRACK-HD are also presented here.  Firstly, a 
study investigating the use of Positron Emission Tomography and peripheral immune 
markers as biomarkers of disease progression followed by a candidate genetic modifier 
study focusing on immune pathways as genetic modifiers of age of onset in 
Huntington’s Disease. 
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1 INTRODUCTION 
In my experience, one of the most striking and challenging aspects of working with 
families with Huntington’s Disease (HD) has been the unpredictability of the disease.  
Between individuals with the same Cytosine-Adenosine-Guanine (CAG) repeat 
expansion, within families and even between siblings and twins; there is a huge 
variability in the stories that we hear; from family history, prodromal symptoms, onset 
of definite clinical features, symptoms and progression.   I have found this remarkable 
considering that HD is a condition caused by a single aberration in a single gene.    
 
It has been 20 years since the discovery of the genetic mechanism underlying HD. In 
the intervening period much has been learned about the natural history of the disease 
and pathogenic mechanisms.  Our understanding of HD is not only crucial to the 
development of treatments that may help HD families but also our ability to carry out 
predictive genetic testing years before onset of disease means that HD can serve as a 
model for the study of common pathways of neurodegeneration giving insights into 
more common neurodegenerative disorders, such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD).  Drug discovery programmes have identified potential disease 
modifying therapies of HD and so clinical trials, long anticipated by family members, 
are becoming a reality.   
 
For such trials to be informative and for the dream of disease modifying therapies for 
HD to become a reality, we still require a better understanding of the variability that 
exists in HD; to better understand the factors that influence onset and progression of 
HD.   
 
The main aim of this thesis is to explore the variability in the age of onset and rate of 
progression in HD with the aim of identifying robust biomarkers of disease onset and 
progression.  This variability has been explored through the multinational prospective 
observational biomarker study of premanifest and early stage HD; TRACK-HD.  I have 
also further investigated the innate immune system dysfunction that exists in HD to 
investigate its potential as a biomarker of disease progression using both Positron 
Emission Tomography (PET) imaging and peripheral immune markers of inflammation.   
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In addition, I have examined variation in certain genes related to the immune system to 
investigate them as potential candidate genetic modifiers of age of onset.   
 
This introductory chapter will set out the epidemiology, clinical and pathological 
features of HD before reviewing the current state of the search for potential genetic 
modifiers, biomarkers and potential therapeutic interventions and then finally setting out 
the aims of this thesis. 
 
1.1 Huntington’s Disease 
Charles Waters first described hereditary involuntary movements in certain afflicted 
individuals in New York State in the 1840’s (Waters 1842).  However, it was following 
a lecture and article entitled ‘On Chorea’ by a twenty-two year old medical student, 
George Sumner Huntington, that the condition became known as Huntington’s disease.  
(Huntington 1872) 
“… is confined to certain and fortunately a few families, and has 
been transmitted to them, an heirloom from generations away back 
in the dim past.  It is spoken of by those in whose veins the seeds of 
the disease are known to exist, with a kind of horror, and not at all 
alluded to except through dire necessity, when it is mentioned as 
“that disorder”.  It is attended generally by all the symptoms of 
common chorea, only in an aggravated degree, hardly ever 
manifesting itself until adult or middle life, and then coming on 
gradually but surely, increasing by degrees, and often occupying 
years in its development, until the hapless sufferer is but a quivering 
wreck of his former self”… “There are three marked peculiarities in 
this disease: 1. Its hereditary nature.  2.  A tendency to insanity and 
suicide.  3.  Its manifesting itself as a grave disease only in adult 
life…” 
 
His description remains largely true today.  HD remains a progressive, autosomal 
dominantly inherited, adult onset, neurodegenerative disorder characterised by a 
movement disorder, neuropsychiatric symptoms and cognitive decline.    
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1.1.1 Epidemiology 
HD is the third most common inherited neurological disorder in the United Kingdom 
(UK), after type 1 neurofibromatosis and Charcot-Marie-Tooth Disease (MacMillan and 
Harper 1991). The prevalence of HD in European populations has previously been 
estimated to be between 4 and 8 per 100,000 (Harper 1992; Pringsheim, Wiltshire et al. 
2012).  Lower incidence and prevalence has been reported in Asian studies compared to 
Europe, North America and Australia (Pringsheim, Wiltshire et al. 2012). Pockets of 
high prevalence are also known to exist, in particular in Venezuela and Tasmania 
(Young, Shoulson et al. 1986; Pridmore 1990).  
 
It is generally held that these figures are an underestimate.  A number of the studies 
were carried out before genetic testing for HD was available so it is likely that some 
patients with HD went undiagnosed or were misdiagnosed.  It is also possible that the 
stigma that has long surrounded HD patients and their families has prevented accurate 
collection of prevalence data (Rawlins 2010).  Aside from these ascertainment biases, 
increased life expectancy due to improved care of HD patients and an ageing population 
would also suggest an increase in prevalence.  
 
New UK prevalence studies are on-going following reports that the Huntington’s 
Disease Association of England and Wales (HDA) cares for over six thousand 
individuals with symptomatic HD which translates to a prevalence figure of 12.4 per 
100,000.  The HDA, however, does not provide services in all areas of England and 
Wales; and there are an unknown number of patients with the disease who have never 
been referred to the Association. This prevalence estimate of 12·4 per 100 000 of the 
population is, therefore, also an underestimate but by how much is uncertain.  A recent 
population study in British Columbia, Canada, also suggests a much higher prevalence 
than previously thought with figures in the region of 14.3 per 100,000 affected with HD 
(Hayden 2012).  Figure 1 illustrates the increasing prevalence of HD. 
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Figure 1 Increasing prevalence estimates of HD in Europe/North 
America/Oceania  
Data from Pringsheim, Wiltshire et al, 2012 and adapted to include new prevalence 
figures from Rawlins, 2010 and Hayden, 2012 
 
 
Prevalence figures do not account for the numbers at risk of developing HD.  Due to the 
dominant inheritance pattern, there is a 50% chance for each child of an affected parent 
of inheriting the expanded HD allele.  As the disease generally remains asymptomatic 
for many years and only a minority of those at risk undergo predictive testing (Morrison 
2010) many more individuals then are counted are at risk of developing the disease and 
in addition, some mutation carriers remain unaware of their at-risk status due to the 
presence of intermediate and reduced penetrance alleles in the general population.  In a 
recent, as yet unpublished study from British Columbia, Canada, this ‘at risk’ figure is 
estimated to be in the region of 1/1000 (Hayden 2012).  
 
Whatever the estimates of prevalence, the impact of HD on families cannot be 
overestimated. Those at risk; often raised in chaotic households due to the effects of 
disease and having witnessed the decline of at least one loved one, live their lives with 
the knowledge that they are at risk of the same condition.   Even more agonizing is the 
grip of HD on the uncounted spouses who not only care for their partners but also are 
left with the knowledge that their children may face the same devastating future.   
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1.1.2 Clinical Characteristics 
The clinical features of HD are often described as a triad of movement disorder, 
cognitive dysfunction and neuropsychiatric or behavioural disturbance.  The nature and 
the severity of each of these features can be hugely variable. 
 
In most research studies, the diagnostic confidence score (Table 1), which forms the 
final part of the Unified Huntington Disease Rating Scale (UHDRS) motor component 
(1996), is used as the basis for the diagnosis of HD. A trained specialist completes the 
diagnostic confidence assessment following examination of a patient using the 124-
point motor score (see Appendix 1). The final assessment of the UHDRS motor 
component is the Diagnostic Confidence Score (DCS) as shown in Table 1 with a score 
of 4 being required for the formal diagnosis of HD.   
 
Description! Score!Normal!(no!abnormalities)! 0!Non1specific!motor!abnormalities!(less!than!50!%!confidence)! 1!Motor!abnormalities!that!may!be!signs!of!HD!(50!1!89!%!confidence)! 2!Motor!abnormalities!that!are!likely!signs!of!HD!(90!1!98!%!confidence)! 3!Motor!abnormalities!that!are!unequivocal!signs!of!HD!(≥!99!%!confidence)! 4!
Table 1 UHDRS diagnostic confidence score 
 
Therefore, the diagnosis of HD is made solely on the basis of characteristic motor signs 
in an individual despite the fact that many patients develop cognitive and/or psychiatric 
symptoms during the prodromal or premanifest period, often many years before any 
motor signs are seen, and it is generally the non-motor symptoms that have the greatest 
impact on a patient and their family and contribute most to the patient’s loss of 
independence. 
 
In a study of 960 patients diagnosed as having undergone ‘motor onset’ only 55.7% 
were felt to have had motor abnormalities as their earliest disease symptom or sign. 
Psychiatric, cognitive and multifactorial presentations were almost as common as 
shown in Figure 2 (Marder, Zhao et al. 2000).  
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Figure 2 Initial presenting feature of HD 
Features determined retrospectively by a clinician in 960 patients with symptomatic 
HD. (Figure created from data presented in Marder, Zhao et al. 2000) 
 
1.1.2.1 Motor Symptoms 
Chorea becomes a feature of HD in over 90% of patients. It is defined as a hyperkinetic 
movement disorder characterised by excessive spontaneous movements that are 
irregularly timed, randomly distributed and abrupt.  Choreic movements in HD are 
continuously present, cannot be voluntarily supressed by the patient and worsen during 
stress (Kremer 2002). While chorea is often the most obvious feature to onlookers, the 
movements are often not noticed by the patients themselves (Snowden, Craufurd et al. 
1998).   
As the disease advances, chorea will tend to decline and non-choreic movement 
disorders; dystonia, rigidity and bradykinesia become more marked.  In Juvenile 
Huntington’s Disease (JHD) and 10% of adult onset cases  (known as the Westphal 
variant) chorea is minimal and a rigid phenotype predominates (Louis, Anderson et al. 
2000). 
Nonspecific impairment of voluntary motor function is also a common motor feature 
with impairment of fine motor control presenting as clumsiness in common daily 
activities (Kremer 2002).    
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Oculomotor disturbances are amongst the earliest of the motor signs and are present in 
the vast majority of affected individuals.  Delayed initiation of voluntary saccades, 
slowing of saccades, impaired pursuit with saccadic intrusions and an inability to 
suppress blinking during saccades are common oculomotor features (Lasker and Zee 
1997; Blekher, Johnson et al. 2006). 
Gait disturbances can be observed even early in the illness and include particular 
difficulties with tandem walking.  The gait disturbances can be worsened by loss of 
postural reflexes.  Trips and falls can cause significant morbidity as the disease 
advances. 
Most patients display speech abnormalities with initially a mild dysarthria which 
progresses and in the late stages of the disease mutism is not uncommon. Dysphagia can 
also occur and is a major cause of morbidity and mortality in later stage HD. 
 
1.1.2.2 Cognitive symptoms 
Cognitive and behavioural changes place the greatest burden on HD families and are 
most highly associated with functional decline.  They are a universal feature of HD and 
frequently emerge early in the clinical course or even several years before overt 
neurological signs (Craufurd 2002; Johnson, Stout et al. 2007; Solomon, Stout et al. 
2007; Paulsen, Langbehn et al. 2008).  The cognitive impairment is often thought of as 
a frontal-subcortical dementia as opposed to the “cortical” phenotype of AD, which is 
characterized predominantly by memory loss.  Cognitive impairment in HD includes 
slowing of thought process and deterioration of executive function.  Typically patients 
report difficulty with multitasking, concentration and short-term memory.  Thinking 
style becomes more concrete and less efficient with particular impairment of planning 
and problem solving. People with HD are often impulsive and develop psychomotor 
perseveration and have difficulty with organisation of time, thoughts and activities.  
Visuospatial perception and construction can also deteriorate (Craufurd 2002). 
A diagnosis of dementia in HD should include evidence of impairment in at least two 
areas of cognition (e.g. attention, speed of processing, executive functions, visuospatial 
abilities, memory) but without a requirement of memory impairment (Peavy, Jacobson 
et al. 2010).   
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1.1.2.3 Psychiatric and Behavioural Symptoms 
Psychiatric manifestations of HD can be disabling and unpredictable and are nearly 
universal (Paulsen, Ready et al. 2001).  However, as opposed to the cognitive features, 
there are somewhat effective symptomatic treatments available. It is, therefore, 
important to recognise the psychiatric symptoms in HD so that symptomatic treatment 
can be offered.   
Depression is the most common psychiatric symptom.  The prevalence of depression in 
HD is up to 50% (compared with 4% in the general population) and can predate the 
diagnosis of manifest HD by up to two decades (Folstein, Abbott et al. 1983; Pflanz, 
Besson et al. 1991; Craufurd, Thompson et al. 2001).  Other studies have shown that 
individuals at risk of HD have an increased risk of depression compared with their 
spouses and that increased risk was the same whether that individual was a gene carrier 
or not (Shiwach and Norbury 1994).  The high prevalence of depression in HD is not 
solely due to the effects of living with an incurable degenerative disease but has its basis 
in neurodegeneration, though there is no clear relationship between affective symptoms 
and the severity of motor and cognitive changes (Mindham, Steele et al. 1985; 
Craufurd, Thompson et al. 2001).  
 
As George Huntington, himself, recognised when he wrote; ‘that form of insanity which 
leads to suicide’ (Huntington 1872), the frequency of suicide is greater in patients with 
HD and their families compared with the general population (Di Maio, Squitieri et al. 
1993).  Suicidal ideation is highest in gene carriers nearing the threshold of being 
diagnosed with manifest disease and in those who are beginning to lose their functional 
ability and independence.  Risk factors for suicide in HD include depression and 
impulsivity (Craufurd 2002).   
Agitation, irritability, apathy and anxiety are also frequent features of HD and can be 
highly challenging behaviours for family members to manage (Paulsen, Ready et al. 
2001).  Other reported psychiatric symptoms include obsessive-compulsive symptoms 
and psychosis (Craufurd 2002). 
The assessment of psychiatric phenomena in HD is a challenge.  Generic scales, such as 
the Beck Depression Inventory (BDI) (Beck, Steer et al. 1996) and the Hospital Anxiety 
and Depression Scale (HADS) (Zigmond and Snaith 1983) lack questions about 
important behavioural manifestations of HD, such as irritability and apathy, or ask 
22 
questions that may be confounded by non-behavioural features common in HD, such as 
weight loss. The Problem Behaviours Assessment (PBA) for HD (Craufurd, Thompson 
et al. 2001) was developed to evaluate the behavioural features of HD based on 
theoretical features of interest from publications of disorders of the frontal lobes, 
symptoms mentioned during clinical consultations and features from the literature in 
HD. It encompassed a 40-point questionnaire, which was thorough and evidence-based, 
but use was limited due to the time taken to administer the assessment.  The PBA-s, a 
shortened version of the assessment, has been developed by the Behavioural Phenotype 
Working Group of the European Huntington’s Disease Network (EHDN) and combines 
the UHDRS behavioural assessment and the longer PBA in the form of a structured 
interview which can be administered in 15-30 minutes. 
 
1.1.2.4 Advanced disease 
The average duration of symptomatic HD is between 15 and 20 years (Kremer 2002) 
though it may be longer than this today, with improved care and medical management 
of symptoms. End-stage disease is characterised by profound disability with severe 
rigidity, akinesia and an inability to communicate.  Cachexia due to a combination of a 
catabolic state and swallowing difficulties can be a profound challenge and death in is 
most commonly due to cardiac failure, aspiration pneumonia or malnutrition (Lanska, 
Lavine et al. 1988).   
 
1.1.2.5 Peripheral Features 
HD is not just a disease of the brain.  Patients with HD have a number of non-
neurological features as shown in Figure 3 and several observations have shown that 
these may not be due to neurological dysfunction or secondary to a general disease 
process.   
Huntingtin (htt) protein is expressed widely (Li, Schilling et al. 1993) and is thought to 
be ubiquitously expressed.  Dysfunction of peripheral cells occurs even when these cells 
are isolated (Panov, Lund et al. 2005; Almeida, Sarmento-Ribeiro et al. 2008; 
Bjorkqvist, Wild et al. 2008; Chaturvedi, Adhihetty et al. 2009).    
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Weight Loss 
Unintended weight loss is the most common non-neurological abnormality in HD.  
Several studies have indicated that this is not secondary to hyperactivity or anorexia but 
results from an increased metabolic rate (Myers, Sax et al. 1991; van der Burg, 
Bjorkqvist et al. 2009).  Patients with a higher body mass index at onset of symptoms 
tend to have a slower rate of disease progression (Myers, Sax et al. 1991).  Clearly, 
weight loss is compounded by dysphagia in the latter stages of the disease. 
   
 
 
Figure 3 Peripheral pathology in patients with Huntington’s Disease. 
Reproduced from (van der Burg, Bjorkqvist et al. 2009) with permission from the 
Elselvier publishing group. 
 
Skeletal Muscle 
Skeletal-muscle wasting is a hallmark of HD. Skeletal muscles undergo substantial 
wasting, despite the muscles being active as a result of dyskinesias.  Myocytes are 
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affected in HD, possibly as a direct effect of mutant huntingtin (mHtt), and muscles 
undergo atrophy as a result.  
The muscle wasting is possibly due to defects caused by the presence of mHtt forming 
inclusion bodies in myocytes (Orth, Cooper et al. 2003), through transcriptional 
dysregulation (Luthi-Carter, Hanson et al. 2002; Strand, Aragaki et al. 2005), or through 
effects on mitochondrial function (Ciammola, Sassone et al. 2006; Turner, Cooper et al. 
2007). 
 
Cardiac Failure 
Cardiac failure occurs in about 30% of patients with HD (compared with only 2% in 
age-matched controls) and is a leading cause of death in these patients (Lanska, Lavine 
et al. 1988) The mechanism underlying cardiac failure in HD is not known but may be 
the same as those involved in the skeletal muscle dysfunction.   
 
Inflammatory Dysfunction in HD 
Blood plasma samples of patients with HD show signs of immune activation, such as 
increased concentrations of interleukins (IL); IL-6 and IL-8 (Dalrymple, Wild et al. 
2007; Bjorkqvist, Wild et al. 2008). This immune activation may be in reaction to 
cellular pathology, such as huntingtin protein aggregation, oxidative damage or necrotic 
cell death.  However, evidence that the immune activation is present many years before 
the onset of symptoms (Bjorkqvist, Wild et al. 2008), suggests that inflammatory 
changes in HD are not secondary to brain pathology or a response to a general disease 
process.  Altered inflammatory signalling in the periphery might contribute to several 
features of HD, including weight loss and muscle wasting and targeting immune 
activation may provide a therapeutic target. Section 1.3 of this Introduction and Chapter 
4 of this thesis will focus further on the immune system in HD. 
 
Endocrine Dysfunction 
Widespread endocrine dysfunction has been described in HD including Hyperactivity of 
the hypothalamic-pituitary-adrenal axis (Aziz, Pijl et al. 2009), autonomic dysfunction 
(Aziz, Anguelova et al. 2010) and dysfunction of thyrotropic and lactotropic axes (Aziz, 
Pijl et al. 2010). Dysfunction of these axes may contribute to signs and symptoms in HD 
patients such as sleep disturbance and unintended weight loss. 
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Osteoporosis might also be part of the HD phenotype and may correlate with CAG 
repeats length (van der Burg, Bjorkqvist et al. 2009). The reason for decreased bone 
mineral density in this disorder is not known, though it may be secondary to neuroleptic 
treatment or might result from immobility rather than being a direct effect of the 
disorder itself.  
1.1.3 Genetics of Huntington’s Disease 
1.1.3.1 Molecular Genetics 
The gene for HD, huntingtin (HTT, previously known as interesting transcript 15, IT15), 
was the first disease-associated gene to be molecularly mapped to a human 
chromosome, 4p16.3, in 1983 (Gusella, Wexler et al. 1983).  Ten years later, following 
an intense and international collaborative effort, HTT and the nature of the HD-
associated mutation were identified (The Huntington's Disease Research Collaborative 
Research Group 1993).  They identified a Cytosine-Adeonsine-Guanine (CAG) repeat 
expansion on one allele of the first coding exon of HTT in affected members from all 75 
HD families examined.  Analysis of individuals with HD showed that they always had 
40 or more CAG repeats; in fact, the largest number of CAG repeats in this first study 
was 100 (The Huntington's Disease Collaborative Research Group 1993).  Non-HD 
controls showed CAG repeats from 6 to 35 in the same region.  
 
Figure 4 represents our understanding of the CAG repeat expansion related to HD 
pathogenesis. HD is fully penetrant within a normal lifespan in individuals with a CAG 
repeat length of 40 or more.  Expansions of between 36 and 39 confer an increased risk 
of developing HD but with reduced penetrance.  CAG repeats of 70 and above 
invariably cause Juvenile Huntington’s Disease (JHD) with repeat of greater than 60 
seen in approximately 50% of cases (Quarrell, O'Donovan et al. 2012). However, 
consistent with findings in adult cases, CAG repeat size does not always correlate with 
age of onset in JHD.  The largest repeat that has been reported had approximately 250 
repeats although repeats of 80 and above are extremely rare (Nicolas, Devys et al. 
2011).   
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Figure 4 Schematic of the HTT gene and the location of the polymorphic CAG 
repeat within exon 1.  
Boundaries denote CAG repeat length categories and descriptors. Adapted from 
(Potter, Spector et al. 2004) 
 
 
Intermediate alleles lie within the CAG repeat range 27-35.  Non-pathogenic alleles 
within this high normal range can expand into the pathogenic range so while individuals 
with an intermediate allele will usually not develop HD, there remains an unknown risk 
for their children and future generations to become affected. 30% of individuals with 
onset at an age greater than 60 do not have a family history of HD and these new cases 
are likely due to expansion from an intermediate allele (Hayden 2012).  The frequency 
of intermediate alleles in the population of British Columbia, Canada, has recently been 
estimated by analysing the CAG sizes of 2000 general population samples.  This 
showed a frequency of intermediate alleles to be 5.78%; approximately 1/17 people 
(Hayden 2012).   
These alleles can be unstable during transmission and a mutation rate of approximately 
10% in each generation has been suggested (Semaka, Collins et al. 2010).   More 
pronounced instability has been observed in paternal transmissions.  In particular, JHD 
is paternally inherited in 80-90% of cases (Trottier, Biancalana et al. 1994; Nicolas, 
Devys et al. 2011). Instability of CAG repeat in somatic tissues has been reported and 
tissue specific somatic expansion may be associated with the age of onset (Telenius, 
Kremer et al. 1994; Kennedy, Evans et al. 2003; Swami, Hendricks et al. 2009). 
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1.1.3.2 CAG repeat length and age of onset  
There is a significant inverse relationship between the CAG repeat length and the likely 
age at which disease signs will appear.  CAG length has been reported to account for up 
to 73% of the variation in the age of onset (Andrew, Goldberg et al. 1993; Duyao, 
Ambrose et al. 1993; Snell, MacMillan et al. 1993).  As shown in Figure 5 repeat 
lengths of 40 and above are associated with over 90% lifetime probability of motor 
onset, assuming a life expectancy of 80 years (Langbehn, Brinkman et al. 2004). With 
higher the CAG repeat lengths, the probability curve is shifted to the left meaning an 
earlier age of onset is observed.  However, the effect is not linear. The curves are 
steeper for higher repeats, and therefore the age range is more narrow. For example, for 
an individual with 40 repeats, the probability of onset increases from 10% to 90% over 
a period of 27 years but for someone with 56 repeats, that probability range spans just 
15 years. 
 
 
Figure 5 Cumulative probability of motor onset for a given age, by CAG repeat 
length 
(Reproduced from Langbehn et al. 2004.  With permission from Jon Wiley and Sons 
publishing group..) 
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1.1.3.3 CAG repeat and rate of progression 
In contrast to the clear relationship between CAG repeat length and age at onset, there 
has been conflicting evidence for a similar correlation with rate of disease progression. 
Some studies report an association between CAG repeat length and rate of progression 
(Illarioshkin, Igarashi et al. 1994; Brandt, Bylsma et al. 1996; Mahant, McCusker et al. 
2003; Rosenblatt, Liang et al. 2006; Ravina, Romer et al. 2008) and some studies report 
no association (Ashizawa, Wong et al. 1994; Kieburtz, MacDonald et al. 1994; Claes, 
Van Zand et al. 1995; Marder, Zhao et al. 2000; Snowden, Craufurd et al. 2001).  In a 
recent study of 569 subjects, CAG repeat length did correlate with rate of progression 
when controlling for age at onset (Rosenblatt, Kumar et al. 2012).  However, the CAG 
repeat lengths in this most recent study varied between 36 and 109 and therefore it may 
be that, where correlations exist, they arise largely from inclusion of atypical juvenile 
cases with very large repeat lengths. 
 
1.1.3.4 Predictive genetic testing  
Discovery of a linked genetic marker for HD in 1983 introduced the possibility for pre-
symptomatic diagnosis of at-risk individuals in HD families where there was DNA 
available from affected members (Gusella, Wexler et al. 1983). Following the cloning 
of the HTT gene in 1993 (The Huntington's Disease Collaborative Research Group 
1993), a direct test became available based on measurement of the CAG repeat length.  
This test is now used for differential diagnosis, confirmation of suspected HD in the 
absence of a clear family history, prenatal diagnosis and predictive testing. Despite early 
surveys that suggested a high amount of interest, only a small number (approximately 
14%) of individuals at risk of HD choose to actually pursue genetic testing (Tibben 
2007).  
Predictive testing for HD may remove the uncertainty of whether HD should be 
anticipated but no certainty can be given as to when or how the disease may manifest.  
The discovery of an intermediate allele may also complicate genetic testing.  Those who 
do undergo testing generally do so usually to reduce uncertainty and to assist in making 
career and family choices.  Predictive testing is not without risk; anxiety and stress may 
remain elevated following a positive result and there is a risk of suicide, though this 
occurs less frequently than was expected before predictive testing was instituted.  
Anxiety may also follow a negative result in the form of survivor guilt and highlights 
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the importance of adequate pre- and post-test counselling (Almqvist, Bloch et al. 1999; 
Broadstock, Michie et al. 2000).  
Current predictive counselling guidelines have been designed to inform those at risk of 
the implications of test results for themselves and relatives, to identify sources of 
subsequent support, to discuss opportunities for research and to discuss options for 
family planning prior to undertaking genetic testing to ensure that individuals are as 
well prepared as possible for the potentially devastating news (Macleod, Tibben et al. 
2012).   
Predictive testing in HD has made research studies involving pre-symptomatic HD gene 
carriers possible.  These have advanced our understanding of the natural history and 
neurobiology of the disease.  In the future, the availability of predictive testing may 
mean that disease-modifying therapies could be administered prior to the onset of 
symptoms.  In addition, our experience of the testing process has served as a model for 
predictive testing in other late-onset disorders.   
 
1.1.4 Pathogenesis 
1.1.4.1 Macroscopic & Microscopic Pathology 
At post-mortem, end-stage HD brains typically weigh approximately 10-20% less than 
age matched controls (Gutekunst 2002), as shown in Figure 6. 
HD is characterized by degeneration of the medium spiny GABAergic projection 
neurons in the caudate and putamen with the dopaminergic and nigrostriatal pathways 
being relatively preserved, although there remains significant generalised cortical 
degeneration (Vonsattel, Myers et al. 1985). Huntingtin (Htt) aggregates, consisting of 
N-terminal fragments of the mutant huntingtin protein (mHtt) from large dense protein 
inclusions in the nucleus of affected cells but also in the cytoplasm, neurites and 
terminals (Bates 2003).  
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Figure 6 Gross and microscopic neuropathology in Huntington’s disease. 
Coronal sections from formaldehyde-fixed cerebral hemispheres at the level of the head 
of the caudate nucleus (CN) and putamen (Put) from an age-matched and normal 
control (A) and a 62-year old female with HD (B).  Note the marked gross atrophy of 
the neostriatum (CN and Put) and enlarged lateral ventricle (lv) in panel B.  The 
corresponding haematoxylin and eosin staining of the caudate nucleus shows 
significant neuronal loss and astrogliosis in HD (D), in comparison with the normal 
control (C). 
Reproduced from (Ryu, Rosas et al. 2005) with permission from the Elselvier 
Publishing group. 
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1.1.4.2 Molecular and cellular pathology 
Our knowledge of the cellular biology of Htt has exponentially increased since the 
discovery of the gene and through the use of multiple animal and cell models.  Though 
the precise mechanisms remain incompletely understood many functions of Htt are now 
known.  It is a large protein (350 kiloDaltons) and is ubiquitously expressed within and 
outside the nervous system (Li, Schilling et al. 1993).  It is found in several different 
subcellular compartments and several Htt-interacting proteins have been identified; 
many of them binding to the N-terminus of the protein (Li and Li 2004).  The functions 
of Htt include endocytosis, vesicular transport, cell signalling, apoptosis and 
transcriptional regulation (Ross and Tabrizi 2011). Htt seems to act as a scaffolding 
protein and once bound with its interacting proteins, allows them to transfer information 
between cellular compartments (Harjes and Wanker 2003).  Post translational 
modifications also play a major role in Htt protein function (Ehrnhoefer, Sutton et al. 
2011).  
 
 
Figure 7 Postulated Intracellular pathogenesis of Huntington’s Disease 
Mutant Htt (mHtt) (shown as a blue helical structure) with an expanded polyglutamine 
repeat (shown in red) undergoes a conformational change and interferes with cellular 
trafficking, especially of Brain Derived Natriuretic Factor (BDNF):  mHtt is cleared at 
32 
several points to generate toxic fragments with abnormal compact β confirmation.  
Pathogenic species can be monomeric or, more likely (and as shown) form small 
oligomers.  Toxic effects in the cytoplasm include inhibition of chaperones, proteasomes 
and autophagy, which can cause accumulation of abnormally, folded proteins and other 
cellular constituents.  There may be direct interactions between mHtt and mitochondria.  
Other interactions between Htt and cellular proteins in the cytoplasm are still poorly 
understood.  Pathognomonic inclusion bodies are found in the nucleus (and small 
inclusions are also found in cytoplasmic regions).  However, inclusions are not the 
primary pathogenic species.  A major action of mHtt is interference with gene 
transcription, in part via PGC1α, leading to decreased transcription of BDNF and 
nuclear-encoded mitochondrial proteins.  ROS=reactive oxygen species. 
(Reproduced from (Ross and Tabrizi 2011) with permission from the Elselvier 
publishing group) 
 
The CAG repeat expansion gives rise to an expanded polyglutamine stretch in mHtt and 
it is most likely that HD is due to a toxic gain of function from the abnormal 
conformation that arises. This theory is supported by a dominant inheritance pattern, the 
presence of abnormal aggregated proteins in cells and the findings from biochemical, 
cellular and mouse model studies. HTT RNA might also have toxic properties.  
However, loss of function of Htt might also contribute to disease pathogenesis as 
normal expression of HTT is essential for early development and targeted knockouts are 
embryonic lethal (Duyao, Auerbach et al. 1995; Nasir, Floresco et al. 1995; White, 
Auerbach et al. 1997).   
mHtt has been implicated in the disruption of multiple cellular processes, including 
protein clearance, protein-protein interaction, mitochondrial function, axonal 
trafficking, gene transcription and posttranslational modification (Ross and Tabrizi 
2011).  
Many of these mechanisms have been implicated as potential therapeutic targets. 
1.1.5 Therapeutic Approaches 
Access to symptomatic treatments and expert multidisciplinary care are key as there are 
currently no treatments that can delay disease progression. However, a concerted effort 
by HD families and the HD research community have led to an explosion of 
interventional human studies of both symptomatic therapies and potentially disease 
modifying agents, with 65 such studies listed in North America of which 15 are open to 
recruitment at the time of writing (clinicaltrials.gov as of May 2013). 
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1.1.5.1 Symptomatic Therapies 
There is a general lack of evidence base for the symptomatic treatment of HD.  A 
multidisciplinary approach to management is recommended and physiotherapy, speech 
and language therapy as well as psychological interventions and behavioural therapies 
play a vital role.   
Tetrabenazine remains the only drug licensed for treatment of chorea in HD though 
exacerbation of depression is a potential adverse effect (Frank and Jankovic 2010). 
However antipsychotic drugs, such as olanzapine, are the preferred treatment amongst 
experts in Europe (Burgunder, Guttman et al. 2011).  Pridopidine, a novel dopaminergic 
stabiliser, looked promising in preliminary trials, however in a recent phase III study, it 
failed to show significant changes to movements though it was found to be safe and 
well tolerated (de Yebenes, Landwehrmeyer et al. 2011; Squitieri, Landwehrmeyer et al. 
2013). 
Selective serotonin reuptake inhibitors, such as citalopram, are suggested for the 
treatment of depression, irritability and obsessive-compulsive symptoms (Videnovic 
2013).  No drug treatments are currently available for cognitive symptoms and many of 
the troublesome behavioural symptoms, such as apathy. 
 
1.1.5.2 Disease Modifying Therapies 
There are now a number of promising disease modifying therapies in the pipeline and 
approaching human clinical trials.  Research is continuing to identify novel therapeutic 
approaches as it is generally held that several parallel approaches will be necessary to 
optimise therapeutic benefit.  A few promising approaches, that are in varying stages of 
development, are discussed here. 
 
Gene silencing 
Reduction of the amounts of mHtt in the brain by preventing protein translation can be 
achieved via targeted small interfering RNA (siRNA), short hairpin RNA (shRNA) or 
antisense oligonucleotides (ASO).  Use of siRNAs and ASOs is safe, can decrease Htt 
expression and improve symptoms in mouse and primate models of HD (Sah and 
Aronin 2011). Selective reduction of mHtt without affecting levels of wild-type Htt is 
also now possible and may avoid the possibility of harmful effects from indiscriminate 
knockdown.  Implantable infusion systems are used in trials for Parkinson’s Disease to 
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deliver glia-cell derived neurotrophic factor and could be used in HD (Patel, Bunnage et 
al. 2005; Lang, Gill et al. 2006). Significant questions regarding distribution and safety 
have recently been partially addressed following a 6-month non-human primate safety 
trial and academic-industry collaborations are bringing the possibility of human trials in 
the near future closer (Grondin, Kaytor et al. 2012).  
 
Stem cell transplantation  
In one early study of foetal stem cell transplantation, three of five patients maintained or 
slightly improved motor and cognitive function after transplantation but the 
improvement was not sustained (Bachoud-Levi, Gaura et al. 2006). There are major 
drawbacks in terms of technical, ethical and legislative concerns surrounding the use of 
foetal stem cells and so readily renewable sources for transplants are being investigated.  
Inducible pluripotent stem cells (iPSCs) isolated and engineered from the patients 
themselves, are being considered for use, thereby avoiding activation of the immune 
system.  This strategy involves genetically reprogramming fibroblasts to iPSCs 
(Takahashi, Okita et al. 2007; Park, Arora et al. 2008), before correcting the CAG 
repeat expansion, differentiating the cells into medium spiny neurons and transplanting 
the cells into the brain of the patient.  So far, several human HD iPSC lines have been 
established (HD iPSC Consortium 2012).  It has been shown that iPSCs can reverse 
mHTT-driven transcription changes and can differentiate into striatal neurons in vitro 
and in vivo after correction of the CAG repeat in mice models of HD, demonstrating the 
potential of this approach for therapy (An, Zhang et al. 2012). 
 
Clearance of mutant huntingtin 
The two major pathways for clearance of misfolded proteins are the ubiquitin-
proteasome system and autophagy.  Autophagy enhancers could improve the removal of 
mHtt from cells. The enzyme mTOR (‘mammalian target of rapamycin’) down 
regulates autophagy and mTOR inhibition with rapamycin reduces aggregate formation 
and improves motor deficits in fly and mouse models of HD (Ravikumar and 
Rubinsztein 2004). However, the stimulation of protein clearance systems are not 
specific and therefore lead to increased degradation of all proteins, increasing the 
likelihood of unwanted side-effects. 
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Targeting transcriptional dysregulation 
Studies have shown Histone Deacetylase (HDAC) inhibitors to be neuroprotective in 
various HD models (Kazantsev and Thompson 2008).  Although the precise mechanism 
is not known, it could include chromatin remodelling and amelioration of transcriptional 
dysregulation, by enhancing the availability of gene promoter sites (Kazantsev and 
Thompson 2008). Selective clearance of mHtt may also be facilitated by 
hyperacetylation of the mutant protein with HDAC inhibitors (Jeong, Then et al. 2009).  
HDAC inhibitors are already used in cancer but work is underway to identify less toxic, 
selective HDAC inhibitors for use in HD (Thomas, Coppola et al. 2008). 
 
The Sirtuins are a highly conserved family of primarily NAD-dependent deacetylase 
proteins.  Sirtuins have been implicated in ageing and there is evidence that they are 
involved in metabolic control and transcriptional regulation (Finkel, Deng et al. 2009; 
Jeong, Cohen et al. 2012; Jiang, Wang et al. 2012).  Sirtuin 1 (SIRT1) has been shown 
to protect against mutant huntingtin neurotoxicity in three different mouse models of 
HD (Jeong, Cohen et al. 2012; Jiang, Wang et al. 2012) and  
Selisistat (SEN0014196), a selective inhibitor of SIRT1 has entered Phase II trials in 
Europe following completion of phase I studies in 2010 (Westerberg, Diamanti et al. 
2012). 
 
Improvement of neuronal function 
One way to improve neuronal function and arrest neuronal loss is to block excitotoxicity 
caused by over activation of the N-methyl-D-aspartate (NMDA) receptor by glutamate 
or kynurenine metabolites. Glutamate receptor antagonists such as riluzole and 
memantine have shown promise in HD mouse models, but have shown little effect in 
clinical settings (Mestre et al., 2009; Milnerwood et al., 2010).  
Modulation of the kynurenine 3-monooxygenase (KMO) pathway to reduce the levels 
of the NMDA receptor agonists 3-hydroxykynurenine and quinolinic acid, whilst 
increasing the levels of the neuroprotective NMDA receptor antagonist, kynurenic acid, 
has shown beneficial effects in yeast, fly and mouse models of HD (Campesan et al., 
2011; Giorgini et al., 2005; Zwilling et al., 2011).  
Another possible way to improve neuronal function in HD is to increase the level of the 
neurotrophin BDNF, which is depleted in the HD brain (Gauthier et al.,2004; Zuccato et 
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al., 2003). Indeed, overexpression of the BDNF gene in the YAC128 HD mouse model 
prevented neuronal loss and motor abnormalities (Xie et al., 2010). Adenoviral 
administration of BDNF into the striatum of R6/2 mice delayed motor impairments and 
prolonged survival (Cho et al., 2007), demonstrating the promise of this strategy. 
1.2 Biomarkers 
Though a number of potential therapeutic strategies are now approaching clinical trials, 
in order to accurately assess the effectiveness of disease-modifying therapies, it is 
necessary to identify biomarkers that will reliably detect subtle changes of disease 
progression.  
 
The Total Functional Capacity (TFC) Scale (Shoulson and Fahn 1979) is used crudely 
to ‘stage’ the progression of HD and was possibly the first biomarker for the disease 
(see Appendix A and also Table 2).  The scale reflects the progression of the disease, in 
particular the psychosocial and functional effects on the patient and their family.  Points 
are assigned according to the individual’s ability to work, to manage money, to perform 
household chores, to perform activities of daily living, and to live at home or in 
supervised care.   
 
 Stage TFC 
Early HD 
1 11-13 
2 7-10 
Moderate HD 3 3-6 
Advanced HD 
4 1-2 
5 0 
Table 2 Staging HD using Total Functional Capacity 
 
The TFC (see Appendix A and Table 2) was integrated with motor, behavioural and 
functional components in 1996 to form the Unified Huntington Disease Rating Scale 
(UHDRS) (HSG 1996) which is now widely used, both clinically and in observational 
and interventional studies of HD.  However, the UHDRS may not be sensitive to change 
in early stages of disease and may be limited by inter-rater and intra-rater variability, 
and floor and ceiling effects (HSG 1996; de Boo, Tibben et al. 1998; Reilmann, Bohlen 
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et al. 2011) and it is clear that more robust markers of disease progression are necessary. 
An ideal biomarker candidate should be readily quantifiable, be user-dependant and 
should correlate with disease progression.  A candidate biomarker should also have low 
variability in the control population and not be affected by unrelated comorbidities.  
Due to the variability in HD, a combination of different biomarkers may be required for 
tracking progression and assessing potential therapies. Until recently, biomarker studies 
were limited by cross-sectional design and limited numbers.  The advent of PREDICT-
HD (Paulsen, Hayden et al. 2006) and, the focus of much of this thesis, TRACK-HD 
(Tabrizi, Langbehn et al. 2009) have allowed the investigation of biomarkers in high 
quality, multi-site, longitudinal observational studies.   
1.2.1 Neuroimaging 
Neuroimaging techniques, such as magnetic resonance imaging (MRI), enable high 
quality images of brain structure and function to be obtained and advanced image 
analysis techniques allow robust measurement of differences between subjects and 
change within individuals.  Neuroimaging techniques used in HD include structural, 
functional and metabolic imaging measures. 
 
1.2.1.1 Structural MRI 
As described earlier, post-mortem studies have shown that the whole brains of HD 
patients are 10-20% lighter at post-mortem (Vonsattel, Myers et al. 1985).  The 
boundary shift integral (BSI) is a semi automated method by which change in brain 
volume can be calculated from registered pairs of scans.  Using this technique, Henley 
et al, demonstrated that whole brain atrophy was significantly faster in early HD than in 
controls, over a 6-month period (Henley, Frost et al. 2006).  Whole brain atrophy, as 
measured by BSI continued over 2 years in the early HD group but significant 
differences were not present in the premanifest group (Wild, Henley et al. 2010).  Other 
whole-brain-based methods used to study the pattern of neurodegeneration and neuro-
anatomical correlates of HD include voxel based morphometry (VBM) and measures of 
cortical thickness.  Cross-sectional studies of both of these identified brain regions 
differentially affected between different disease groups and controls (Kassubek, 
Juengling et al. 2004; Rosas, Hevelone et al. 2005; Nopoulos, Aylward et al. 2010).  
Widespread white matter (WM) changes have been noted in premanifest HD (Paulsen, 
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Nopoulos et al. 2010) and have been shown to progress over 2 years using VBM 
(Hobbs, Henley et al. 2010). 
Region of interest (ROI) structural imaging including measures of caudate nucleus and 
putamen atrophy may provide more specific biomarkers.  In HD, striatal atrophy 
correlates with age of onset, CAG repeat length and motor dysfunction and has been 
reported in individuals 15-20 years from predicted disease onset with rapid, almost 
linear, striatal tissue loss over time (Harris, Codori et al. 1999; Aylward, Sparks et al. 
2004; Paulsen, Langbehn et al. 2008). Longitudinal studies have been shown to confirm 
striatal measures and WM change measures as potential biomarkers (Aylward, 
Nopoulos et al. 2011). 
Diffusion tensor imaging (DTI), an MRI technique that provides information on 
neuronal fibre orientation and on patterns of WM connectivity, is also being 
investigated. DTI has been used to differentiate premanifest individuals from controls 
and to measure WM degeneration longitudinally (Rosas, Tuch et al. 2006; Weaver, 
Richards et al. 2009). Altered WM connections of the sensorimotor cortex have also 
been described in both manifest and premanifest HD and correlate with phenotypic 
deterioration and estimates of probability to disease onset (Dumas, van den Bogaard et 
al. 2012).  
 
1.2.1.2 Functional imaging, metabolic and molecular imaging 
Neurodegeneration in HD is likely to be preceded by substantial neuronal dysfunction.  
Therefore, techniques such as functional MRI (fMRI), magnetic resonance spectroscopy 
(MRS) and positron emission tomography (PET), which are used to measure functional 
and metabolic changes in brain tissue, might enable identification of neuronal 
dysfunction prior to macroscopic tissue loss.  These techniques may allow monitoring 
of very early disease as compared to structural imaging techniques and may measure 
processes that could be reversed by therapeutic interventions. However, these 
techniques have limitations as biomarkers for clinical trials in HD.  In particular, they 
are costly, the equipment and expertise required are less widespread than conventional 
MRI techniques and scanning times are typically longer; hence the limited number of 
large longitudinal studies. 
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Functional MRI 
Functional MRI uses changes of blood-oxygen-level dependent contrast during neuronal 
activity to identify brain regions active during performance of experimental tasks. fMRI 
studies have demonstrated functional abnormalities in premanifest and early HD cross-
sectionally (Paulsen, Zimbelman et al. 2004; Wolf, Vasic et al. 2007; Zimbelman, 
Paulsen et al. 2007; Saft, Schuttke et al. 2008; Kloppel, Draganski et al. 2009; Gray, 
Egan et al. 2013) but the only longitudinal study to date failed to show change over a 2-
year period (Wolf, Sambataro et al. 2011). 
 
Magnetic Resonance Spectroscopy 
MRS is a magnetic resonance technique that is used to measure metabolite 
concentrations within brain regions.  Lactate levels have been shown to be elevated in 
the striatum in premanifest and early HD but this has not been reproduced across all 
studies.  MRS has identified cross-sectional changes in N-acetylaspartate (a putative 
marker of neuronal viability) and creatine, which correlate with declining motor 
function (Hoang, Bluml et al. 1998; Sanchez-Pernaute, Garcia-Segura et al. 1999; 
Sturrock, Laule et al. 2010).  It has also been used in a trial of creatine therapy to 
demonstrate that the compound entered the brain (i.e. as a pharmacodynamic 
biomarker) (Hersch, Gevorkian et al. 2006). 
 
Positron Emission Tomography 
PET uses positron emission by radioisotopes to identify molecular variations in the 
brain in vivo.  Post-mortem studies in HD have shown a 50% loss of dopamine 
receptors.  Dopamine receptors have been widely studied using the PET ligands 11C-
raclopride (which binds to D2 receptors) and 11C-SCH23390 (which binds to D1).  PET 
studies have shown a dramatic reduction of D2 and D1 binding sites in manifest 
premanifest HD gene carriers and have demonstrated correlation with the duration of 
motor manifestations (Turjanski, Weeks et al. 1995; Ginovart, Lundin et al. 1997; van 
Oostrom, Maguire et al. 2005).  Longitudinal studies have shown consistent decreases 
in D2 binding in both manifest and premanifest disease, with faster rates of loss in those 
approaching motor onset, suggesting that 11C-raclopride biding may detect both 
progression and incipient motor onset (Andrews, Weeks et al. 1999).   
Microglial PET imaging is discussed in more detail in section 1.3.1 
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A means of quantifying wild-type and mutant huntingtin in the brain would be a 
valuable tool for demonstrating central nervous system (CNS) target engagement of 
huntingtin-lowering therapies in the brain. Work is under-way to develop and test PET 
ligands that will enable visualisation of huntingtin load, as a predictive tool and a means 
of assessing response to therapy 
1.2.2 Quantitative Clinical Measures 
Clinical rating scales, such as the UHDRS are the present standard assessment of 
progression in HD.  As already described, the UHDRS motor component (Appendix A) 
(HSG 1996) is based on examination of these key motor features of HD and forms a 
124-point motor scale.  Though extensively validated, these scales are somewhat 
subjective and inter- and intra-rater variability remains (HSG 1996; Hogarth, Kayson et 
al. 2005; Klempir J. 2006).  In addition, hyperkinetic movement disorders (dystonia and 
chorea) contribute 48 points whilst impairment of voluntary movements contributes 
only 32 and bradykinesia 16; even though the latter two categories are each 
independently more important than chorea in contributing functional disability 
(Shoulson 1981; Thompson, Berardelli et al. 1988).   There are now a number of 
promising automated techniques aimed at detecting motor abnormalities earlier in 
premanifest HD and increasing the reliability of motor measures in manifest disease.  
These have been developed to largely to reflect components of the UHDRS motor rating 
scale. 
 
1.2.2.1 Oculomotor  
Observations of oculomotor abnormalities form the first 3 assessments of the UHDRS 
motor scale and are an established and consistent feature of HD as described earlier in 
this chapter.  Computerised quantitative eye movement measurement has demonstrated 
a number of reproducible oculomotor abnormalities in HD that may function as 
biomarkers. Several studies have demonstrated delays in voluntary saccade initiation 
which correlated with disease stage in manifest HD, and estimated pathological disease 
burden in premanifest HD (Golding, Danchaivijitr et al. 2006; Hicks, Robert et al. 
2008).  Portable ‘saccadometer’ devices have made possible the incorporation of 
oculomotor assessments into large-scale biomarker studies such as TRACK-HD.  
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1.2.2.2 Tapping  
Finger tapping and dysdiodochokinesis each form one section of the UHDRS motor 
examination.  Tapping tasks can be easily converted to automated measurement and 
analysis. Several studies have reported reduced tapping rates in manifest HD patients as 
compared to controls, but not in premanifest individuals; UHDRS motor scores and 
duration of the disease were highly correlated with the tapping results (Paulsen, Hayden 
et al. 2006; Saft, Andrich et al. 2006; Paulsen, Langbehn et al. 2008; Biglan, Ross et al. 
2009).  Longitudinal studies have shown a significant decline in tapping rate over a 
period of 3 years in manifest HD patients, and a strong correlation between UHDRS 
scores and the motor tests (Andrich, Saft et al. 2007).  In addition, the variability of 
finger tapping correlated with an index of the probability of motor onset (Hinton, 
Paulsen et al. 2007).   
 
1.2.2.3 Grip force 
Assessment of grip force is a test of non-repetitive voluntary movement encompassing 
sensorimotor integration and motor persistence.  In a cross-sectional study, automated 
measurement  (Figure 8) revealed a greater variability in force during static gripping in 
HD patients compared with controls that correlated with TFC and cognitive scores 
(Gordon, Quinn et al. 2000).  Longitudinally, grip force variability increased in 100% of 
subjects over 3 years (Reilmann, Kirsten et al. 2001).  Grip force variability has also 
been shown to be increased in premanifest HD and correlates to disease burden score 
and UHDRS motor score (Reilmann, Bohlen et al. 2010).  
 
 
Figure 8 Grip force apparatus and sample recordings 
The force transducer above used for assessing grip force may also be adapted for use in 
tongue force and tapping tasks. 
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Reproduced from the TRACK-HD protocol v2.0 October 2008 
 
1.2.2.4 Tongue force 
Observation of tongue protrusion forms one component of the UHDRS motor 
examination.  Objective measurement of tongue force variability ‘glossomotography’ is 
able to distinguish between controls, premanifest and symptomatic HD groups and 
showed correlation with the UHDRS motor score and disease burden score, cross-
sectionally (Reilmann, Bohlen et al. 2010). On the basis of this, the assessment has been 
incorporated into TRACK-HD for longitudinal study. 
 
1.2.2.5 Gait Analysis 
Gait and tandem walking are both observed as part of the UHDRS motor assessment.  
Easy to use instrumented carpet devices have made the possibility of automated gait 
analysis possible in HD.  Cross-sectionally, both premanifest subjects (with no 
impairment of gait or balance as measured by UHDRS) and HD patients showed 
decreased gait velocity and stride length (Rao, Muratori et al. 2008).  Clinical 
assessments of gait have not been found to be as effective as carpet devices in detecting 
gait abnormalities (Rao, Louis et al. 2009).  
 
1.2.2.6 Cognitive Measures  
There have been numerous studies of cognitive tasks as potential biomarkers in HD and 
a full discussion is beyond the scope of this thesis.  Cognitive tasks are, undoubtedly, 
important as they may relate to functional impairment in HD.  However, they may be 
subject to practical limitations such as difficulty in standardisation across languages, 
practice effects and the confounding influences of psychiatric and motor symptoms of 
HD. PREDICT-HD has studied the largest reported cohort with prodromal Huntington's 
disease to identify biological predictors of disease onset and progression (Paulsen, 
Hayden et al. 2006). Data from the full PREDICT-HD standardised cognitive battery of 
51 tasks have shown that tasks of psychomotor processing, emotion recognition, and 
working memory are the most sensitive in distinguishing individuals according to time 
to predicted disease onset (Stout, Paulsen et al. 2011). These tasks have formed the 
basis of cognitive assessment design for subsequent studies, such as TRACK-HD.  
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1.2.3 Biofluids 
Markers that can be quantified in biofluids, such as blood, urine or CSF, would be ideal 
biomarkers due to the opportunity for rapid bulk processing of specimens, the 
availability of reliable assays, and because several analyses could be carried out on a 
single sample.  Both candidate approaches and unbiased ‘omic’ approaches have been 
employed in HD. In particular, markers of endocrine function and metabolism, 
oxidative stress, immune response and neurochemicals have been investigated 
(reviewed in (Weir, Sturrock et al. 2011)).  To date, no robust, reproducible, 
longitudinal biochemical biomarkers of HD have been identified.  
Accurately measuring levels of mHtt and Htt in biosamples will be essential for testing 
therapeutics aimed a reducing mHtt levels including gene-silencing treatments and those 
targeting clearance of mHtt.  Until recently, the detection of Htt was limited by the 
insensitivity of assays, and a lack of suitable antibodies.  Novel antibodies and a 
fluorescence-enhance antibody assay using time-resolved Förset resonance energy 
transfer (TR-FRET) have been developed to quantify concentrations of soluble mHTT 
in brain, plasma and CSF samples(Weiss, Trager et al. 2012)  
As with the search for genetic modifiers of disease onset and progression, large 
longitudinal ‘biobanks’ of well-characterised samples are essential for the development 
of robust biofluid biomarkers and may be provided by the PREDICT-HD and TRACK-
HD cohorts. 
 
1.3 Inflammation and Immune dysfunction 
Neurodegenerative disorders; including Parkinson’s Disease and Alzheimer’s Disease 
as well as HD, are associated with a variety of inflammatory responses.  Inflammation 
in neurodegenerative disorders can result from a number of causes: protein aggregates, 
accumulation of other abnormally modified cellular constituents, molecules released 
from or associated with injured neurones or synapses, and dysregulation of 
inflammatory control mechanisms, as shown in Figure 9 (for review see (Wyss-Coray 
and Mucke 2002). It is less clear whether the resulting inflammatory responses are 
protective or if they contribute to the disease process. 
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Figure 9 Schematic representation of the Inflammatory Response to CNS 
Degeneration. 
Pathogenic triggers, such as accumulation of abnormal proteins in the cells or 
extracellular spaces, elicit cellular stress responses and can result in the progressive 
dysfunction and degeneration of neurons.  Interactions indicated by arrows involve a 
large number of soluble factors.  Cytokines and other mediators of the innate immune 
response are released by astrocytes and microglia to orchestrate defence mechanisms 
and initiate the removal or sequestration of the pathogenic triggers.  A selection of 
molecules and receptors involved in the recognition of abnormal proteins and 
degenerating cells is illustrated.   
Abnormal proteins and degenerating neurons are tagged by complement proteins such 
as C3b or C1q or by antibodies for recognition and phagocytosis by glial cells.  
Degenerating neurons may also be phagocytosed if they display intercellular adhesion 
molecule-3 (ICAM-3), phsophatidyl serine (PS) or oxidised lipids on their cell surface.  
Receptors on glial cells recognise these tags and initiate inflammatory responses.  MHC 
molecules might display abnormal proteins with novel antigenic epitopes to 
lymphocytes, resulting in acquired immune responses.  C1qRp, C1q receptor for 
phagocytosis, CR3, complement receptor 3; FcR Fc receptor; PSR phosphatidyl serine 
receptor; SR scavenger receptor. 
Reproduced from (Wyss-Coray and Mucke 2002) with permission from the Elselvier 
publishing group. 
 
Triggers of inflammatory reactions can engage the immune system at multiple levels.  
Initially they recruit the innate immune system and subsequently the acquired immune 
system may also become involved.  The responses of the central nervous system (CNS) 
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cells are more closely related to the innate than the acquired immune system (Wyss-
Coray and Mucke 2002).  The innate immune system consists of phagocytes, natural 
killer cells and molecules that mediate local inflammatory responses or support acquired 
immune responses. Components of the innate immune system in the CNS include 
microglia and astrocytes (see Figure 9) which are strongly activated in most 
neurodegenerative diseases and produce a variety of inflammatory mediators and other 
injury response factors, including Tumour Necrosis Factor α (TNFα) and IL-1β (Wyss-
Coray and Mucke 2002; Czirr and Wyss-Coray 2012).    
1.3.1 Central immune dysfunction in HD 
Increased complement production by microglia and complement activation of neurones, 
myelin and astrocytes have been demonstrated in the striatum of HD patients (Singhrao, 
Neal et al. 1999) and post-mortem studies of HD brains have shown an accumulation of 
activated microglia and reactive gliosis in regions affected by HD, such as the stratum 
and cortex (Vonsattel, Myers et al. 1985; Sapp, Kegel et al. 2001).  These findings are 
supported by in-vivo PET imaging studies, using 11C-(R)-PK11195 (PK) which bind to 
18kDA translocator protein (TSPO) (formerly known as the peripheral benzodiazepine 
receptor) as a surrogate marker of microglial activation.  Microglial activation correlates 
with D2 receptor loss, as measured by 11C-Raclopride PET, and with disease severity, as 
measured by the UHDRS total motor score (Pavese, Gerhard et al. 2006).   The same 
group demonstrated early microglial activation in premanifest gene carriers in the 
striatum and cortex (Tai, Pavese et al. 2007).  
1.3.2 Peripheral immune dysfunction in HD 
In addition to dysfunction of CNS immune cells, there is evidence of dysfunction in the 
peripheral immune system in HD.  Proteomic profiling of HD plasma samples identified 
several proteins which were significantly up-regulated in HD patient plasma compared 
with controls and showed correlation with disease progression (Dalrymple, Wild et al. 
2007).   The abnormal proteins included IL-6, complement proteins (C7 and C9) and 
clusterin, which are involved in the regulation of the innate immune system.  
Widespread activation of the innate immune system is detectable in HD plasma 
throughout the course of disease.  Abnormal IL-6 levels in plasma are detectable, on 
average, sixteen years before predicted onset of clinical signs and other pro-
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inflammatory cytokines (such as IL-8 and TNFα) are increased significantly in HD 
patient samples compared to controls (Bjorkqvist, Wild et al. 2008).  Chemokine levels 
are also elevated in plasma from HD patients compared with controls (Wild, Magnusson 
et al. 2011). Peripheral human monocytes express mHtt and are hyper-reactive in terms 
of IL-6 production upon Lipopolysaccharide (LPS) stimulation in vivo.  LPS is a 
component of bacterial cell walls, which acts as an endotoxin eliciting a strong immune 
response.  The same hyperstimulation effect was found after stimulation of 
macrophages and microglia from different HD mouse models, suggesting that mHtt 
triggers a cell autonomous innate immune activation in the CNS in parallel with the 
periphery (Bjorkqvist, Wild et al. 2008). 
 
 
Figure 10 Immune activation, induced by mHtt, in both peripheral and central 
immune cells in HD. 
A cell-autonomous effect of the mutant protein may be responsible for the innate 
immune response in HD.  The NFκB signalling pathway that triggers IL-6 release is 
known to be up-regulated by mutant huntingtin (Khoshnan, Ko et al. 2004) and 
microglia-derived toxicity can influence disease progression (Khoshnan, Ko et al. 2004; 
Giorgini, Guidetti et al. 2005).  This figure shows that the innate immune response 
detectable in plasma very early in the disease is strongly linked to disease progression 
and recapitulated in HD striatum, that human monocytes express mHtt and that 
monocytes, macrophages and microglia overexpress IL-6 when stimulation.  
© Björkqvist et al., 2008.  
Originally published in The Journal of Experimental Medicine. The Rockefeller 
University Press, doi: 10.1084/jem.20080178. 
 
The pathway responsible for this immune activation is not yet certain.  One candidate 
pathway is the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
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pathway.  The NFκB signalling pathway is one pathway which triggers IL-6 release.  It 
has previously been implicated in HD pathogenesis as overexpression of mHTT exon 1 
in in vitro cell models of HD has been shown to activate this pathway (Khoshnan, Ko et 
al. 2004). 
1.3.3 The immune system as a modifier of disease progression 
It is not clear whether activation of the immune system is protective or detrimental to 
disease progression in HD.  Several recent studies have suggested the peripheral 
immune system can act as a modifier of HD neuropathology.  Bone marrow 
transplantation of wild-type cells into lethally irradiated HD mouse models normalises 
abnormal peripheral levels of cytokines and chemokines, and partially suppresses motor 
and neuropathological defects (Kwan, Magnusson et al. 2012).  
Excitotoxicity in HD has been linked to metabolites of the Kynurenin Monooxygenase 
(KMO) pathway.  Oral administration of a small-molecule prodrug of KMO extends the 
lifespan and decreases microglial activation in a mouse model of HD.  As the drug 
cannot cross the blood brain barrier, the neuroprotective effect is secondary to inhibition 
of KMO in peripheral immune cells (Zwilling, Huang et al. 2011).  Studies in an HD fly 
model have shown similar results (Campesan, Green et al. 2011). 
The cannabinoid receptor 2 (CB2) is expressed on central and peripheral immune cells 
and is critical in regulating the production of pro-inflammatory cytokines during 
inflammation by dampening the NFκB signalling cascade. Knockdown of CB2 has been 
shown to accelerate HD progression in mouse models and treatment with CB2 agonists 
extended lifespan (Bouchard, Truong et al. 2012).  
Together these studies provide strong evidence that the immune system plays a disease-
modifying role in HD neuropathogenesis, but the exact mechanism has not yet been 
established. 
 
1.4 Genetic Modifiers 
Even though all individuls with HD have the same mechanism of mutation, namely an 
expanded CAG repeat length, and the CAG length shows an inverse correlation with 
age at neurologic onset, two individuals with the same CAG repeat length are unlikely 
to present with symptoms at exactly the same age (see Figure 11).  Two individuals 
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with the same CAG repeat length are also unlikely to display identical psychiatric, 
cognitive or peripheral phenotypes; symptoms are unlikely to progress at the same rate 
and duration of disease is equally unlikely to be precisely the same.  The age at onset, 
rate of progression and precise disease manifestations are, therefore, clearly modifiable 
by other factors.  These factors are likely to be a combination of environmental, 
experiential and genetic factors.  
A gene is a disease modifier if altering its structure or expression alters the 
manifestation of phenotypes associated with the primary disease mutation, in this case, 
the HD CAG expansion.  Modifier genes have become increasingly recognised as an 
important source of phenotypic variation in Mendelian disorders.  (Slavotinek and 
Biesecker 2003).  
The ultimate aim of identifying genetic modifiers of HD is that they could be used to 
target particular biochemical pathways for development and validation of therapeutic 
interventions.   
Additionally, once robust genetic modifiers of a particular phenotype are known, they 
could be incorporated into the design of clinical trials involving that phenotype.  This 
would increase the power of clinical trials to detect an effect of an intervention by 
controlling for the effect of the genetic background of the participant.  
The HD-MAPS study was the first to explore the heritability of the variation in age at 
motor onset.  (Djousse, Knowlton et al. 2003; Li, Hayden et al. 2003).  It found that 
while the CAG repeat length accounted for 67% of the variability in the age at motor 
onset, the heritability of the residual variance was high (h=0.56).  This was confirmed in 
large HD pedigrees from Venezuela (Wexler, Lorimer et al. 2004), where 
approximately 40% of the variance remaining in onset age was attributable to genes 
other than the HD gene and 60% was environmental.  Other phenotypes have not yet 
been examined but it is likely that genetic modifiers will play some role in the 
variability of each disease feature.  
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Figure 11 Inverse correlation of age at neurologic onset and HD CAG repeat 
length. 
The plot shows data points from 1200 HD subjects of known age at neurologic onset.  
For each individual, the measured CAG repeat length in blood DNA (x-axis) is plotted 
against the age a neurologic onset (y-axis).  The line represents the best-fit simple 
logarithmic regression to the data.  The CAG repeat length accounts for approximately 
67% of the overall variation in age at neurologic onset, and the remaining variation 
shows a heritability of approximately 0.56.  Reproduced  from (Arning, Kraus et al. 
2005) under the BioMed Central copyright and licence agreement.    
1.4.1 Candidate gene approach to identifying genetic modifiers 
Examining ‘candidate genes’; genes connected to pathways and processes thought to be 
involved in HD pathogenesis has been the most utilised approach to identifying genetic 
modifiers in HD.  These genes are examined for genetic variation, usually in the form of 
single nucleotide polymorphisms (SNP) in humans, and variants linked to the gene of 
interest are chosen for genotyping in Deoxyribose Nucleic Acid (DNA) from manifest 
HD individuals to test for an effect of genotype on age at motor onset. There are several 
approaches to identifying potential genetic modifiers and these are listed in Table 3. 
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Classes of genes that may include genetic modifiers of HD 
Genes known to influence normal ageing 
Genes encoding proteins known to interact with huntingtin 
Genes encoding proteins involved in pathways suggested to be important in HD 
pathogenesis  
Genes encoding proteins with glutamine tracts (glutamine tracts bind to each other) 
Genes predisposing to DNA repeat instability, particularly repeat expansion 
Table 3 Classes of genes that may include genetic modifiers of HD 
 
A number of candidate genes have been explored but the results have been mixed and 
no outstanding candidate has yet been reproducibly identified.  
The normal HTT allele has been extensively studied as a genetic modifier of age of 
onset in HD.  Whether or not the normal allele acts as a genetic modifier is a crucial 
question as it would have implications for the development of nonselective gene 
therapies in HD and also the potential for using wild-type huntingtin as a therapeutic 
protein. In some, but not all, studies conducted soon after the identification of the HTT 
gene, it was suggested that the number of CAG repeats in the nonexpanded allele might 
influence the timing of disease onset (Farrer, Cupples et al. 1993; Snell, MacMillan et 
al. 1993; Djousse, Knowlton et al. 2003).  More recently, the debate has been reopened 
as an interaction between the expanded and normal allele was reported to modify age at 
onset based upon motor signs, cognitive change and behavioural manifestations (Aziz, 
van Roon-Mom et al. 2011).  Longer normal alleles (e.g. 30 CAG repeats) delayed age 
at onset of subjects with longer expanded CAG alleles.  A subsequent replication study 
initially found a similar effect but when the data were analysed further, they found that 
a single outlier with a mutant allele of 120 CAGs and a normal allele of 11 CAGs was 
driving this effect (Lee, Ramos et al. 2012).  Excluding this outlier removed the 
modifier effect of the unexpanded allele.  
GRIK2 (Glutamate receptor, inotropic kainate 2), encodes the GluR6 subunit of the 
predominant excitatory neurotransmitter receptor family in the human brain and was 
considered an attractive candidate as an HD modifier due to its potential role in 
excitotoxic cell death (Naze, Vuillaume et al. 2002).  GRIK2 was the earliest reported 
genetic modifier and for some time remained the most promising.   It showed an effect 
in multiple studies where a 16 TAA repeat allele at the 3’ untranslated region (UTR) 
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TAA trinucleotide repeat appeared to be associated with an earlier motor onset in HD.  
These studies were small with the largest including fewer than 300 HD subjects 
(Holbert, Denghien et al. 2001; Naze, Vuillaume et al. 2002; Chattopadhyay, Ghosh et 
al. 2003; Cannella, Gellera et al. 2004; Metzger, Bauer et al. 2006). In a recently 
published study, a large sample of 2911 HD subjects with known age at onset were 
tested for a potential modifier effect of GRIK2 using a variety of statistical approaches 
and showed no evidence of a modifier effect on motor, psychiatric or cognitive age at 
onset (Arning, Saft et al. 2007).   
Another candidate genetic modifier, which has been intensively studied, is PPARGC1A, 
which encodes peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α).  It 
is a transcriptional regulator of adaptive thermogenesis, mitochondrial respiration and 
oxidative stress (Rodgers, Lerin et al. 2008). PGC-1α knock down produces an HD-like 
phenotype in mice (Lin, Wu et al. 2004; Leone, Lehman et al. 2005).  Additionally, 
mutant, but not wild type, huntingtin has been shown to down-regulate the expression of 
PGC-1α and its target genes leading to mitochondrial dysfunction and 
neurodegeneration in mouse models of HD (Cui, Jeong et al. 2006; Weydt, Pineda et al. 
2006).  Several studies have reported an association of one particular polymorphism in 
PPARGC1A with a later age of onset of HD symptoms (Taherzadeh-Fard, Saft et al. 
2009; Weydt, Soyal et al. 2009; Che, Metzger et al. 2011) and an additional study 
reported that polymorphisms in PGC-1α downstream target genes, namely nuclear 
respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM) may also 
influence the age of onset in HD.  (Taherzadeh-Fard, Saft et al. 2011).  A recent 
replication study of 1727 HD subjects of European origin showed a significant effect in 
the entire cohort (Ramos, Latourelle et al. 2012).  However, cases of Southern European 
origin had an increased minor allele frequency of the SNP consistent with it being an 
ancestry-tagging SNP.  When the sample was controlled for ancestry, PPARGC1A was 
no longer significantly associated with age at onset.   Interestingly, the Southern 
European cases, despite similar mean CAG allele size, had a significantly older mean 
age of onset, suggesting population differences in the genetic or environmental factors 
which certainly merits further investigation. 
Brain-derived neurotrophic factor (BDNF) is a protein thought to be important for the 
maintenance of striatal neurons (Nagahara and Tuszynski 2011).  There is evidence that 
huntingtin may play an important role in regulating BDNF expression (Zuccato and 
Cattaneo 2007).  A functional polymorphism in BDNF is associated with a number of 
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altered phenotypes in mood disorders (Fan and Sklar 2008; Rybakowski 2008) and 
several studies have shown it to be a modifier of PD pathogenesis (Parsian, Sinha et al. 
2004; Karamohamed, Latourelle et al. 2005), though a recent meta-analysis showed no 
detectable association (Dai, Wang et al. 2013).  A number of studies have shown that 
this functional polymorphism does not modify age at neurologic onset in HD (Di Maria, 
Marasco et al. 2006; Kishikawa, Li et al. 2006; Mai, Akkad et al. 2006).  BDNF 
continues to be studied as a potential therapeutic intervention in neurodegenerative 
disease including HD (Nagahara and Tuszynski 2011) but it is not yet certain whether it 
may play a critical role in the events that occur after motor onset or in development of 
other disease features in HD. 
Other potential candidate genes chosen for their involvement in processes thought to be 
related to HD pathogenesis have been studied and found to have some effect on age of 
onset.  GRIN2A and GRIN2B (glutamergic transmission) (Arning, Kraus et al. 2005; 
Arning, Saft et al. 2007);  UCLH1 (protein degradation) (Naze, Vuillaume et al. 2002; 
Metzger, Bauer et al. 2006); TCERG1 and TP53 (gene transcription) (Holbert, 
Denghien et al. 2001; Chattopadhyay, Baksi et al. 2005); DFFB, MAP3K5, MAP2K6 
(stress response/apoptosis); APOE (lipoprotein metabolism); HAP1 (neuronal 
trafficking) (Metzger, Rong et al. 2008); and MTHFR (folate metabolism)(Brune, 
Andrich et al. 2004).  In some cases, gender stratification implied a sex-specific effect 
(APOE, GRIN2A, GRIN2B, MAP2K6) (Kehoe, Krawczak et al. 1999; Hansen, Saft et al. 
2005; Arning, Saft et al. 2007; Arning, Monte et al. 2008).  In many cases, initial 
positive reports have been followed by negative studies of the same polymorphisms (for 
example, GRN2B, UCHL1, TP53, DFFB, APOE, MTHFR) (Naze, Vuillaume et al. 
2002; Saft, Andrich et al. 2004; Andresen, Gayan et al. 2007).  In some cases they have 
not yet been confirmed (HAP1, MAP3K5, MAP2K6) or they have shown very small 
effects and require further confirmation in a larger sample size (TCERG1, GRIN2A) 
(Andresen, Gayan et al. 2007; Saft, Epplen et al. 2011).  More recently a SNP in the 
Kalirin gene (KALRN) was investigated.  Kalirin is a protein involved in spinal 
plasticity and interacts with huntingtin-associated protein (HAP-1).  The results did not 
reveal an association between the analysed SNP and the age at onset in HD (Tsai, 
Metzger et al. 2012). 
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1.4.2 Genomewide Association Studies 
Initial studies used genetic linkage to search for chromosome regions associated with 
alteration of age at neurologic onset from that expected based upon the CAG repeat 
length in the individuals tested.  A large international collaborative study, HD-MAPS, 
performed this analysis in sibling pairs and small families and identified a number of 
regions of interest (Li, Hayden et al. 2003).  A follow-up study with additional samples 
achieved a genome-wide significance score for a region of 6q (Li, Hayden et al. 2006).  
A study investigating sibships by the US-Venezuela Collaborative Group identified 
genome-wide linkage to 2p and several other possible regions including 6q (Gayan, 
Brocklebank et al. 2008). The regions implicated are large and have not yet yielded 
specific genes responsible for the effect. 
Advances in the understanding of human genetic variation and in technologies for 
investigating that variation in a large number of individuals have made GWAS using 
densely spaced SNPs and copy number probes in HD possible.  These studies are on 
going, using large sample sizes of several thousand HD subjects.  GWAS studies should 
be able clarify the candidate genes already suggested, narrow known linkage peaks and 
identify new polymorphisms that exhibit association with age at neurologic onset.  They 
should also be able to investigate the variation of phenotypes other than neurologic 
onset.   
There are a number of potential pitfalls, however.   Due to the large number of SNPs 
being investigated, sample size is a huge consideration for any GWAS.  In HD the 
major genetic modifier is already known; namely the CAG repeat length.  Using a 
GWAS approach, genetic variants that are rare, or likely to exert a small effect are 
unlikely to be detected. A third major challenge facing GWAS in HD is that of 
identifying an independent replication cohort of suitable size and power to follow up 
any genes identified.   
 
1.5 Aims of this thesis 
This introduction has provided a review of the aetiology, epidemiology and pathogenic 
processes involved in HD as well as the current state of research relating to emerging 
therapies, biomarkers and genetic modifiers. 
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The remaining chapters of this thesis will present my own research relating to 
developing biomarkers and identifying genetic modifiers of HD.  Chapter 2 will outline 
the general methods relating this thesis.  Methods specific to particular studies will be 
described in the relevant chapters.   
 
The main aims of this thesis are;  
 
1. To identify robust clinical and imaging biomarkers of HD onset and progression in 
HD patients in the longitudinal observational TRACK-HD study. (Chapter 3) 
 
2. To investigate whether central and peripheral markers of immune activation may 
provide biomarkers of disease onset and progression in premanifest HD. (Chapter 4) 
 
3. To investigate genes involved in the immune system as potential genetic modifiers of 
disease onset and progression in HD patients. (Chapter 5 and Chapter 6) 
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2 GENERAL METHODS 
Four studies make up this thesis  
The TRACK-HD Study 
A study characterising central and peripheral immune activation in HD 
A study to identify genetic modifiers of age of onset in HD 
A study examining the importance of accurately estimating the age of onset 
in HD. 
This chapter will outline the general methods relating to this thesis. However, the 
studies and data presented in this thesis are wide ranging and methods specific to 
particular studies are presented in the relevant chapters. 
2.1 Consent and ethics 
All studies mentioned in this thesis were carried out at approved research institutions. 
All experiments were carried out in accordance with the declaration of Helsinki. All 
human subjects gave informed, written consent to participate.  
The author’s own work was all carried out at University College London’s (UCL) 
Institute of Neurology in conjunction with the National Hospital for Neurology and 
Neurosurgery, UCL Hospitals NHS Trust. 
Human subjects at UCL, Institute of Neurology were enrolled into at least one of the 
following studies: UCLH/04/N008 (Identification of biomarkers that can be used to 
track the progression of Huntington’s disease), UCLH/07/H0717/47 (TRACK-HD) and 
UCLH/10A/VSE04/7 (The European Huntington’s Disease Network REGISTRY v3.0). 
All these studies were approved by the London – Queen Square National Research 
Ethics Committee (formerly known as the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Research Ethics Committee and then Central 
London Research Ethics Committee 3). 
The PET imaging studies to assess neuronal dysfunction and microglial activation in 
TRACK-HD premanifest subjects (TRACK-PET study) had additional ethical approval 
from the Hammersmith and Queen Charlotte’s and Chelsea Hospital Research Ethics 
Committee (Ethics No: 10/H0707/18). 
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2.2 Overall principles of subject selection 
2.2.1 TRACK-HD  
The TRACK-HD study and data collected as part of it forms the basis of much of this 
thesis.  Subjects with the HD gene expansion were recruited from the National Hospital 
for Neurology and Neurosurgery, London, the Department of Medical Genetics at 
University of British Columbia, Vancouver, the Department of Genetics and 
Cytogenetics at the Hôpital de la Salpêtrière-Université Pierre and Marie Curie and the 
Department of Neurology at Leiden University Medical Centre.  
Recruitment targets were 90 per centre, including 30 control, 30 premanifest HD and 30 
early HD. Premanifest gene carriers required a ‘disease burden score’ >250 (see section 
2.6.3.1) approximating to less than 15 predicted years to onset based on Langbehn et 
al’s conditional onset probability calculations (Langbehn, Brinkman et al. 2004) (see 
section 2.6.3.2) and a total motor score of ≤5 in the UHDRS motor assessment (see 
appendix 1) indicating lack of significant motor signs.  
 
Individuals in the premanifest group were divided at the group median for predicted 
years to diagnosis (10·8 years) into preHD-A (further from predicted diagnosis age) and 
preHD-B (nearer to predicted diagnosis age) on the basis of the survival analysis 
formula described by Langbehn as explained further in section 2.36.3.2 (Langbehn, 
Brinkman et al. 2004). Patients with early HD were divided into two subgroups—HD 
stage 1 (HD1) and HD stage 2 (HD2)—on the basis of their score on the total functional 
capacity scale (see Table 2).  Controls were age-matched and gender-matched to 
individuals in the combined preHD and HD groups and were selected from the spouses 
or partners of individuals with premanifest or early HD or were gene-negative siblings, 
to ensure consistency of environments with HD gene carriers.  
TRACK-HD subjects were assessed at baseline, 12 months, and 24 months.  Full details 
of the participant demographics are shown in Chapter 3.   
2.2.2 TRACK-HD PET imaging and peripheral inflammatory markers sub-study 
Samples and data from subjects recruited to the ‘Identification of biomarkers that can be 
used to track the progression of Huntington’s disease’ study at UCL Institute of 
57 
Neurology were used in the initial part of this study examining the activity of 
monocytes in a large cohort of HD gene carriers.   
Subsequently, 12 Premanifest gene carriers enrolled in TRACK-HD London Site were 
also recruited to the TRACK-HD PET imaging and inflammatory markers sub-study.  
They were chosen to be representative of the premanifest cohort and also due to their 
willingness to undergo further imaging and blood sample donation.  The study was run 
in parallel with the 24-month time point of TRACK-HD and corresponded to visit 3. 
Further details of the subjects enrolled in this study are presented in Table 10.  
 
2.2.3 Genetic Modifiers and Age of Onset Study 
Samples from subjects recruited in TRACK-HD, who had a recorded age of onset at the 
12 month time point (visit 2), were analysed as part of the Genetic Modifiers of Age of 
Onset in Huntington Disease and The Importance of Accurately Recording Age of 
Onset in Huntington’s Disease studies.   
In addition to those samples analysed from TRACK-HD, samples were also requested 
from European Huntington’s Disease Networks (EHDN) REGISTRY study. The EHDN 
(http://www.euro-hd.net) was established in 2004 and is a collaborative network of HD 
researchers, clinicians and HD family members.  REGISTRY is a multicentre, 
prospective observational study with annual follow-up visits.  The participants are 
manifest and premanifest HD gene carriers, individuals at risk of HD, gene-negative 
family members and controls (no family history of HD).  At August 2010, REGISTRY 
included 6476 participants from 136 study sites in 16 countries (Orth, Handley et al. 
2011).  Of these, 663 were pre-manifest (with a diagnostic confidence score of <4 on 
the UHDRS motor scale as shown in Table 1) and 375 spouse or companion controls. 
Data from at least two visits was available for 3473 participants.   
The EHDN is committed to facilitating HD research.  Data and biomaterials collected in 
the REGISTRY database are available to investigators via application to the Scientific 
and Bioethics Advisory Committee (SBAC).  For inclusion in the ‘Genetic Modifiers of 
Age of Onset in Huntington Disease' and ‘The Importance of Accurately Recording Age 
of Onset in Huntington’s Disease’ studies a proposal was submitted requesting access to 
samples for which the information in Table 4 was available. 
 
58 
eCRF category Information Requested 
DNA sample available Mandatory 
Date of Birth Mandatory 
Sex Mandatory 
Ethnicity Mandatory 
HD diagnosed Mandatory 
Symptoms first noted by subject  
Symptoms first noted by family  
Rater's estimate of onset Mandatory 
Predominant Symptom noted at onset  
CAG repeat length large  
CAG repeat length; small  
Total Motor Score (all visits) Mandatory 
Diagnostic Confidence Interval Mandatory 
Total Functional Capacity  
Table 4 Information requested from the REGISTRY database 
 
2.3 Data Collection 
For both TRACK-HD and REGISTRY, data are entered online using an electronic web 
based data capture system.  Electronic case report forms (eCRF) have been translated 
into several languages allowing data to be collected in the local language.  Entries for 
medication are coded according to the Anatomical Therapeutic Chemical classification 
(http://www.whocc.no.atcddd), and co-morbidities are coded according to ICD-10 
(W.H.O. 1992).  To ensure the highest quality data, entries onto the web portal are 
subject to automatic plausibility checks.  Study site investigators are annually trained, 
assessed and certified to reduce inter- and intra-rater variability.  Following data entry, 
monitors fluent in the language of the contributing study site monitored data online and 
on-site.   
For the ‘Identification of biomarkers that can be used to track the progression of 
Huntington’s disease’ study, biosamples were collected from participants and clinical 
and demographic data recorded in a secure database housed at UCL, Institute of 
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Neurology.  Biosamples were allocated a numerical code and processing and 
experimental work was carried out blind to patient status and stage of disease. 
 
2.4 Clinical assessments 
2.4.1 TRACK-HD 
The study was planned as a longitudinal study with three annual time-points.  Full 
enrolment at each time point was completed over an eight month time period.  In most 
cases, data were collected in a single visit including demographic information, motor 
tests, quantitative motor tests, cognitive tasks, neuropsychiatric interviews and 
questionnaire measures, functional/quality of life measures and 3Tesla (3T) brain 
magnetic resonance imaging (MRI).  A small team of study site investigators at each 
site assessed subjects.  Raters underwent training to perform assessments to decrease 
inter- and intra- rater variability.  Training was updated at each time point and raters 
remained the same, wherever possible.  Further details of the clinical assessments used 
in TRACK-HD are given in Chapter 3.3.   
 
2.4.2 REGISTRY  
At each study site, clinicians with longstanding experience in HD take a careful history 
and examine patients clinically; motor, psychiatric and cognitive signs are scored using 
the UHDRS (HSG 1996).  Additional self-rating scales of mood, quality of life and 
health economics are available for some subjects (see Figure 12).  Disease stage is 
derived from the TFC scores. 
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Figure 12 Flowchart illustrating REGISTRY study design  
Reproduced from (Orth, Handley et al. 2011) with permission of BMJ Publishing Group 
Ltd.  
 
2.5 Biosample Collection 
All blood samples were collected from the antecubital fossa.  
2.5.1 CAG genotyping 
To overcome known discrepancies in reporting CAG repeat lengths (Quarrell, Handley 
et al. 2012) all HD gene carriers included in this thesis underwent CAG repeat sizing 
carried out by Biorep® Technologies Inc., (Milan, Italy).  DNA was extracted using 
standard techniques using an NA3000 automated DNA extractor (AutoGen, MA). 
Repeat lengths were analysed by fluorescent PCR amplifying the triplet repeat region 
followed by size fractionation and fragment sizing using an Applied Biosystems 
3730XL genetic analyser and GeneMapper software (Applied Biosystems, CA). 
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2.6 Statistical methods 
Due to the differences between the studies presented in this thesis, this section is limited 
to topics of relevance to all studies, or those applying to many aspects of one study.  
Specific analyses are discussed separately in the statistical methods sections of the 
following chapters. 
 
Data were collated in Microsoft Excel 2007 (Microsoft Inc.). Statistical analysis was 
carried out using Stata Statistical Software: Release 10. (StataCorp. 2007. College 
Station, TX: StataCorp LP.) and GraphPad Prism software version 6.0a for Mac OS X, 
(GraphPad Software, Inc., San Diego California USA, www.graphpad.com) and PLINK 
(Purcell, Neale et al.  2007). 
2.6.1 Tests for normality of data 
Linear regression modelling and other parametric statistics rely (among other 
requirements) on the data in question having a normal (Gaussian) distribution. Formal 
statistical testing for whether data are normally distributed can be performed, but such 
tests can fail to detect non-normality in small data sets and in larger data sets may 
falsely infer that a small or localised deviation from the normal distribution is ‘not 
significant’. Instead, visual comparison of the distribution of the data was used to 
establish normality or otherwise, by inspection of simple histograms and comparisons 
of data quantiles against those of a normal distribution with equivalent parameters. 
2.6.2 Handling of non-normal data 
Three options were available for the statistical analysis of data that were not normally 
distributed. Non-parametric tests of hypothesis can be used. Simple mathematical 
adjustment of data can be attempted to transform the data into a normal distribution 
(e.g. log-transformation) but such transformation is not always possible. Finally, the 
data can be resampled using a bootstrapping technique. This involves repeatedly 
constructing a new sample set based on random resampling a subset of subjects within a 
sample to produce a new data set; some subjects may be sampled more than once and 
others may be omitted. This is repeated many times (typically 2-3000). It enables the 
use of the same parametric statistical models as were applied to normally distributed 
62 
data, including covariates, without having to apply specific mathematical 
transformations.  
In this thesis, all three methods were employed.  The specific test is mentioned where 
appropriate. 
2.6.3 Modelling predictors of disease course 
2.6.3.1 Disease Burden Score 
The burden of pathology score has been used in HD biomarker studies to assess the 
relation among variables of interest and the estimated burden of disease (Golding, 
Danchaivijitr et al. 2006; Kloppel, Draganski et al. 2008).  Penney and colleagues 
(Penney, Vonsattel et al. 1997) showed that the degree of post-mortem striatal 
pathology was predicted by age at death and the length of the CAG repeat. On the basis 
of this observation, Sanchez-Pernaute (Sanchez-Pernaute, Garcia-Segura et al. 1999), 
who was studying striatal MRI abnormalities in vivo, found a similar relation between 
age and the length of the CAG repeat. 
The burden of pathology score was proposed as an index of disease burden on the basis 
of these findings. The score is calculated from a formula; (age×[CAG−35·5]), (Penney, 
Vonsattel et al. 1997) and functions are calculated as a simple estimate of an 
individual's lifetime exposure to mutant huntingtin, at any age, before and after motor 
onset. Other authors have reported that effect sizes could be estimated for different 
stages of preHD (Paulsen, Hayden et al. 2006; Paulsen, Langbehn et al. 2008). The 
disease-burden score was used in TRACK-HD to optimise the recruitment of 
individuals with premanifest HD to compile a cohort with the best chance of showing 
detectible changes in one or more outcome measures over the course of the study. A 
more broad-ranging preHD sample would result in smaller differences between the 
preHD groups and controls and would have required a larger sample size to detect group 
differences, a possibility that is prohibited by the limited time and funds available for 
the study. 
There are a number of limitations to using the disease burden score as a predictor of 
disease course in analyses, as has been pointed out by others (Rosenblatt, Margolis et al. 
1998).  First, it is derived from cross-sectional post-mortem data, with its inevitable bias 
towards end-stage brain changes (which can only be avoided by limiting study to 
subjects who have died prematurely from causes unrelated to HD).  The validity of 
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using such data to make inferences about the progression of pathology in vivo is 
limited. Second, the study of Penney et al. was based on quantification of caudate 
atrophy, which, based on MRI measurements, is certainly selectively increased early in 
the disease course but does not appear to increase linearly throughout the disease as 
Penney and colleagues propose (Aylward, Sparks et al. 2004), nor is there any reason to 
believe that the trajectory of caudate atrophy is capable of acting per se as a universal 
marker of pathology. 
 
2.6.3.2 Conditional onset probability calculation 
A more widely accepted measure of the combined contributions of age and CAG is the 
conditional onset probability calculation of Langbehn and colleagues (Langbehn et al. 
2004). Based on a very large cohort of 2913 individuals from 9 countries, it uses a 
parametric survival model to predict for a given subject the probability p that they will 
remain disease-free for a specified number of years (conventionally five): 
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Where agenow is the subject’s current age, ageonset is the projected disease-free age (e.g. 
agenow + 5) and CAG is the subject’s CAG repeat length. 
This can be rearranged to predict, for a given individual, the number of years of disease-
free life that must elapse before they reach a conditional onset probability of interest 
(conventionally 50 or 60%): 
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Where agenow is the subject’s current age, CAG is the subject’s CAG repeat length and p 
is the conditional onset probability of interest. 
 
64 
Conditional onset probabilities calculated using this method have several advantages. 
First, they are based on genuine population data from a large sample using the most 
widely agreed-upon event in premanifest HD: diagnosis of motor onset. Second, they 
make no assumptions of linearity of progression but, rather, attempt to model the non-
linearity of onset probability. Third, unlike models that simply use an individual’s CAG 
repeat length to predict their probability of onset at a given age, this conditional model 
makes use of the additional clinical information that the individual has survived to 
agenow without developing motor signs, to modify the onset probability. For example, an 
individual with a repeat length of 44 would be predicted, at birth, to have a 77% 
probability of onset by the age of 50 years; but if the same individual remained disease-
free at 45, their conditional probability of onset by the age of 50 would be reduced to 
53%, because of the information about their genotype-phenotype concordance encoded 
in 45 years’ disease-free survival. 
Because of these advantages, the Langbehn et al. model is widely used in the study of 
premanifest gene carriers (Paulsen, Hayden et al. 2006). However, though the modelling 
of the interaction between CAG and age is considerably more sophisticated than in the 
Penney et al. formula, because the model was developed in premanifest subjects, and 
moreover carries the assumption of a lack of motor signs at agenow, it would be 
meaningless if applied to subjects with manifest disease and cannot be used to carry out 
analyses across both groups. 
 
 
The chapters following will present the experimental work related to this thesis.  As 
mentioned at the start of this chapter, the methods specific to each study will be 
presented in the relevant chapters. 
Chapter 3 presents the longitudinal observational biomarker study; TRACK-HD 
Chapter 4 present a study characterising central and peripheral immune activation in HD 
Chapter 5 presents a study to identify genetic modifiers of age of onset in HD and 
Chapter 6 presents a study examining the importance of accurately estimating the age of 
onset in HD. 
The final conclusions arising from this thesis will be presented in Chapter 7.
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3 TRACK-HD 
3.1 Introduction 
Onset of HD is defined as the unambiguous presence of an otherwise unexplained 
movement disorder.  This diagnostic practise, as already discussed, disregards the fact 
that many patients show cognitive or behavioural disturbances many years before onset 
of motor symptoms.  In addition, sub-clinical changes are known to precede the onset of 
overt clinical manifestations as discussed in Chapter 1.2.  
 
Though the first trials of potential disease modifying interventions are likely to be 
carried out in early symptomatic patients, the optimal point at which to introduce 
disease modifying agents in the hope of delaying symptom onset or slowing the rate of 
disease progression is likely to be in the premanifest stage before the onset of rapid 
neuronal degeneration and emergence of clinical symptoms. In order to trial potential 
treatments, it is, therefore, necessary to identify sensitive and stable markers of change 
in both premanifest and early HD patients. Current clinical rating scales lack sensitivity, 
display floor or ceiling effects particularly in premanifest subjects, and require long 
observation periods to unequivocally demonstrate change. Improvements in the 
precision of objective measurement of disease progression in premanifest and early 
stage HD could lead to biomarkers better able to assess progression and measure the 
effects of therapeutic interventions.  
 
The genetic predictability of HD affords a unique opportunity to examine the pattern of 
signs and symptoms and neurobiological changes as they emerge.  The aim of TRACK-
HD was to provide the essential methodological advances required to optimise disease-
modifying clinical trials.  The study was designed using similar principles to a clinical 
trial with rigorous quality assurance and quality control and blinded data analysis.   
3.2 Contributions and Collaborations 
Sarah Tabrizi was global Principal Investigator (PI) of TRACK-HD based at UCL, 
Institute of Neurology, London, UK.  Along with the other members of the TRACK-HD 
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steering committee, she was responsible for the study concept and design.  Blair Leavitt 
was the PI for the University of British Columbia, Vancouver, Canada; Alexandra Durr 
was the PI for the Université Pierre and Marie Curie, Paris, France; Raymund Roos was 
the PI for the Universiteit Leiden, Netherlands.  The members of the steering committee 
and the full list of site staff are listed in Appendix B. 
I was the clinical research fellow at UCL, Institute of Neurology, London UK. Miranda 
Say (clinical research psychologist) and Joy Read (clinical research assistant) were the 
other clinical site staff in London.  Together we recruited all the subjects for the London 
site and performed all assessments.  As the clinical research fellow, it was my 
responsibility was to collect all clinical data and I also collected and processed all 
biosamples.  I administered the oculomotor and quantitative motor assessments and was 
trained in the administration of the cognitive and neuropsychiatric assessments to act as 
a backup rater.  I worked closely with Gail Owen, Clinical Trial Manager, on revisions 
to the Biosamples Standard Operating Procedure (SOP) and submission of protocol 
revisions for approval by the local research ethics committee.  The statistical analysis 
was carried out by a dedicated team of statisticians under the supervision of Douglas 
Langbehn (University of Iowa) and Chris Frost (London School of Hygeine and 
Tropical Medicine). The study was funded by the CHDI Foundation. 
3.3 Methods 
TRACK-HD was a multi-centre, multi-national and multi-lingual observational 
biomarker study of pre-manifest and early HD. TRACK-HD was designed using similar 
principles to a clinical trial with rigorous quality assurance, quality control and blinded, 
pre-defined primary data analysis using a range of novel neuroimaging and clinical 
assessment tools to identify sensitive clinical and biological markers of HD disease 
progression.  The protocol was also designed to be flexible, allowing any promising 
potential clinical tests to be incorporated during the course of the study. 
TRACK-HD was designed as a prospective study for which each participant was 
enrolled for 24 months with assessments at baseline, 1 year and 2 years.  
The analyses from the entire cohort are presented. However, only a subset of the data 
collected is included in this thesis, focussing on the assessments to which I contributed a 
significant amount data; the clinical, imaging, motor, oculomotor and quantitative motor 
assessments.   
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3.3.1 Measures 
At each time point, full enrolment and testing was completed over an 8-month period.  
In most cases, data were collected in a single visit and included demographic 
information, the UHDRS-99, 3T brain MRI, quantitative oculomotor and motor tests, 
cognitive tasks, neuropsychiatric interview and questionnaires, functional/quality of life 
measures and biosample collection. Methods for the measures presented in this thesis 
are described below. 
 
3.3.1.1 UHDRS-99 
The UHDRS (HSG 1996; Marder, Zhao et al. 2000) assesses four major clinical 
domains of impairment: (1) motor, (2) cognitive, (3) neuropsychiatric, and (4) 
functional capacity.  In devising this scale, items were selected that were likely to be 
sensitive to measure progression in the early stages of the illness.  The UHDRS-99 has 
undergone extensive testing of reliability and consistency and has been shown to have a 
good inter-rater reliability for the total motor score (HSG 1996; Marder, Zhao et al. 
2000).  The UHDRS has been widely used in HD clinical trials ((Tabrizi, Blamire et al. 
2005; Hersch, Gevorkian et al. 2006; Kieburtz, McDermott et al. 2010).  
 
Motor Assessment:  
The UHDRS motor examination is the gold standard for HD (see Appendix A).  The 
total motor score (TMS) measures a range of motor features characteristically impaired 
in HD including gait, tongue protrusion, ocular function and postural stability.  Higher 
scores indicate more severe motor impairment than lower scores.  The raters in both 
TRACK-HD and REGISTRY must be certified by the EHDN UHDRS-TMS online 
certification (www.euro-hd.net). This requires successful rating of three sample 
patients, filmed during UHDRS-TMS application, within a range defined as acceptable 
by experts in the field (as determined by a task force of the EHDN Motor working 
group). 
 
UHDRS Total Function Capacity:  
The goal of the UHDRS TFC (see Appendix A) is to obtain a clinician’s assessment of 
the participants’ capacity to perform in each of the five functional domains including 
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occupation, finances, domestic chores, activities of daily living and care level.  The TFC  
(see Appendix A) is a clinical rated 14-unit scale (range 0-13) with higher scores 
indicating better functioning than lower scores.  It is sensitive in manifest HD and is a 
standard in the field for diagnosed HD.  
 
UHDRS Functional Checklist and Independence Scale:   
The UHDRS Functional Checklist and Independence Scale (see Appendix A) have a 
relatively greater focus on more basic activities of daily living (i.e. toileting, 
ambulation) compared to the TFC.  
 
3.3.1.2 TRACK-HD Imaging 
MRI data were acquired using standardized T1-weighted and T2-weighted protocols 
developed for the TRACK-HD study. This involved a 3D magnetization-prepared rapid 
gradient echo (MPRAGE) acquisition sequence on a 3T Siemens (London and Paris) or 
a 3T Phillips (Leiden and Vancouver) whole body scanner with the following imaging 
parameters (Siemens/Philips): Repetition time (TR) = 2200ms/7.7ms, Echo Time (TE) 
= 2.2ms/3.5ms, Flip Angle (FA) = 10°/8°, Field of View (FOV) = 28cm/24cm, matrix 
size 256x256/224x224, yielding 208/164 sagittal slices to cover the entire brain with a 
slice thickness of 1.0 mm with no inter-slice gap.  
During the study, each incoming image was checked for quality. This consisted of 
checking the images for complete brain coverage, wrap, missing data, motion artefact, 
noise, inhomogeneity, flow, susceptibility, and other artefacts as well as ensuring the 
imaging protocol parameters had not changed from baseline to follow-up. All scans 
were rated on overall quality with regards to the overall image quality and the quality of 
deep grey structures, such as the caudate, which are to be delineated. Two T1-weighed 
MPRAGE scans were acquired during each scanning session to better ensure that one 
high quality scan was available for analysis. The quality of the images was compared 
during the quality control process, and a further grade was given to determine whether 
the T1 images were of comparable quality or if one T1 weighted image was of higher 
quality. 
Rigorous quality control was performed on all image datasets (IXICO Ltd, London, 
UK) and image data were archived at Laboratory of Neuroimaging at University of 
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California, Los Angeles. Four image analysis techniques were applied at three image 
analysis specialty sites: 1) semi-automated measurements of intracranial volume (ICV) 
and whole-brain volumes were performed using MIDAS (Freeborough, Fox et al. 
1997). 2) automated segmentation of intra cranial volume (ICV), whole brain, caudate 
and putamen tissue volume were performed on collected images using BRAINS (Brain 
Research: Analysis of Images, Networks, and Systems, Iowa City, Iowa, USA 
(Magnotta, Harris et al. 2002); 3) cortical thickness analysis was performed using the 
Freesurfer method of Fischl et al (Fischl, Liu et al. 2001); and 4) voxel-based 
morphometry (VBM) analysis was performed using SPM5 (Statistical Parametric 
Mapping 5) (www.fil.ion.ac.uk/spm). 
 
3.3.1.3 Quantitative Motor Assessments 
A pre-calibrated and temperature controlled force transducer (Mini-40, ATI Industrial 
Automation, NC, USA) was used for all force transducer based assessments (see 
Figures 13-15).  The force transducer had a circular plane contact surface measuring 40 
mm in diameter. It could be easily attached to the different setups used for tongue and 
grip force assessment and tapping in a modular fashion. All data was sampled at 400 
Hz, stored and analysed on a flexible laboratory computer system 
(WINSC/WINZOOM, University of Umeå, Sweden). All sites were equipped with 
identical systems and software. All data evaluation was performed blinded in the motor 
laboratory at the University of Munster using automated software.  
 
Tongue Force Measurement 
Isometric tongue protrusion force was measured with subjects seated upright on a chair 
in front of a table with their chin resting on a height-adjustable base as shown in Figure 
13. The force transducer was mounted 2 cm in front of their lips. A disposable plastic 
cover covered the surface of the transducer. A monitor was placed 30 cm in front of the 
subject’s eyes presenting feedback about the tongue force exerted. Following a cueing 
tone subjects were instructed to open their mouth widely, protrude their tongue and 
generate an isometric force with their tongue matching a target force level presented as 
a straight line on the monitor. After 20 seconds a second cueing tone marked the end of 
each trial and subjects were instructed to retract their tongue. Following three test trials, 
four trials were recorded for each of the two target force levels “low” 0.25 N (=Newton) 
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and “high” 0.5 N. Variability of tongue protrusion forces (expressed as coefficient of 
variation) was calculated during a 15 second period prior to the second cueing tone 
(Reilmann, Bohlen et al. 2010). 
 
 
Figure 13 Photograph illustrating the isometric tongue protrusion force 
assessment.   
 
Isometric Grip force and involuntary movements measurement 
Assessment of isometric grip forces and involuntary choreatic movements (orientation-
index and position-index) were performed as previously described (Reilmann, Bohlen et 
al. 2010; Reilmann, Bohlen et al. 2011) and as shown in Figure 14.  Subjects were 
seated upright on a height-adjustable chair with their right shoulder in front of the grip 
instrument and both elbows positioned at about 90° of flexion and forearms resting on a 
table. Following an auditory cue, subjects extended the forearms, grasped the 
instrument between the thumb and index finger with their right (dominant) hands, and 
lifted it next to a marker approximately 10 cm high to obtain standardized movements. 
They were instructed to hold it as stable as possible for 35 seconds; a second auditory 
cue signalled the end of the trial. The object was replaced on the table surface and 
released.  The force transducer measured the grip (normal) and load (tangential) force 
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components (0.025N resolution) of the thumb and index finger.  An electromagnetic 
sensor (Polhemus, VT) continuously measured the position (x, y, z; 0.75-mm 
resolution) and orientation (roll, pitch, yaw; 0.025° resolution) of the instrument.  Five 
trials were conducted with both a 250g and 500g object with the dominant and non-
dominant hand. 
 
 
 
Figure 14 Photograph illustrating the isometric grip force and involuntary 
choreatic movements assessment.   
 
Tapping tasks 
Force transducer based tapping was measured with the subject placing their non-
dominant hand palm down on a support surface located on the table in front of the force 
transducer such that they could comfortably tap on the transducer surface with their 
index finger as shown in Figure 15. A cueing tone was presented at 1.8 Hz and subjects 
were instructed to tap at the same rate as the cue and to continue tapping at this rate 
when the cuing tone stopped. Five trials were performed. The subject continued to tap 
for 10 seconds after the cuing tone ceased. Variability of tap deviation, from the pre-
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defined 1.8 Hz frequency, was calculated during this period (Hinton, Paulsen et al. 
2007). 
 
 
Figure 15 Photograph illustrating the force transducer based tapping 
assessment. 
   
Gait Assessment 
Gait analysis was measured by asking subjects to walk barefoot on an automated gait 
analysis carpet (Platinum GAITRite, 4.27 m length, GAITRite, Havertown, 
Pennsylvania, USA) as shown in Figure 16. Six walks were recorded at normal speed. 
Subjects started their walks 3m in front of the carpet to ensure assessment of gait in 
regular motion. Variability (expressed as coefficient of variation) of stride length was 
calculated by the software provided by GAITRite. Due to practical considerations, Gait 
assessments were removed from the protocol after the baseline assessments so cross-
sectional data only are presented here. 
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Figure 16 Photograph illustrating the gait analysis assessment. 
 
3.3.1.4 Oculomotor Assessments 
Eye-tracking and stimuli presentation were carried out using a Saccadometer Advanced 
(Ober Consulting): a head-mounted, infrared system that measured horizontal eye 
position based on the averaged reflectance off the inner canthi of both eyes as shown in 
Figure 17A. Acquisition rate was 1KHz at 12 bit resolution. Horizontal linearity was 
assured for ±15°. Four head mounted lasers projected the stimuli directly on a wall ~2 
74 
metres in front of the subject, and consisted of a red and green central cue and two red 
targets at ±10° as shown in Figure 17B. Subjects were presented with a random, 
centrally cued mixed pro/anti saccade paradigm (Hicks, Robert et al. 2008). Testing was 
carried out in normal lighting conditions and saccade latency, direction, amplitude and 
velocity were recorded. 
 
 
Figure 17 Photograph illustrating the oculomotor assessment. 
A) Set-up of the Saccadometer and B) Projection of the head mounted lasers 
 
The first task was a prosaccade task in which a variable length central fixation (500 – 
2000 ms) was followed by a 200 ms gap and then replaced by a central green cue and a 
red target on either the left or right. The subject was asked to look quickly at the target 
until it disappeared and then return their gaze to the centre when the fixation 
reappeared. Subjects performed one block of 40 trials; the data serving as a baseline for 
saccade latency and velocity. 
The second task was a centrally cued mixed pro/anti saccade task with the same 
temporal parameters as above. After the fixation and gap, a green or red central cue 
would appear, along with a target on either the left or right. Subjects were asked to 
perform a prosaccade to target at the green cue, and an antisaccade away from target at 
the red cue, with the instruction to behave “quickly and accurately”. Both central cue 
colour, and target position were varied randomly. Subjects performed three blocks of 70 
trials, with an inter-block break and reinstruction of at least one minute. 
A 
B 
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The prosaccade, and the first mixed pro/anti saccade tasks were preceded by an 
experimenter led, laser guided instruction set where each condition was projected onto 
the wall. Subjects were asked to demonstrate their comprehension of the rules before 
commencing the task. Data was downloaded from the Saccadometer using 
LatencyMeter (Ober Consulting) and checked for quality. Saccades with latencies less 
than 70ms and amplitudes less than two degrees were removed from the analysis. The 
first four trials from each block were also removed to reduce the effect of learning. 
3.3.2 Statistical Analysis 
The statistical analyses for TRACK-HD were complex and therefore carried out by an 
expert team of statisticians lead by Douglas Langbehn and Christopher Frost. 
 
3.3.2.1 Baseline Cross-sectional Study 
The five HD subgroups defined in TRACK-HD (control, preHD-A, preHD-B, HD1, 
HD2) were the predictor variables of interest in the primary statistical analyses. The 
potential confounders, controlled for in all formal analyses, were age, gender, study site, 
and education level (as a proxy for premorbid intelligence).  For the imaging variables, 
education level was not controlled for but intracranial volume was controlled for.  
Age is a complicated factor to control for as HD measures show a non-ignorable 
relationship to age in control subjects and this “normal” aging relationship also is 
presumed present in preHD subjects who are not experiencing any notable HD 
impairment. Nonetheless, among HD subjects, aging is also inevitably associated with 
HD progression. The intent in the models used was to control for the latter consideration 
via division of subjects into the above-defined HD subgroups. As a secondary check, 
potential age-by-HD-group interactions were checked in all formal analyses and none 
were found among the results reported. Study site was included among confounders to 
help control unappreciated systematic differences or measurement biases related to site. 
Adjusted differences among HD subgroups and controls were estimated using linear 
models. All outcome measures were continuous or suitably quasi-continuous for this 
approach. HD subgroup (including control) membership was treated as a categorical 
variable, as was study site and gender. Primary comparisons of interest were formed by 
linear contrasts of subgroup membership. Age and education level were modelled as 
linear effects. The default estimation method was ordinary least squares; however, 
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iterative weighted least squares (WLS) estimation, with weighting by HD subgroup, 
was used when residual variance showed notable systematic heteroscedasticity among 
these groups (Draper 1998). Additionally, simple outcome transforms (inverse, log, 
square root) were used when these substantially improved linearity and residual 
normality. 
TRACK-HD was designed to quantify clinically meaningful longitudinal changes over 
a two-year period.  Sample size was determined on the basis of projected uncertainty in 
the resultant sample size recommendations for future clinical trials. The sample size 
provides ample power to detect meaningful cross-sectional difference among the HD 
subgroups. 
 
3.3.2.2 24-Month Longitudinal Study 
Group Differences in 24-month change 
Each outcome was analysed separately using a generalised least squares (GLS) 
regression model, since GLS allows variances to differ between participant groups and 
also for correlations among measurements from the same participant. Participant data 
were only included if data from at least two of the three timepoints (baseline, 12 and 24 
months) were available for a given assessment.   
 
Non-imaging outcomes were analysed using models for absolute measures at baseline, 
12 and 24 months. Many of these assessments are subject to practice effects, which 
would be expected to be greatest from the first to second exposure. Thus both time from 
baseline and an indicator variable were included; allowing for an additional practice 
effect between the baseline and first follow-up. To allow the linear effect of time, 
practice effect and average performance over all three time periods to vary according to 
HD status, GLS models were used with group-specific intercepts, slopes and practice 
effect indicators. Neuroimaging outcomes were measured directly as change between 
two timepoints from registered scan pairs. The response variables were either change 
between 0-12 and 0-24 months (whole brain, ventricular and caudate volume) or change 
between 0-12 and 12-24 months (WM and GM), expressed as a percentage of baseline 
volume.   
 
All analyses were controlled for age, sex and study site as well as their interactions with 
time and practice effects (or acceleration effects). Models for non-imaging outcomes 
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were additionally corrected for educational level (an ordered categorical variable treated 
as a continuous covariate) and its interactions with time and practice effects. So as not 
to constrain the residual variances for different timepoints or the covariances between 
pairs of timepoints, unstructured covariance matrices were specified that were allowed 
to differ according to HD group. Marginal means at baseline, 12- and 24-month follow-
up in each subgroup were computed and displayed graphically for each outcome.   
 
Effect Sizes 
Effect sizes (ES) are unit-free measures, allowing case-control differences to be 
compared between different variables. Standardised ES for differences in the rate of 
change over 24 months for each assessment were calculated as the estimated adjusted 
difference in longitudinal change in each gene-expanded group relative to controls, 
standardized by the residual standard deviation (SD) of change in the gene-expanded 
group. We report bias-corrected and accelerated (BCA) bootstrap 95% confidence 
intervals (CI) based on 2000 replications (Carpenter and Bithell 2000). (This method is 
an adjustment that accounts, at least partially, for non-normality in the underlying 
statistic and typically leads to more accurate CIs.) For selected outcomes, we applied 
the 24-month ES described above to calculate estimates of the sample sizes necessary to 
detect 50% and 20% differences in longitudinal change between placebo and treatment 
groups with 90% power using the standard formula based on two-group z tests (Julious 
2009). 
 
Progression analysis 
The associations of each change measurement with HD progression, as defined by 
traditional clinical measures, were measured. For the early manifest groups, partial 
Pearson correlations between each variable’s rate of change and the change in the 
UHDRS total motor score (TMS) and total functional capacity (TFC) scores are 
reported. Partial correlations were corrected for age, gender, study site and education 
level. In several instances, the estimates were sensitive to the influence of outlying, 
though not necessarily invalid, measures. In these cases, we also report the rank-based 
(Spearman) partial correlations of residuals after least-squares regression of the affected 
variables on the demographic covariates. 
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In the preHD subjects, TMS and TFC have poor metric properties if treated as 
continuous, often showing no decline and highly skewed overall change distributions. 
Consequently we identified an objectively defined milestone, which we considered 
suggestive of individuals approaching clinical onset. The criterion was defined as 
change in one or more of three variables: a new-onset UHDRS Diagnostic Confidence 
Score (DCS) of 4 (the criteria for clinical diagnosis of early HD (HSG 1996), any net 
24-month decline in TFC, or an increase in TMS of 5 or more. We termed this group of 
individuals ‘progressors’, although recognising that the remainder may also have shown 
disease progression below the specified threshold. We compared change rates in the 
progressors versus non-progressors using an analysis of variance (ANOVA) model, 
adjusting for the demographic variables above and incorporated unequal within-group 
variances via iteratively reweighted least squares.  
3.4 Results 
3.4.1 Baseline Cross-sectional Study 
3.4.1.1 Participants 
Three hundred and eighty-five potential participants were screened, and 381 were found 
to meet inclusion criteria and enrolled in the study. Of these, 13 were subsequently 
excluded because they were unable to undergo MRI, one due to presence of stage 3 
disease, and one due to participant-initiated withdrawal of consent. Thus, the final 
sample included 366 participants, of whom 123 were controls, with the remaining 243 
people in the HD (n=123) and preHD groups (n=120). Demographic data and 
pathological disease burden scores are summarised in Table 5. The preHD group was 
significantly younger than the HD group, as expected. Groups were gender-matched by 
design, and controls were age-matched to the combined preHD and HD distribution. 
Education levels were not significantly different across groups except for the HD2 
group, which had lower education levels. Table 6 shows adjusted between- and within-
group differences with all p values for the imaging and motor assessments reported in 
this thesis.  
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Characteristic 
 
Controls 
(N=123) 
PreHD Group HD-Group 
PreHD-
A 
(N=62) 
PreHD-
B (N=58) 
Combined 
(N=120) 
HD1 
(N=77) 
HD2 
(N=46) 
Combined 
(N=123) 
Age (years) 
mean (SD) 
46.1 
(10.2) 
41.1 
(8.6) 
40.6 
(9.2) 
40.8 
(8.9) 
47.2 
(10.3) 
51.4 
(8.6) 
48.8 
(9.9) 
Gender 
Female N (%) 
Male N (%) 
 
68 (55.3) 
55 (44.7) 
 
33 (53.2) 
29 (46.8) 
 
33 (56.9) 
25 (43.1) 
 
66 (55.0) 
54 (45.0) 
 
46 (59.7) 
31 (40.3) 
 
21 (45.7) 
25 (54.3) 
 
67 (54.5) 
56 (45.5) 
Education 
mean (SD) 
4.0  
(1.3) 
4.1  
(1.1) 
3.8  
(1.3) 
3.9  
(1.2) 
3.8  
(1.3) 
3.2  
(1.4) 
3.6  
(1.3) 
Disease 
Burden Score 
mean (SD) 
_ 259.1  (30.1) 
333.1  
(30.0) 
294.8  
(47.7) 
364.1  
(74.3) 
397.6  
(67.5) 
376.6  
(73.3) 
Centres 
Leiden N 
London N 
Paris N 
Vancouver N 
 
30 
30 
30 
33 
 
16 
14 
14 
18 
 
14 
16 
16 
12 
 
30 
30 
30 
30 
 
16 
19 
26 
16 
 
14 
11 
4 
17 
 
30 
30 
30 
33 
Table 5 Demographic characteristics of the TRACK-HD Cohort at baseline 
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3.4.1.2 Neuroimaging assessments  
Simple visual inspection of representative MR images showed shrinkage of the caudate 
nuclei and expansion of the CSF spaces, both in preHD and early HD compared with 
controls (Figure 18A). Semi-automated volumetric analysis demonstrated that 
intracranial volume (ICV) did not differ significantly between the groups. Semi-
automated whole-brain measures (as a percentage of ICV) showed a stepwise decline 
across the groups, with significantly reduced volumes in the preHD-B and HD groups 
compared with controls (Figure 18Bi). The magnitude of these volume reductions 
compared with controls were 0.02%, 3%, 6% and 10% in the preHD-A, preHD-B, HD1 
and HD2 groups respectively. Figure 18Bii demonstrates the association between 
disease burden and whole-brain volume. 
Cortical thinning increased in magnitude from the premanifest to the HD groups (Figure 
18C). PreHD-A showed localised thinning in the posterior frontal region. In the preHD-
B group there was involvement of the occipital, parietal, superior temporal and superior 
frontal lobes. HD1 and HD2 showed similar patterns with extensive thinning throughout 
the cortex and relative sparing of the anterior frontal and lateral temporal regions.   
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Figure 18 Whole Brain and Regional Atrophy 
Figure 18A: 3T volumetric MRI scan in a 50 year old healthy control, a 55 year old 
preHD subject and a 49 year old early HD subject. Brain volumes shown are corrected 
for ICV.  
Figure 18Bi: Box plot showing brain volume as a percentage of ICV in all subject 
groups.  
Figure 18Bii: Scatter plot showing brain volume as a percentage of ICV against disease 
burden. 
Figure 18C: Cortical thinning in subject groups compared with controls. The top panel 
shows statistical maps corrected using the false discovery rate and magnitude maps are 
shown below.  Results are adjusted for age and gender. 
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VBM comparisons between each HD subgroup and controls suggested progressive 
abnormalities in both grey and WM in all groups (Figure 19). In the preHD-A group, 
grey matter (GM) loss was relatively circumscribed to the putamen, but also beginning 
to appear in the caudate. This pattern became more apparent in preHD-B, with 
increasingly widespread GM loss in HD1 and HD2, extending well beyond the 
neostriatum into the cingulate, pre-central and pre-frontal cortices, as well as into 
occipital, parietal, and temporal cortices. WM loss in the posterior-frontal regions was 
also apparent very early in the disease process, with preHD-B showing more 
widespread involvement than preHD-A, and more involvement still in HD1 and HD2, 
which appeared similar.  
Overall, findings across these four independent quantitative neuroimaging techniques 
are striking for the consistency of evidence they provide. Brain imaging indicates that 
abnormalities occur prior to diagnosis, in the absence of overt motor signs, in both grey 
and WM and involve both cortical and subcortical regions.  
 
 
Figure 19 Voxel Based Morphometry 
Statistical parametric maps of grey and WM differences in subject groups compared 
with controls. Age, gender, study site and ICV were adjusted for and results are 
corrected for multiple comparisons using familywise error at the p<0.05 level. 
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3.4.1.3 Oculomotor and quantitative motor assessments 
Oculomotor: 
Antisaccade error rates showed stepwise increases across groups, with more errors in 
preHD-B than preHD-A, in HD1 than preHD-B, and HD2 compared to HD1 (Figure 
20Ai). PreHD-A did not differ from controls. Higher error rates were also associated 
with higher disease burden scores (Figure 20Aii). 
 
Tongue force variability: 
Tongue protrusion force variability also showed stepwise increases across groups 
(Figure 20Bi). Variability was greater in preHD-A compared to controls, in preHD-B 
compared to preHD-A, and in HD1 compared to preHD-B.  Variability did not differ 
between HD2 and HD1. This pattern of results suggests that variability in tongue 
protrusion force is an early sign of the disease process but that it may level off as 
individuals progress beyond the earliest stage of diagnosis. Tongue force variability was 
also clearly associated with increasing disease burden scores (Figure 20Bii).  
 
Self-paced tapping: 
Precision of self-paced tapping (defined as 1/SD of the deviation of taps from the 
training tap rate) was very sensitive, showing differences between all adjacent group 
pairs (Figure 20Ci). Specifically, precision was lower in preHD-A than controls, 
preHD-B than preHD-A, HD1 than preHD-B, and HD2 compared to HD1. Thus, self-
paced tapping was sensitive from the earliest to the latest timepoints we assessed. Self-
paced tapping was also clearly associated with disease burden (Figure 20Cii).  
 
Gait: 
Gait, measured as the coefficient of variation for stride length at normal walking speed, 
was less sensitive than the other quantitative motor measures across all groups, as 
evidenced by small effect sizes (Figure 20Di).  Only the HD2 group differed 
significantly from controls, although when composite groups were compared (HD to 
controls, preHD to controls, HD to preHD), these comparisons reached significance 
(Figure 20Dii)  
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Figure 20 Oculomotor and Quantitative motor Measures 
Figure 20A) Antisaccade error rate; Figure 20B) Static tongue force variability; Figure 
20C) Self-paced tapping; and Figure 20D)Gait- normal speed stance, all shown as i)box 
plots across all groups and ii)against disease burden score for all HD gene carriers. 
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3.4.2 24 month Longitudinal Study 
3.4.2.1 Participants 
Of the 366 subjects enrolled at baseline, 347 (95%) and 332 (91%) completed 12- and 
24-month follow-up assessments, respectively (Table 7). At 24-months, 10 controls 
(8·1%), 1 preHD-A (1·6%), 5 preHD-B (8·6%), 5 HD1 (6·5%), and 5 HD2 (10·9%) 
subjects had withdrawn, and a further 8 participants were unable to attend, but remained 
in the study. All data were analysed according to baseline subgroup. However, at 24 
months, 12 (10·8%) of the premanifest group had reached a UHDRS DCS of 4, and 17 
(15·3%) of the HD group met the criteria for HD Stage 3 or greater (See Table 2 and 
Appendix A). All participants who contributed at least two datasets were included in the 
statistical analysis for each assessment; the maximum numbers for analysis were 116 
controls, 62 preHD-A, 55 preHD-B, 73 HD1 and 43 HD2. Details of the cohort at 24 
months are shown in Table 7.  The lower section of the table gives a breakdown of 
participants’ disease progression.  For example, of the 58 participants who were 
designated PreB at baseline, 51 attended the 24-month assessment.  Of these 51, 28 
were still classified as premanifest after 24 months, while 15 had become perimanifest 
and 8 were diagnosed as having progressed to stage I disease.  Thirteen of these preHD-
A subjects had advanced to preHD-B but the “transition” from preHD-A to –B, as 
opposed to progression from HD1 to HD2, does not have its basis in clinical change as 
the calculation is merely based on CAG repeat length and age. Progressing from 
preHD-A to -B means only that, due to ageing, a subject is likely to be within 10·8 
years to diagnosis but there is no implication that anything has changed clinically. 
 
3.4.2.2 Imaging 
Over 24 months, the preHD-B, HD1 and HD2 groups all showed statistically 
significantly greater mean annual change in whole-brain volume loss and ventricular 
expansion relative to controls (Figure 21A and B) and significantly elevated atrophy in 
the caudate and putamen was evident in all subgroups (Figure 21 C and D).  
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Figure 21 Longitudinal changes in brain volume 
Mean values at baseline, 12 months and 24 months for (A) whole-brain volume, (B) 
ventricular volume, (C) caudate volume and (D) putamen volume.  Significant change 
differences relative to controls over 0-12, 12-24 and 0-24 months are represented by 
*p<0.05, **p<0.01, and ***p<0.001. 
 
Figure 22 A and B show statistical parametric maps of WM and GM loss for each 
subgroup, indicating regions where atrophy rates differed significantly from controls. 
Elevated rates of WM loss were evident from the very earliest disease stage: preHD-A 
subjects showed loss around the striatum, corpus callosum and in the posterior WM 
tract; all other groups showed extensive WM loss throughout the brain. In the preHD-A 
group GM loss was limited to the striatum, but the preHD-B group additionally showed 
early occipital involvement. In early HD GM loss was widespread. Quantification 
88 
showed significantly higher rates of GM atrophy in preHD-B, HD1 and HD2 compared 
with controls over 24 months and WM atrophy rates were elevated in all gene-expanded 
groups (Figure 22). 
 
 
 
Figure 22 Longitudinal changes in grey and WM. 
 
89 
Parametric maps showing regions with statistically significant atrophy in (A) WM and 
(B) GM over 24 months, relative to controls.  Results were adjusted for age, sex, study 
site, and scan interval and are corrected for multiple comparisons with family wise-
error at the p<0.05 level.  Corresponding longitudinal plots show mean values at  
baseline, 12 months and 24 months.  Significant change differences relative to controls 
over 0-12, 12-24 and 0-24 months are represented by *p<0.05, **p<0.01, and 
***p<0.001. 
 
 
3.4.2.3 Motor 
UHDRS  
Mean annual change in TMS was greater in all subgroups relative to controls (Figure 
23A). Compared to the preHD groups, the mean TMS change was larger, but variability 
was also substantially greater in HD1 and HD2. In these two groups there was also a 
significant decrease in TFC relative to controls (Figure 23B).   
 
 
Figure 23 Longitudinal changes in the UHDRS. 
Mean values at baseline, 12 months, and 24 months for (A) UHDRS total motor score 
and (B) UHDRS total functional capacity.  Significant change differences relative to 
controls over 0-12, 12-24 and 0-24 months are represented by *p<0.05, **p<0.01 and 
***p<0.001
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91 
Quantitative Motor 
Over 24 months, statistically significantly greater change in the early HD groups 
relative to controls was observed in the chorea orientation and chorea position indices, 
grip force variability, speeded tapping tap duration variability and mean inter-tap 
interval (Figure 25).  The latter was also significantly elevated in both premanifest 
groups compared with controls.  
 
 
Oculomotor 
Over 24 months, the amplitude of the primary pro-saccade became increasingly variable 
in the HD2 group compared with controls (Figure 24).  
 
 
Figure 24 Longitudinal change in oculomotor measures 
i) Boxplot showing 0-12 and 0-24 month change and ii) longitudinal plots showing 
mean values and significant change differences relative to control at  baseline, 12- and 
24- months for prosaccade amplitude variability (s). Significant change differences 
relative to controls over 0-12, 12-24 and 0-24 months are represented by *p<0.05, 
**p<0.01, and ***p<0.001
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3.4.2.4 Effect Sizes 
Table 8 contains the TRACK-HD assessments proposed as potential outcome measures 
for future clinical trials in early HD. The table shows longitudinal 24-month effect sizes, 
presenting differences for each subgroup compared with controls, including 
bootstrapped 95% confidence intervals (CI).   
 
In terms of effect sizes for the combined early HD group, the imaging variables 
provided the largest effects, ranging from 1·01 (95% CI: 0·82 to 1·24) for GM atrophy 
to 2·04 (95% CI: 1·68 to 2·48) for caudate atrophy. Effect sizes for the quantitative 
motor variables ranged from 0·33 (95% CI: 0·08 to 0·60) for tongue force variability to 
0·68 (95% CI: 0·39 to 1·00) for speeded tapping tap duration variability, whilst the 
UHDRS TMS and TFC variables provided effect sizes of 0·81 (95% CI: 0·63 to 1·04) 
and 0·85 (95% CI: 0·62 to 1·09) respectively. Effect sizes for the oculomotor 
assessments were relatively small at 0·41 (95% CI: 0·16 to 0·66).  
 
3.4.2.5 Progression analysis 
Table  compares the rate of decline in the 33 preHD progressors with the remaining 78 
non-progressors. All imaging measures showed higher rates of atrophy in progressors, 
with the exception of the putamen, which had borderline statistical significance 
(p=0·07). Rates of deterioration in the chorea orientation index, speeded tapping tap 
duration variability and grip force variability were also greater.  
 
In the early HD group there was only modest partial correlation between changes in 
TMS and TFC (Pearson: -0·192, p=0.039, Spearman: -0·145, p=0.121). Most structural 
imaging showed similar, statistically significant associations with both worsening TFC 
and TMS (Table ). The exception was ventricular volume change which did not have a 
significant partial correlation with either measure. Putamen change was preferentially 
associated with TMS rather than TFC and conversely caudate change associated with 
TFC alone. The quantitative motor tasks showed fewer significant associations with 
TMS and none with TFC. Grip force variability and speeded-tapping inter-tap interval 
were both significantly associated with TMS change. 
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24-Month Change Outcome 
Variable Progressor N=33 
 Unadjusted 
Mean (SD)  
Non-
Progressors 
N=78 
Unadjusted 
Mean (SD) 
Progressor 
vs Non-
progressors 
(Adj Mean Diff) 
95% CI p-value 
Neuroimaging Measures      
Whole-brain atrophy  
(% of baseline volume)   
1.083   
(0.703) 
0.604  
 (0.788) 0·440  
0·108 to 
0·771 0·010 
Ventricular atrophy  
(ml) 
11.335   
(7.692) 
7.260  
 (8.289) 4·028 
0·404 to 
7·653 0·030 
Caudate atrophy  
(% of baseline volume)   
5.589  
 (2.231) 
3.560  
(2.407) 2·297 
1·336 to 
3·259 <0·0001 
Putamen atrophy  
(% of baseline volume)   
7.174  
(5.148) 
5.339   
(3.620) 1·825 
-0·135 to 
3·784 0·067 
White matter atrophy 
(% baseline) 
2.619  
 (0.574) 
1.860   
(0.637) 
0·625 
0·375 to 
0·874 <0·0001 
Grey matter atrophy 
(% baseline) 
0.399  
 (0.452) 
0.216  
 (0.349) 
0·207 
0·020 to 
0·394 0·031 
Quantitative Motor Measures      
Chorea position index  
(log cm/s) 
0.134  
(0.379) 
0.015  
(0.357) 0·113 
-0·035 to 
0·261 0·132 
Chorea orientation index  
(log °/s) 
0.157  
(0.348) 
-0.071 
 (0.379) 0·235 
0·089 to 
0·381 0·002 
Grip force variability, 250g, non-
dominant hand (log CV) 
0.132 
 (0.527) 
-0.164  
(0.529) 0·316 
0·086 to 
0·547 0·008 
Tongue force variability, 1·5 N target 
force (log CV) 
-0.179 
 (0.366) 
-0.211 
 (0.381) 0·038 
-0·123 to 
0·199 0·642 
Speeded tapping tap duration 
variability, non-dominant hand (log s) 
0.127 
 (0.337) 
-0.044  
 (0.377) 0·190 
0·037 to 
0·343 0·016 
Speeded tapping mean inter-tap 
interval, non-dominant hand (s) 
0.008  
(0.028) 
0.008   
(0.021) 0·001 
-0·010 to 
0·012 0·845 
Table 9 Comparisons of 24-month change in premanifest HD progressors and non 
progressors. 
All estimates are adjusted for age, gender, educational level and study site.   
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24-Month Change Outcome Variable 
UHDRS functional 
capacity (TFC)  
(change in score) 
UHDRS motor 
assessment (TMS) 
(change in score) 
Partial 
Correlation  p-value 
Partial 
Correlation p-value 
Neuroimaging Measures     
Whole-brain atrophy (% of baseline volume)   0·305 0·003 -0·232 0·023 
Ventricular expansion (ml) -0·108 0·294 0·174 0·089 
Caudate atrophy (% of baseline volume)  0·260 0·011 -0·152 0·141 
Putamen atrophy (% of baseline volume)  0·017 0·874 -0·258 0·012 
Grey matter atrophy (% baseline) 0·362 0·0003 -0·230 0·026 
White matter atrophy (% baseline) 0·250 0·015 -0·241 0·019 
Quantitative Motor Measures 
    Chorea position index (log cm/s) -0·053 0·582 -0·060 0·538 
Chorea orientation index (log °/s) 0·052 0·592 -0·008 0·930 
Grip force variability, 250g, non-dominant 
hand (log CV) -0·071 0·462 0·269 0·005 
Tongue force variability, 1·5 N target force 
(log CV) 0·148 0·139 -0·187 0·061 
Speeded tapping tap duration variability, 
non-dominant hand (log s) 0·073 0·456 0·027 0·780 
Speeded tapping mean inter-tap interval, 
non-dominant hand (s) -0·034 0·727 0·219 0·024 
Table 10 Partial correlations of change rates between TRACK-HD measures and 
the UHDRS TFC and TMS in early HD 
All values adjusted for age, gender, educational level and study site.   
 
3.5 Conclusions 
3.5.1 Baseline Cross-Sectional Study 
The cross-sectional TRACK-HD study collected data from rigorous assessments that 
included novel multi-site applications of 3T MRI, quantitative motor, cognitive, and 
neuropsychiatric methods. The findings have shown an increasing separation of the 
disease course of preclinical HD from healthy individuals at an early stage, in a cohort 
of premanifest HD gene carriers with no or minimum motor signs, and continuing into 
stage 2 disease. The results from the TRACK-HD cross-sectional data analyses build on 
what has been learned from PREDICT-HD (Paulsen, Hayden et al. 2006; Paulsen, 
Langbehn et al. 2008) and other studies to show that preHD findings can be detected, 
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even in the absence of early clinical motor signs, and that some measures are sensitive 
to disease effects across a broad range of stages. The observations support the 
hypothesis that neuronal dysfunction occurs many years before the development of the 
motor signs that are diagnostic of HD.  
Using advanced imaging techniques structural changes in many brain regions were 
detected. Even in the premanifest stages, atrophy is not confined to the striatum; whole-
brain volume loss is seen in the preHD-B group, who are up to 11 years from predicted 
age of onset, as well as cortical thinning, particularly in the posterior regions of the 
brain, with whole-brain volumes being reduced by 0.8%, even in those furthest from 
onset. Atrophy becomes increasingly widespread as the disease progresses through 
stages 1 and 2, which is in agreement with other reports (Rosas, Liu et al. 2002; 
Paulsen, Magnotta et al. 2006; Henley, Wild et al. 2009). In accordance with previous 
studies (Aylward, Sparks et al. 2004; Ciarmiello, Cannella et al. 2006) Voxel-based 
morphometry and volumetric measures showed volume reductions in the caudate and 
putamen in the preHD-A group, who are up to about 16 years from expected disease 
onset. There were no significant differences in the volume of the caudate or putamen 
between HD stage 1 and 2 showing that the rate of volume loss seems to slow early in 
the disease. Striking WM loss was evident before motor onset, which is consistent with 
other reports (Ciarmiello, Cannella et al. 2006) and suggests that a loss of connectivity 
might underlie many of the early clinical decrements. These findings support the 
reduction in functional connectivity in premanifest individuals that has been reported 
previously (Wolf, Vasic et al. 2007).  
 
The results show that there are subtle deficits in motor coordination in individuals more 
than a decade before a diagnosis of HD. Variability in tongue force is a useful measure 
in the premanifest stage of HD, converting a clinical impression (unsteady tongue) into 
a quantitative measure. The variability in the timing of voluntary finger taps was 
significantly different between all sub-groups, showing that impairment of voluntary 
movements is a feature of the disease, even in premanifest HD gene carriers, up to 16 
years before the predicted onset. Gait analysis was a less sensitive measure for 
separating subgroups, although differences between controls, all premanifest, and 
symptomatic individuals were significant.  For this reason, and for a number of practical 
reasons, gait analysis was not included in the longitudinal analysis. The oculomotor 
antisaccade error rate also increased proportionally with disease progression.  
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These results show that individuals who are classified as “premanifest” on the basis of 
current definitions (HSG 1996; Munoz and Everling 2004) are not “pre-motor” in the 
sense that they have no reproducible, measurable motor abnormalities.  They have also 
reinforced that the current convention of defining the onset of HD as the onset of the 
movement disorder does not do justice to the full spectrum of presentations of this 
heterogeneous condition. The presence of neuronal dysfunction while individuals are 
still functioning at a high level and in full employment suggests that disease-modifying 
interventions should be initiated in the premanifest phase; while functional capacity is 
still within normal range and any deficits might be fully reversible. Finally, the strong 
association between pathological disease burden scores and most phenotypic features, 
biological (MRI) and clinical read-outs, suggest that a panel of markers to detect these 
early changes will enable testing of novel therapeutic drugs in this population, which 
have been tested in the longitudinal study.  
3.5.2 24-month Longitudinal Study 
There is clear, widespread change over time in the early HD groups. Whole-brain, GM, 
WM and striatal atrophy measures proved highly sensitive, with caudate volume loss 
showing an effect size of 2·18 (95% CI:1·54 to 3·69) for the HD2 group. Variability of 
speeded tapping tap duration, the most sensitive of the quantitative motor assessments, 
had an effect size of 1·10 (95% CI: 0·65 to 2·19), larger than that of the most widely 
used clinical assessments in HD: TMS (0·91; 95% CI: 0·57 to 1·50) and TFC (0·83; 
95% CI 0·53 to 1·16). Oculomotor deficits were statistically significant in HD2 only 
and, in its current form, the oculomotor protocol does not show promise for clinical trial 
application.  
Imaging markers appear to be the most effective in detecting disease-related group 
differences, over both 12- and 24-month intervals. However, before they are adopted as 
outcome measures for use in clinical trials, it is vital to establish their relationship to 
functional measures. Associations between changing structural brain measures and 
underlying genetic burden risk have been documented (Bechtel, Scahill et al. 2010; 
Tabrizi, Scahill et al. 2011). The 24-month data has now shown an association between 
the progression of regional and whole-brain atrophy and advancing clinical progression 
(as defined by decline in the TFC and TMS). There are, however, significant challenges 
to using imaging as an outcome measure in clinical trials of HD.  Firstly, changes in 
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imaging outcomes in response to a treatment may not necessarily be accompanied by 
functional improvements, and secondly, improved clinical function may occur in the 
absence of observed changes in imaging measures. Therefore a wide range of functional 
measures in conjunction with imaging measures will be required. It is unlikely, in fact, 
that any single modality will be sufficient to assess the impact of a treatment. 
In contrast to findings in the early HD group, the 24-month data have not revealed 
robust outcomes to track disease progression during the premanifest stages. Striatal and 
total WM atrophy appeared to be the most sensitive measures, with significantly greater 
rates in premanifest than in control subjects, even in the preHD-A group, where the 
estimated time to manifest HD is greater than 10 years. However, despite this 
cumulative structural brain loss, there was limited decline in quantitative motor and 
oculomotor measures. These findings are important because they demonstrate that over 
a 24-month period, there is limited functional decline in this group, despite striking 
progressive brain changes. It is likely that functional reorganisation of neural networks 
accompanies this widespread structural loss, and protects against functional deficits in 
premanifest HD (Eidelberg and Surmeier 2011). Symptom onset may occur when this 
functional neural plasticity is no longer able to compensate for the progressive 
neurodegenerative process.  
3.6 Discussion 
A major goal of TRACK-HD has been to discover potential outcome measures for 
therapeutic trials in HD. Using highly standardised data collection across multiple sites, 
blinded quality control and centralised, independent statistical analysis, assessments 
from multiple domains have shown detectable disease-related change over 24 months. 
The study was able to suggest outcome measures suitable for proof-of-concept and 
future phase II and III studies of potential disease-modifying agents in early HD. These 
validated measures represent a pool from which a custom-made battery can be 
constructed, depending on the requirements of the trial.  
The results from the cognitive and neuropsychiatric assessments have not been 
presented here. There was clear evidence of measurable longitudinal cognitive decline 
in early DH.  SDMT, Stroop word reading and the indirect circle tasks had effect sizes 
of greater that 1.00 in the HD2 group.  Neuropsychiatric measures, with the exception 
of PBA apathy, did not show significant change over the 24-month interval(Tabrizi, 
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Reilmann et al. 2012). The relative insensitivity of the quality of life scales show the 
need for a more sensitive measure of HD-specific assessments for assessing response to 
therapeutic intervention. 
TRACK-HD attempted to mimic the recruitment standards and procedures, training 
methods and site selection for a clinical trial involving a small number of research sites. 
Large trials will require the inclusion of multiple sites, and considerable resources need 
to be invested to ensure between-site consistency and good quality control. This will 
also allow the assessment of site-specific effects and reliability, which are essential for 
the translation of experimental trial efficacy to clinical effectiveness.  
3.7 Suggestions for future study 
The potential outcome measures recommended by the TRACK-HD study await 
validation in clinical trials in early stage disease. The TRACK-HD study was extended 
based on the findings from the 24 month timepoint and have recently been published 
(Tabrizi, Scahill et al. 2013).  In the preHD-B group several quantitative motor and 
cognitive tasks shown significantly increased rates of decline at 36 months compared 
with controls, whereas few had at 24 months.  There remained little evidence of reliable 
change in non-imaging measures in the preHD-A group. 
Studies focussed on identifying potential biomarkers, using more challenging tasks 
which may show increased sensitivity, in the premanifest stages of HD have been 
initiated in the TRACK-ON study (Tabrizi 2012). This study will also investigate the 
hypothesis that compensatory functional neural networks exist, but are eventually 
overwhelmed in the preclinical phase of HD neurodegeneration.  
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4 CHARACTERISING CENTRAL AND PERIPHERAL IMMUNE 
ACTIVATION IN HD 
4.1 Introduction 
There is evidence of microglial activation in the pathogenesis of HD (Sapp, Kegel et al. 
2001; Giorgini, Guidetti et al. 2005). There is evidence from previous PK PET imaging 
studies that microglial activation is an early event in HD (Tai, Pavese et al. 2007; Tai, 
Pavese et al. 2007) and that microglial activation, as measured by PK PET imaging, 
increases with severity and may therefore provide a biomarker for HD disease 
progression.  However, PET imaging is challenging in HD as it is time-consuming, 
requires patients to remain still for long periods of time and is expensive, thereby 
limiting its usefulness in large studies and reducing its utility as a potential outcome 
measure in clinical trials.  
As described in section 1.3.2, peripheral immune dysfunction is also described in HD 
with increased levels of plasma cytokines detectable in premanifest HD.  In addition 
patient monocytes are hyper-reactive, producing increased levels of IL-6 upon 
stimulation with LPS in vitro (Bjorkqvist, Wild et al. 2008).   
Firstly, the aim of this study was to extend these findings to include other cytokines by 
examining the activity of monocytes in a large cohort of HD gene carriers.  Secondly, 
by performing PK PET imaging in a sub-group of TRACK-HD premanifest subjects, 
the aim was to evaluate the use of  PK PET as a potential marker of disease onset and 
progression.  Thirdly, by performing PK PET imaging and monocyte stimulation 
studies, in parallel, in a cohort of premanifest gene carriers, the aim was to evaluate the 
possibility that peripheral production of pro-inflammatory cytokines may reflect central 
microglial activation and thus may provide a useful alternative to PET scanning as a 
biomarker of disease onset and progression. 
4.2  Contributions and collaborations 
The study was designed jointly by the author with M Politis, S Tabrizi, P Piccini.  The 
author performed subject recruitment, clinical characterisation and blood sample 
processing. Monocyte stimulation experiments were performed by the author with 
support from R Andre, A Magnusson and U Träger.  PET imaging was performed at the 
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Centre for Neuroinflammation and Neurodegeneration, Imperial College London and 
image data processing was performed by M Politis.  Statistical analysis and data 
interpretation was performed by the author with input and advice from M Politis, S 
Tabrizi and P Piccini.  
 
4.3 Methods 
4.3.1 Subject recruitment 
4.3.1.1 Monocyte Stimulation Experiments 
Samples from 53 HD gene carriers, ranging from premanifest to moderate-stage disease, 
and control subjects were collected for the initial monocyte stimulation experiments. 
Subjects were recruited from the ‘Identification of biomarkers that can be used to track 
the progression of Huntington’s disease’ study as described in section 2.2.2. Subject 
demographics are shown in Table 9. 
 
Subject Group  Number Age (mean ± SD) CAG (mean ± SD) 
Control 27 45.4 ± 11.7  
Premanifest HD 17 42.2 ± 9.9 42.8 ± 2.1 
Early HD (stage 1&2) 22 49.1 ± 11.7 43.5 ± 2.8 
Moderate HD (stage 3) 14 59.4 ± 7.3 43 ± 1.3 
Table 9 Demographic details of subjects participating in the HD monocyte 
stimulation study 
 
4.3.1.2 TRACK-PET study 
12 premanifest subjects already enrolled in TRACK-HD at the London Site were 
recruited to take part in the TRACK-PET sub-study. The subjects were recruited to be 
representative of the TRACK-HD premanifest population.  The full demographic and 
clinical details are shown in Table 10.  The probability of being diagnosed with HD in 
the next 5 years was estimated using the algorithm published by Langbehn and 
colleagues (Langbehn, Brinkman et al. 2004) see section 2.6.3.2.  
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Subject Sex Age CAG Large 
5-year probability 
of Disease Onset 
1 M 40.8 41 0.07 
2 M 31.5 48 0.48 
3 M 43.9 44 0.49 
4 M 48.5 42 0.34 
5 F 37.1 45 0.38 
6 F 37.5 44 0.26 
7 F 40.4 44 0.37 
8 F 44.7 43 0.37 
9 F 45.0 41 0.13 
10 M 36.1 45 0.34 
11 F 58.6 40 0.28 
12 F 29.6 47 0.28 
Mean ± SD 41.14±7.84 43.67±2.42 0.32±0.12 
Table 10 Demographics of Premanifest Subjects enrolled into TRACK-PET study 
4.3.2 Functional Studies of Human Monocytes 
Whole blood was collected in heparin (CP Pharmaceuticals).  Leukocytes were isolated 
by density gradient centrifugation over Histopaque 1077 solution (Sigma-Aldrich).  
Monocytes were obtained by magnetic sorting to increase yield and minimize handling 
time.  Mononuclear cell suspensions were labelled with anti-CD14 microbeads and 
sorted through magnetic cell separation columns (Miltenyi Biotec) to at least 95% 
purity.  Monocytes were counted and 5 x 105 cells per well were seeded into 24-well 
culture plates in RPMI culture medium supplemented with 5% FBS, 2mM L-glutamine, 
and 1% penicillin/streptomycin (Invitrogen).  Cells were incubated for 16 hours before 
stimulation.  The medium was then changed to fresh culture medium with or without 
10ng/ml IFN-γ and LPS (R&D Systems). After 24 hours, supernatants were harvested 
from two separate wells for each subject/condition.  The cells remaining were lysed in 
50mM Tris, pH 8, 150 mmol NaCl, 0.5% sodium deoxycholate, and 0.5% Triton X-100 
and assayed for total protein concentration using a protein assay kit according to the 
manufacturer’s instructions (Bio-Rad Laboratories).  Cytokine concentrations were 
quantified using Meso Scale Discovery (MSD) assays as per the manufacturer’s 
protocol and analysed on a SECTOR 2400 instrument (MSD).   
  
For the initial monocyte stimulation experiments, multiplex ELISA assays for 
inflammatory cytokines IL1β, Il-6, IL-8, IFNγ, TNFα, IL-12p70 and IL-10 were carried 
out using the mesoscale platform (MSD).  
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For subsequent monocyte stimulation experiments, multiplex ELISA assays for 
inflammatory cytokines IL1β, Il-6, IL-8, IFNγ, TNFα were performed using the 
mesoscale platform (MSD).  
Cytokine production by LPS-stimulated monocytes was normalised to the cytokine 
production of non-stimulated cells from the same subject.  Cytokine production by non-
stimulated monocytes was very low with less than 10pg/ml for all cytokines besides IL-
8, for which levels were around 1ng/ml in supernatants from non-stimulated cells.  
Cytokine production by non-stimulated cells did not differ between control and HD 
subjects.  
4.3.3 11C-(R)-PK11195 Imaging 
The PK PET scans were carried out within 3 months of TRACK-HD visit.  To prevent 
any possible effect of the ligand on the TRACK-HD volumetric MRI data, the PET scan 
was always performed after the TRACK-HD visits.  Control data for PET scans were 
taken from existing age and sex matched normal control data.  
 
4.3.3.1 Imaging methods 
The PK PET scan was performed using the GE Discovery RX PET/CT scanner that has 
an axial field of view (FOV) of 15.7 cm. The mean image transaxial resolution over a 
10 cm radius FOV (from the centre) is 5.4 ± 0.5 mm (2D and 3D modes) and the axial 
resolution is 5.6 ± 0.8 (2D) and 6.2 ± 0.4 (3D) (Kemp, Kim et al. 2006). 
The mean injected dose for PK was 360 MBq (range: 344-372 MBq) and scanning 
began 30s before tracer infusion as an intravenous (iv) bolus, generating 18 time frames 
of tissue data over 60 min. PK tracer was supplied by Hammersmith Imanet plc, 
London.  
Subjects were positioned supine with their transaxial planes parallel to the line 
intersecting the anterior-posterior commissure (AC–PC) line. Head position was 
maintained with the help of individualized foam holders and monitored by video. 
Subjects were scanned at rest in a quiet room with low light. Smoking and consumption 
of alcohol, coffee and other caffeinated beverages were not allowed for 12 hours before 
scanning. Eating and drinking were not allowed for 8 hours before PET scanning. 
Each subject also received a a T1 Volumetric (TR = 1900, TE = 3.53, TI = 1100, Flip 
angle 15, 1mm isotropic voxels) and T2-weighted (Axial T2-spin echo: TR = 4540, TE 
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= 97, 5mm slice thickness; Axial FLAIR: TR = 9000, TE = 114, T I= 2500, 5mm slice 
thickness) MRI sequences were also undertaken for purposes of PET co-registration, to 
facilitate with localising the ROIs and for excluding secondary structural brain 
pathology. MRIs were performed using a clinical 1.5-Tesla (T) MRI system (Siemens 
MAGNETOM Avanto, Ehrlangen, De) 
 
 
4.3.3.2 Imaging Data Analysis 
Following reconstruction of the dynamic PK image volume, a summed image volume 
was created from the entire dynamic dataset. The input function was derived using the 
SUPERPK software package (Imperial Innovations) (Turkheimer, Edison et al. 2007; 
Tomasi, Edison et al. 2008; Boellaard 2009; Yaqub, van Berckel et al. 2012). 
In brief, the supervised clustering algorithm models the time-activity curves (TAC) of 
each pixel as the sum of the kinetics of 4 predefined tissues (normal GM and WM, and 
the 2 sources of specific binding, activated microglia and the vasculature) obtained from 
a database of control subjects and patients. Additional signals from the skull and 
extracerebral muscle tissue are excluded by elimination of nonbrain voxels with the use 
of the coregistered GM and WM components extracted from the individual MRIs. The 
reference kinetic is obtained by averaging on the whole brain, whereas each pixel TAC 
is weighted by its normal GM index. The reference TAC is then used as input for a 
simplified reference region modeling approach (Gunn, Lammertsma et al. 1997) which 
additionally incorporates the specific (but of no interest) binding of PK to the 
vasculature (Tomasi, Edison et al. 2008) and is applied to the PET dynamic volume to 
generate a pixel-by-pixel map of PK binding potential of the specifically bound 
radioligand relative to the nondisplaceable radioligand in tissue (BPND). 
PK parametric images of each subject were coregistered to their respective MRI scans 
using the mutual information registration algorithm in the SPM8 software package. This 
same transformation was applied to the thresholded (probability of 0.5) GM and WM 
masks and to the 83 ROIs generated with the MAPER approach. Multiplication across 
these co-registered images and masks created BPND maps, the patients’ individual 83 
ROIs in which then were sampled with the ANALYZE medical imaging software 
(version 11, Mayo Foundation). 
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4.3.4 Clinical assessments 
The TRACK-PET study corresponded with the 24-month assessments of TRACK-HD 
and therefore data from 3 visits were available for analysis.  Clinical and imaging 
variables encompassing a range of domains were chosen for correlation with PK PET 
imaging data based on 12-month longitudinal performance in the premanifest cohort in 
TRACK-HD but the number of variables chosen were limited to avoid the pitfalls of 
multiple testing (Tabrizi, Scahill et al. 2011). 
Variables used in this analysis were the BSI imaging variable, inter-tap time and tap 
duration quantitative motor variables (see section 3.3.1 for a full description of these 
clinical assessments); the Problems Based Assessment–Short (PBA-S) apathy score 
from the neuropsychiatric assessments and the negative emotion recognition score and 
indirect circle tracing annulus length from the cognitive assessments (Tabrizi, Scahill et 
al. 2011). 
4.3.5 Statistical Analysis 
ANOVA followed by post-hoc Tukey HSD testing was used for the monocyte 
stimulation experiments.  Parametric statistical tests were used for 2 group comparisons 
(students un-paired t-test); where values were non-normally distributed, non-parametric 
statistical tests were used (Mann–Whitney U test).  To interrogate correlations between 
PK BPND values and variables of interest, Spearman's correlations were used. All 
significance levels reported are two-tailed. 
4.4 Results 
4.4.1 HD monocytes are hyper-reactive after LPS stimulation 
CD14 + monocytes were isolated and seeded in vitro, before being primed with IFNγ 
and stimulated with LPS.  In multiplex ELISA assays, stimulated monocytes from HD 
subjects at each disease stage were found to produce more of the pro-inflammatory 
cytokines, IL-6 and TNFα, than control cells (see Figure 26).  Production of IL1β was 
also significantly increased in LPS-stimulated premanifest HD monocytes.  Levels of 
the chemokine IL-8, anti-inflammatory IL-10 and pro-inflammatory IL-12 did not differ 
between stimulated HD and control monocytes. 
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Cytokine production by LPS-stimulated monocytes was normalised to the cytokine 
production of non-stimulated cells from the same subject.  Cytokine production by non-
stimulated monocytes was very low with 10pg/ml for all cytokines besides IL-8, for 
which levels were around 1ng/ml in supernatants from non-stimulated cells.  Cytokine 
production by non-stimulated cells did not differ between control and HD subjects at 
each stage.  
 
 
Figure 26 Pro-Inflammatory cytokine production by monocytes is elevated in HD 
patients.   
Monocytes were isolated from control and HD patient blood samples using magnetic 
cell sorting.  After stimulation with 10ng/ml IFN and 2 g/ml LPS for 24 h, multiplex 
ELISA demonstrated that innate immune regulators IL-1, IL-6 and TNF are elevated in 
culture media of HD patient blood monocytes.  Data shows mean concentrations 
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corrected to basal condition ± SEM, n= individual biological repeats.  Analysis 
*p<0.05, **p<0.01, ***p<0.001. 
4.4.2 TRACK-PET study 
4.4.2.1 Whole brain volumes of subjects are no different to controls. 
To investigate whether any difference in PK BPND may be the function of cerebral 
atrophy, the whole brain volumes subjects enrolled in the TRACK-PET study compared 
with age and sex matched controls and no significant difference was found (Figure 27). 
 
 
Figure 27 Comparison of whole brain volumes from the TRACK-PET cohort  
There is no significant difference in the whole brain volumes of premanifest gene 
carriers enrolled in TRACK-PET compared with age and sex matched TRACK-HD 
controls. (Mean and SD.  p=0.068. Mann Whitney Test) 
 
4.4.3 11C-(R)-PK11195 binding is increased in premanifest gene carriers  
There were no differences in the whole brain PK BPND between premanifest subjects 
and age and sex matched controls.  
ROI analyses, focussed on brain regions specifically implicated in disease pathogenesis 
in HD, revealed cross-sectional differences in PK BPND between age and sex matched 
controls in the insula, thalamus, pallidum and striatum (comprising the caudate nucleus, 
putamen and nucleus accumbens) as shown in Figure 28.  
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Figure 28 PK binding potentials of premanifest gene carriers enrolled in the 
TRACK-PET study 
Mean PK BPND per unit volume ± SD  *Consisting of Caudate nucleus, putamen and 
nucleus accumbens.  
 
4.4.4 11C-(R)-PK11195 Binding Potential may be associated with disease 
progression 
To investigate whether PK BPND correlates with markers of disease progression, the PK 
BPND from the 4 ROI were compared with the 5-year probability of disease onset 
(Langbehn, Brinkman et al. 2004).  PK BPND in the caudate nucleus, but in no other 
ROI, showed significant correlation with 5-year probability of disease onset (Figure 29).  
111 
 
Figure 29 PK BPND correlates with 5-year probability of disease onset in 
premanifest HD.  
(Spearman Correlation. r=0.64, p=0.028) 
 
To further investigate the potential of PK PET as a biomarker of disease progression.  
PK BPND of ROI was correlated with measures of disease progression selected from the 
TRACK-HD study and based on good longitudinal performance. Whilst most measures 
did not show any significant correlation with PK PET, PK BPND in the corpus striatum 
was related to differences in tap duration as measured at visit 3 (see Figure 30) and PK 
BPND in the thalamus was associated with progression of subclinical motor phenotype in 
premanifest subjects as measured by the mean change in intertap time from baseline to 
24 months (see Figure 30).  These findings raise the possibility that microglial 
activation in the thalamus can reflect subclinical progression and therefore act as a 
marker of disease onset.  
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Figure 30 PK Binding Potential correlates with quantitative motor impairment 
PK BPND per unit volume are plotted.  Corpus Striatum consists of Putamen, Caudate 
Nucleus and Pallidum. PK BPND of the corpus striatum shows correlation with tap 
duration.  PK BPND of the correlates with mean change in intertap time over 24 months. 
 
4.4.5 Central microglial activation in premanifest HD does not correlate with 
peripheral monocyte stimulation. 
In multiplex ELISA assays, stimulated monocytes from premanifest HD subjects 
participating in the TRACK-PET study were found to produce more of the pro-
inflammatory cytokine IL-1β (Figure 31) than control cells. Mean levels of IL-6, TNFα 
and IL-8 were higher in premanifest subjects compared with controls but the differences 
did not reach statistical significance. There was no significant correlation between PET 
BPND of any ROI (whole brain, thalamus or corpus striatum; encompassing putamen, 
caudate and pallidum) and the inflammatory markers tested. 
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Figure 31 Results from the monocyte stimulations from TRACK-PET premanifest 
subjects. 
Monocytes were isolated from controls and premanifest HD gene carriers using 
magnetic cell sorting.  After stimulation with 10ng/ml IFN and 2 g/ml LPS for 24 h, 
multiplex ELISA demonstrated that innate immune regulator IL-1β is elevated in the 
culture media of premanifest HD gene carriers.  Data shows mean concentrations 
corrected to basal condition ± SD. 
 
4.5 Conclusions 
Monocytes isolated directly from HD patients and stimulated with LPS produced 
significantly more IL-6, IL-8 and TNFα compared with controls and in addition 
monocytes isolated from premanifest HD gene carriers (n=17) were hyper-reactive for 
IL-1β.  This supports previous findings that in premanifest subjects with a mean of 16 
years to expected onset, myeloid cells isolated from premanifest HD patients were 
hyperactive to the same degree as cells isolated from late-stage patients (Bjorkqvist, 
Wild et al. 2008).  This suggests that an early deficit is already present many years 
before disease onset and this may offer an early marker of HD pathogenesis.  Stimulated 
monocytes from the 12 premanifest subjects from TRACK-HD were hyper-reactive for 
IL-1β but did not produce significantly more IL-6, IL-8 or TNFα.  It may be that this 
study was insufficiently powered to show a significant difference and, in addition, 
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cytokine levels were extremely variable in this cohort as shown by the large standard 
deviations presented in Figure 31.  
This study confirmed previous findings of increased microglial activation in 
premanifest HD gene carriers compared to healthy controls (Pavese, Gerhard et al. 
2006; Tai, Pavese et al. 2007; Politis, Pavese et al. 2008; Politis, Pavese et al. 2011).  As 
in previous studies, microglial activation in the striatum has been shown to predict the 
5-year disease clinical onset in premanifest HD patients (Tai, Pavese et al. 2007; Politis, 
Pavese et al. 2011).  In this study PK BPND in the thalamus reflected subclinical 
progression of HD in premanifest gene carriers, with increased binding in those subjects 
whose performance on one of the TRACK-HD tapping tasks had deteriorated most over 
the previous 24 months.  This finding was not reproduced for the cognitive or 
neuropsychiatric tasks investigated. This observation suggests that PK PET is a marker 
of subclinical motor progression and could be helpful in stratifying those that are closer 
to motor onset in clinical trials of disease modifying agents. In this cohort, monocyte 
stimulation in the periphery did not reflect central microglial activation and would not 
be a suitable alternative to PET imaging as a biomarker of disease progression. 
Cytokines are known to vary diurnally and this pattern may change with disease 
progression, furthermore cytokine levels can be altered by infections, smoking, diet and 
a number of other factors challenging their reliability as use as a biomarker.  However, 
the relation between central and peripheral immune reaction is worth exploring in a 
larger sample of HD gene carriers and by applying corrections for partial volume and 
vascular effects in the PK PET data.  
4.6 Future Directions 
Despite a large number of research studies, the exact role of immune activation in 
chronic neurodegenerative disease remains uncertain.  In line with the high plasticity of 
microglia that allows them to perform numerous CNS functions, they are likely to play 
a dichromatic role in disease, depending on signals present in their microenvironment 
and the duration of activation.  While early immune activation could present a beneficial 
response (i.e. removal of CNS threat, promotion of tissue repair and removal of 
misfolded protein) chronic exposure could induce detrimental effects by promoting 
neuronal death (i.e. through the sustained release of neurotoxic factors), thus 
contributing to progression of disease.   
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PET imaging may be a tool that allows us to track the progression and severity of 
neuroinflammation in the brain as a useful indicator of active CNS disease. A 
longitudinal study of PK PET in premanifest HD is essential to assess whether it is truly 
a marker of disease progression. However, there are limitations associated with the use 
of PK including a high level of non-specific binding (Petit-Taboue, Baron et al. 1991) 
and a poor signal to noise ration, which complicates its quantification (Boutin, 
Chauveau et al. 2007).  This has prompted the search for novel PET radioligands of 
TSPO, such as 11C-PBR28, 11C-DAA1106 and 18F-DPA-714 (Ching, Kuhnast et al. 
2012).  As yet none of these have shown definite superiority when compared with 11C-
PK11195 but are now being used in studies of neurodegeneration.   
Early detection of microglial activation could offer opportunities for pharmacological 
interventions to limit the potential disruptive effects of chronic microglial activation and 
could be used as outcome measures in therapeutic trials, particularly for those therapies 
targeting immune dysfunction in HD; such as KMO inhibitors and CB2 receptor 
agonists. 
Further investigation into the pathways by which hyperstimulation of monocytes and 
macrophages occur, may lead to novel therapies targeting immune dysfunction.  One 
study, to which the author has contributed, has shown that by lowering total HTT levels 
in primary human monocytes and macrophages, HD-specific phenotypes, such as 
increased cytokine production and transcriptional dysregulation can be, at least partially, 
reversed (Trager 2013). The NFkB pathway and its role in immune dysfunction in HD 
should also be further investigated; especially since NFkB signaling is not only crucial 
in innate immune activation but also in neuronal survival (Khoshnan, Ko et al. 2004; 
Teng and Tang 2010; Trager 2013). 
  
116 
5 GENETIC MODIFIERS OF AGE OF ONSET IN HUNTINGTON 
DISEASE 
5.1 Introduction 
CAG repeat length accounts for 42–73% of the variance in the age of onset in 
Huntington’s disease (HD) (Andrew, Goldberg et al. 1993; Stine, Pleasant et al. 1993; 
Brinkman, Mezei et al. 1997). The remainder of the variance is likely due to 
environmental and other genetic factors (Wexler, Lorimer et al. 2004).  Genes that 
influence age of onset of HD must lie in pathways where they can modulate onset of 
disease symptoms; and thus finding such genetic variants and identifying the genes 
associated with them gives a direct insight into molecules and pathways that are 
important in the manifestation of the disease and may provide therapeutic targets.   
Several loci may be undetectable by genome-wide association studies due to small 
effects; however, genetic analysis of candidate genes is an appropriate alternative to 
identify modifier genes. 
 
The aim of this study was to use age of onset data and DNA samples collected as part of 
the TRACK-HD and REGISTRY Studies to employ a candidate gene approach to 
identify genetic modifiers of HD.  The genes in question were CLU, PICALM, CR1, and 
APOE, which have all been implicated as modifying genes in Alzheimer’s Disease 
pathogenesis.   These genes were chosen as potential candidate genes given that there 
are parallels between the neurodegenerative diseases and the processes that occur in AD 
and HD are likely to involve similar pathways.  The genes are described below. 
The innate immune system dysfunction is potentially important in the pathogenesis of 
neurodegenerative diseases as discussed in Section 1.3.  CLU encodes the protein 
Clusterin, also known as Apolipoprotein J, and is a key modulator of the innate immune 
system and the complement cascade and has been implicated in neuroinflammation.  
There is widespread evidence of immune activation throughout the course of HD 
(Bjorkqvist, Wild et al. 2008) and clusterin has been shown to be upregulated in 
peripheral blood in HD subjects (Dalrymple, Wild et al. 2007).  It is therefore 
interesting that 2 large genome-wide association studies have identified variants in the 
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clusterin gene to be associated with an increased risk of sporadic AD (Harold, et al 
2009; Lambert, et al 2009). 
The CR1 gene encoding the main receptor of the complement C3b protein and has also 
been associated with increased risk of late-onset AD (Lambert, Heath et al. 2009).  The 
PICALM gene, encoding the PICAL protein (phosphatidylinositol-binding clathrin 
assembly protein) which is involved in intracellular trafficking of growth factors and 
neurotransmitters, also showed an association with increased risk of sporadic AD 
(Harold, Abraham et al. 2009). 
The ε4 allele of the apolipoprotein E (APOE) gene has been defined as a critical factor 
for early onset neurodegeneration in Pick's, Parkinson's, and Alzheimer's disease.  A 
number of HD genetic modifier studies have previously investigated the effects of the 
APOE on age of onset with conflicting results. APOE ε4 allele appeared to delay onset 
(Panas, Avramopoulos et al. 1999) and APOE ε2ε3 genotype was associated with an 
earlier onset in males than females (Kehoe, Krawczak et al. 1999). However, these 
reports have been followed by a number of negative studies using a larger number of 
samples (Saft, Andrich et al. 2004; Andresen, Gayan et al. 2007).  We feel that APOE 
merits further study and that the large cohort of REGISTRY samples might resolve the 
questions of whether or not APOE is a modifier of HD. 
5.2 Contributions and Collaborations 
The author and Sarah Tabrizi were responsible for the concept, design and data 
interpretation of the study with input from Peter Holmans and Lesley Jones.  The author 
performed all the laboratory work and data processing under the supervision of Simon 
Mead and Jon Beck.  The author contributed to age of onset and phenotypic data 
collected in the TRACK-HD and REGISTRY studies as a named co-investigator.   The 
full list of co-investigators for TRACK-HD is given in Appendix B and for REGISTRY 
is given in Appendix C.  Statistical analyses were performed jointly by the author and 
Denise Harold under the supervision of Peter Holmans. 
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5.3 Methods 
5.3.1 Subjects 
Data from two longitudinal, multicentre, observational research studies were analysed; 
the European Huntington’s Disease Network’s REGISTRY study (Orth, Handley et al. 
2011), which collects data in Europe from symptomatic and premanifest HD gene 
expansion carriers and TRACK-HD (Tabrizi, Langbehn et al. 2009), a prospective 
observational biomarker study of premanifest and early stage HD at 3 European (UK, 
France, the Netherlands) and 1 Canadian site. 
An application was made to the REGISTRY SBAC for DNA samples and clinical 
information as specified in Section 2.2.3.  A total of 1832 samples were received.  From 
TRACK-HD, samples and clinical information for all premanifest gene carriers and 
subjects with manifest HD were genotyped. 
5.3.2 Genotyping 
DNA was extracted using standard techniques by Biorep® Technologies Inc., (Milan, 
Italy) and CAG repeat sizes were determined as outlined in section 2.5.1.  
1 SNP from each candidate gene; CLU (rs7982), CR1 (rs1408077), PICALM 
(rs3851179) and 2 SNPs in APOE (rs429358 and rs7412) were selected based on 
previous study (Harold, Abraham et al. 2009; Lambert, Heath et al. 2009).  
All samples were genotyped using an allelic discrimination assay on the Applied 
Biosystems 7500 FAST Real Time Polymerase Chain Reaction (PCR) instrument with 
TaqMan ® probes.  TaqMan® pre-designed SNP Genotyping Assays were purchased 
from Applied Biosystems (Applied Biosystems, Foster City, CA, USA).  Assays 
included primers and fluorescently labelled FAM™ and VIC® MGB™ probes for 
detection of both alleles.  Samples were prepared on a MicroAmp™ Optical 96-Well 
reaction plate using a reaction volume of 25µl per sample comprising 12.5µl 2xTaqMan 
Universal PCR Master Mix, No AmpErase UNG (PN 4324018), 1.25 20X SNP 
Genotyping Assay, 10.25µl of DNase-free water and 1µl of DNA at a concentration of 
20ng/µl.  PCR was carried out with the following conditions; 10 minutes at 94oC 
followed by 40 cycles of 15 seconds at 92oC and 1 minute at 60oC followed by a hold at 
4oC.  Allele discrimination was carried out in Applied Biosystems 7500 Fast System 
Sequence Detection Software v1.3.1 and downloaded to Microsoft® Excel. 
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5.3.3 Statistics 
The relationship between age of onset of Huntington disease and CAG repeat length in 
curvilinear.  To model this relationship, we fitted a simple linear regression predicting 
the natural log of age of onset of HD from CAG repeat length (Figure 32).  To evaluate 
the effect of genetic markers in candidate genes on age of onset of HD, we included 
these markers as predictors in the regression model.  Age, sex, large CAG repeat length 
and study region were included as covariates in the model.  Analysis was carried out in 
PLINK (Purcell, Neale et al. 2007).  
  
5.4 Results 
838 subjects from REGISTRY and 131 subjects from TRACK-HD were included in the 
analysis giving a total of 969 cases.  The demographic details of the participants are 
shown in Table 13. 
 
Demographic Mean (± SD) unless otherwise indicated 
Sex M=481 
Age at Onset 44.9 (±11.76) 
CAG (Large) 44.28 (range 36-68) 
Table 13 Demographic details of subjects included in genetic modifiers study 
Total n=969 
 
The mean age at onset was 44.94 years (SD ± 11.76). There was a significant negative 
correlation between large CAG repeat length and age of motor onset (r2=0.59, 
p,<0.0001) (see Figure 32).  Consistent with other studies, the large CAG repeat length 
accounted for 59% of the variability in age of onset. 
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Figure 32 Age at motor onset in TRACK-HD and REGISTRY studies 
5.4.1 Effects of SNPs on Age at onset 
5.4.1.1 Motor onset 
For the genotypes at each individual locus we did not find any evidence of an 
association with motor age of onset as shown in Table 14. 
 
Gene SNP Additive p-value 
CR1 rs1408077 0.675 
CLU rs7982 0.895 
PICALM rs3851179 0.984 
APOE codon 158 rs429358 0.117 
APOE codon 112 rs7412 0.451 
APOE genotype  0.867 
Table 14 P-values from linear regression between variables analysed and age at 
motor onset 
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5.5 Conclusions 
In this cohort, approximately 60% of the variance in age of onset is attributable to the 
length of the large CAG repeat.  The goal of this study was to investigate whether 
genetic polymorphisms in other genes; CLU, CR1, PICALM or APOE could account for 
some of the remaining 40% of variance.  None of the polymorphisms investigated in 
this study revealed an association with age of onset.  However, this study does not 
exclude the possibility that other DNA variants in these genes, or in other genes 
involved in these pathways, may act as genetic modifiers   
As already discussed in Section 1.4, genetic studies have suggested over 20 loci that 
may modify age of onset or progression of HD. Many of the specific polymorphisms 
assessed in multiple studies have failed to replicate. One recent study has exposed 
genetic ancestry as a critical factor in HD association studies (Ramos, Latourelle et al. 
2012).  Though only ‘Caucasian’ samples were included in this study, genetic 
background was not corrected for.  Larger samples sizes are better powered to reveal 
genetic modifiers.  To increase the power of this study, two different study populations 
were included any differences between them may also have affected the analysis.  This 
is discussed further in Chapter 6.  
Another complicating factor in the search for genetic modifiers is that age-related 
instability of the HD allele may increase the severity of disease process.  Studies have 
shown that somatic expansions of the CAG repeat in the brain are associated with an 
earlier age of disease onset (Veitch, Ennis et al. 2007; Swami, Hendricks et al. 2009).  It 
is challenging to investigate this phenomenon in large-scale genetic modifier studies of 
peripheral blood or to control for somatic effects in age of onset studies. However, it 
may be that investigating the processes involved in generating these somatic CAG 
repeat length differences might itself yield potential modifiers. 
5.6 Future Work 
Whilst candidate genetic studies are a valuable approach to identifying potential genetic 
modifiers of age of onset alternative approaches may prove more successful.  GWAS 
studies to investigate common DNA variants that may be associated with age of onset in 
HD are ongoing but are yet to report.  Recent advances in next-generation sequencing 
technologies now allow cost-effective methods for whole genome sequencing to 
investigate both rare and common variation.  One approach, which may be fruitful, in 
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HD would be to examine individuals with extremes of phenotype; ie.to carry out whole 
genome sequencing to examine variants in those whose onset is either much earlier or 
much later than predicted by their CAG repeat size.  This approach is being investigated 
in the TRACK-HD cohort. 
An alternative approach would be to investigate epigenetic changes, including DNA 
methylation and histone modifications.  Epigenetic pathways act as mediators between 
the environment and the genome and can be activated by various conditions such as 
stress or exposure to environmental toxins to result in a variety of responses including 
gene transcription or silencing.   
Epigenetic changes are dynamic and unlike genetic mutations, they can be reversed for 
therapeutic purposes by targeting enzymes or other factors that control or maintain 
them.  Investigation of epigenetic changes as part of the variability in age of onset may 
be of particular relevance in HD given the interest in HDAC inhibitors and sirtuin 
inhibitors as potential disease modifying agents. 
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6  THE IMPORTANCE OF ACCURATELY RECORDING AGE OF 
ONSET IN HUNTINGTON’S DISEASE 
6.1 Introduction 
As discussed earlier in this thesis, identifying modifiers of age of onset in HD may help 
to elucidate pathogenic mechanisms and hence provide therapeutic targets for the 
disease for which, at present, no disease modifying treatments are available.  In 
addition, understanding of modifying factors may help us to more accurately estimate 
age of onset, which would be of paramount importance in clinical trials of disease 
modifying therapies in pre-symptomatic HD gene carriers. 
Robust genetic modifiers of other neurodegenerative diseases, such as Alzheimers 
Disease and Parkinson’s Disease have been identified through both candidate gene 
studies and GWAS (Gasser, Hardy et al. 2011; Bertram and Tanzi 2012).  In HD, as 
already discussed, a number of potential genetic modifiers have been but many have 
failed to replicate in subsequent studies.  Further, higher resolution, genome-wide 
association studies are planned but none have yet been reported.   
Genetic modifier studies in HD are complicated by the fact that the expanded CAG 
repeat already accounts for much of the observed variation in age of onset but also due 
to the smaller numbers of subjects, differences in the genetic background between 
subjects and, possibly, variability in the data collected.   
Collaborative studies such as the European Huntington’s Disease Network’s 
REGISTRY study (Orth, Handley et al. 2011) and the Huntington Study Group’s 
COHORT study (Dorsey 2012) have made large scale genetic modifier identification 
projects possible by making large sets of comparable data available for study.  Smaller, 
but more rigorously controlled studies, such as TRACK-HD may provide more robust 
data sets but the power to identify genetic modifiers is likely to be limited by their size.  
The aim of this study was to investigate whether the ages of onset for a given CAG 
repeat length are comparable between large scale, clinically less detailed, and smaller 
scale, more detailed, observational studies of HD.  
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6.2 Contributions and Collaborations 
The author and Sarah Tabrizi were responsible for the concept, design and data 
interpretation of the study with input from Peter Holmans, Lesley Jones and Doug 
Langbehn.  The author contributed to data collected as part of the TRACK-HD and 
REGISTRY studies as a co-investigator.  The full list of co-investigators for TRACK-
HD is given in Appendix B and for REGISTRY is given in Appendix C.  The data was 
collated and processed by the author. Denise Harold carried out the statistical analysis. 
6.3 Methods 
6.3.1 Subjects 
Retrospective data from two on going longitudinal, multicentre, observational research 
studies were analysed: the European Huntington’s Disease Network’s REGISTRY 
study (Orth, Handley et al. 2011), which collects data in Europe from symptomatic and 
premanifest HD gene expansion carriers and TRACK-HD (Tabrizi, Langbehn et al. 
2009), a prospective observational biomarker study of premanifest and early stage HD 
at 3 European (UK, France, the Netherlands) and 1 Canadian site. 
In both studies age of onset in symptomatic subjects is estimated retrospectively by a 
‘rater’ via a combination of questioning the participant and their relatives, and 
examination of their medical records. Prospective estimation of age of onset occurs 
during both studies for premanifest gene carriers via a combination of physical 
examination using the Unified Huntington’s Disease Rating Scale (motor component) 
and questioning the participants, their relatives and examination of their medical 
records.   
Data from all participants recorded as having symptomatic HD and a DNA sample that 
had been genotyped for the CAG expansion were requested.  
All Caucasian individuals (131) from TRACK-HD with a recorded age at motor onset 
were included in the analysis.  
From the REGISTRY study data, the age of onset was taken to be the earliest age at 
which symptoms had appeared as determined by the rater.  Only Caucasian subjects 
were included in these analyses.  Only those with ‘motor’ symptoms as the prevalent 
symptom at onset were included in this study. The final number of subjects from 
REGISTRY included in the analysis was 838.  
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6.3.2 CAG Genotyping 
CAG repeat sizes were determined as outlined in section 2.5.1. 
6.3.3 Statistical Analysis 
Motor age of onset was used as the dependent variable in an analysis of covariance 
(ANCOVA), to test for a difference in the mean age of onset between studies after 
adjusting for the expanded CAG repeat length and gender.  
To correct for potential differences in populations between the two studies, we went on 
to repeat the analysis with Caucasian subjects from the 3 European TRACK-HD sites 
(94 subjects) and REGISTRY sites from those 3 countries; UK, France and Netherlands 
(259 subjects). 
The analysis was then repeated to perform a comparison between the mean adjusted age 
of onset of all countries within each study. 
6.4 Results 
The demographics details of the 2 cohorts are presented in Table 15.  The ages of onset 
for a given CAG repeat length for each cohort are shown in Figure 33.  The expanded 
CAG repeat length accounted for 59% of the age of onset for each study and was not 
significantly different between studies. 
 REGISTRY TRACK-HD 
N 838 131 
Sex M=412 (49%) M=69 (53%) 
Mean CAG 44.38 (36-68) 43.58 (39-59) 
Mean adjusted age of onset 45.2 43.2 
Stage at visit 1 :    
PM*/Stage 1 (TFC≥11) 35% 66% 
Stage 2 (TFC 7-10) 33% 44% 
Stage 3+ (TFC ≤6) 32% 0 
TMS at visit 1  37.37 (SD ± 20.1) 21.34 (SD ± 12.32) 
Age at visit 1 - Age at diagnosis 6.54 (SD ± 5.0) 3.53 (SD ± 3.52) 
Table 15 Demographic details of REGISTRY and TRACK-HD subjects include in 
age of onset study.  
*PM; premanifest 
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The mean adjusted age of onset (when covaried for sex and large CAG repeat length) in 
REGISTRY was 45.2 years (95%CI 44.7-45.7) and in TRACK-HD 43.2 years (95%CI 
42.0-44.5). These are significantly different (p=5x10-3).   
Figure 33 Age of onset in TRACK-HD and REGISTRY Studies. 
 
As population-dependent differences in age of onset of HD have previously been noted 
in Europe (Ramos, Latourelle et al. 2012), an analysis including only the subjects from 
geographical areas common to both studies was performed.  The mean adjusted age of 
onset in UK, France and the Netherlands in the REGISTRY study were 47.0 years (95% 
CI 46.1-47.9) and in TRACK-HD were 43.888 years (95% CI 42.3-45.4).  These are 
also significantly different (p=1x10-3).  
From these results it appeared that the mean adjusted age of onset between the UK, the 
Netherlands and France was almost 2 years later than the whole REGISTRY cohort.  To 
formally test whether this difference in adjusted age of onset was statistically 
significant, mean adjusted age of onset between the UK, the Netherlands and France 
and the rest of the REGISTRY study were compared.  There was no significant 
difference.   
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6.5 Discussion 
The mean age of onset of motor symptoms in TRACK-HD is two years earlier than in 
the REGISTRY study.  This difference remains significant when analysis is restricted to 
matching populations between the 2 studies.  The expanded CAG repeat length does not 
account for this difference.   
Taking the initial results, the age of onset in sites from the UK, France and the 
Netherlands alone were nearly 2 years later than the age of onset in the full REGISTRY 
cohort. This is consistent with the observation that population stratification may bias 
analysis of genetic modifier studies (Ramos, Latourelle et al. 2012).  However, when 
this was formally tested, there was no significant difference in age of onset across the 
REGISTRY study.     
The difference in age of onset between TRACK-HD and REGISTRY are likely to 
represent systematic differences in data collection rather than genetic differences 
between the populations studied.  The TRACK-HD cohort is smaller and more 
rigorously characterised with the assessments being carried out by a small number of 
highly trained raters.  In addition, as the study enrolled either early stage HD subjects or 
premanifest HD gene carriers (11% compared to 3.6% in REGISTRY) who may have 
started to show some symptoms during the course of the study, the age of onset was 
more recent (on average within 3.5 years of the first visit) and therefore likely to be 
subject to fewer recollection biases.    
If the discrepancy in age of onset between these two observational studies of HD is 
widely applicable, this is likely to reduce the power of any genetic modifier studies in 
HD unless it is recognised and dealt with.  Controlling any studies for geographical 
location is also likely to be critical as in HD, in order to obtain the sample size needed 
for many genome-wide studies, data from many countries is likely to be aggregated: the 
Registry study has at least 136 study sites from 16 countries contributing (Orth, 
Handley et al. 2011) and ENROLL aims to have over 200 sites in 30 countries 
contributing (http://clinicaltrials.gov/ct2/show/NCT01574053).   
Our findings may provide part of the explanation as to why genetic modifier studies in 
HD have not been as successful or reproducible as studies in other, more common 
neurodegenerative disease.  GWAS in other diseases have primarily been aimed at 
identifying genetic loci influencing presence or absence of disease as a dichotomous 
trait.  In HD the modifier with largest influence on age at onset is already known to be 
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the size of the expanded CAG repeat. The previous linkage studies in HD were powered 
to find relatively high-risk variants for onset modification and therefore it is most likely 
that genetic loci influencing age of onset are of moderate or low risk. Discrepancies in 
ages of onset in HD in the order of 2 years are likely to substantially reduce the power 
to identify low to moderate risk modifiers. 
We have not investigated discrepancies in the onset of symptoms other than motor 
symptoms, as the numbers are smaller.  In previous versions of REGISTRY, earliest age 
of onset were recorded with the predominant symptom. These data are now being re-
defined with the introduction of an ‘HD clinical characteristics’ questionnaire trialled as 
part of TRACK-HD, which aims to give ages of onset for major HD symptoms.  It is 
possible that the variability in different clinical characteristics are due to a variety of 
heritable and environmental factors, so these data will be useful in future genetic 
analyses.  
These results highlight the importance of data collection of the highest quality and of 
understanding the differences in data collection within studies.  With the advent of the 
ENROLL-HD study, a global observational study of HD, whose subjects are likely to 
contribute to global genetic modifier studies, it is paramount that data collection is 
rigorous and reproducible and that raters are adequately trained.  Analyses of these data 
must take into account both the genetic differences and systematic differences in data 
collection between all the participating sites.  
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7 CONCLUSIONS 
The aims of this thesis were to;  
 
1. Identify robust imaging and clinical biomarkers that could be used reliably in 
clinical trials through the TRACK-HD study. 
2. To further investigate the phenomena of microglial activation and 
hyperstimulation of the peripheral immune system with the particular aim of 
developing them as biomarkers of disease onset and progression in premanifest 
HD. 
3. To identify potential genetic modifiers of disease onset and progression. 
 
One of the potential reasons why previous therapeutic trials in HD have failed to show 
efficacy is the use of measures that, perhaps, are not sensitive to change in HD over the 
timescale of the studies.  TRACK-HD was an ambitious study which has assessed the 
ability of various outcome measures to track disease progression when administered 
annually at four highly trained sites in premanifest and early manifest stages of HD.  
The study was incredibly successful in demonstrating that robust data acquisition over a 
wide range of disciplines and within the strict time scales required for a pharmaceutical 
company sponsored clinical trial is possible in HD.  In addition, a number of imaging, 
and clinical measures that would be relatively straightforward to administer in a clinical 
research facility have successfully been validated for use in trials of early HD.  
However, the selection of a battery of outcome measures for any given clinical trial will 
depend on multiple factors including the phase of trial, disease stage, numbers of 
subjects and sites, duration, cost, expected primary endpoint and mechanism of action 
of the putative therapeutic agent. The longitudinal results of TRACK-HD are most 
relevant for the design of Phase IIb and III clinical trials aimed at slowing the 
progression of the disease in the early stages of disease. The performance of these 
outcome measures in trials may be different, as it is likely that assessments will be 
performed more frequently, that practice effects will be minimized by prior exposure to 
the battery, and that the comparison will be drug to placebo rather than HD to control. 
Furthermore, the assessment of outcome measures by how they track disease 
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progression discounts the potential for signs of disease to actually improve, and this is 
clearly the aim of future disease-modifying therapies.   
Whilst TRACK-HD has been an incredibly successful study, there is still work to be 
done.  The imaging markers have far out-performed the clinical measures tested and 
there remains potential for the development of more sensitive clinical assessments.  In 
particular, the oculomotor assessments have not performed as well as expected at the 
outset of the study and it may be that a better understanding of the eye movement 
abnormalities in HD, analysis of other variables within the oculomotor battery or 
development of a more sensitive device might create a more robust marker of disease 
progression.  The Gaitrite gait assessment was removed from the TRACK-HD battery 
after baseline.  In the cross-sectional analysis it was able to distinguish between 
premanifest HD and controls and between HD and controls but was not sensitive within 
groups.  The main consideration for the removal of the Gaitrite device was for practical 
reasons.  It was unwieldy and a challenge to store.  There is great scope for the 
development of a smaller device which is more easily operated, particularly with the 
widespread availability of wireless technology, sensors which can be attached to the 
ankles, for example, would be much less cumbersome and generate more natural data.  
The cognitive and neuropsychiatric assessments are beyond the scope of this thesis, 
however, measures with functional relevance will be of paramount importance when 
data from clinical trials are assessed by drug regulatory authorities and more sensitive 
tools are still required. 
With hindsight it seems unfeasible that measures designed to detect progression in early 
HD would also be sensitive in the premanifest period. This may reflect the different 
pathogenic processes with neuronal dysfunction predominating in the premanifest 
period and neuronal death in manifest HD.  Premanifest subjects did show progression, 
as measured by imaging markers, over a 24 month period but the clinical measures were 
less clear and even over 36 months TRACK-HD has not been able to define a battery of 
assessments with effect sizes suitable for use in trials of premanifest HD (Tabrizi, 
Scahill et al 2013).  The TRACK-On study has been designed to address this and to 
evaluate novel measures aimed particularly at detecting change in the premanifest 
cohort.   
 
With the aim of developing novel biomarkers of disease onset and progression, 
particularly in the premanifest stage, I investigated the potential of microglial activation, 
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as measured by PK PET imaging, and peripheral markers of immune activation in a 
well-characterised subgroup of premanifest subjects from TRACK-HD. From this 
study, PK PET seems to be a marker of subclinical motor progression and could be 
helpful in stratifying those that are closer to motor onset in clinical trials of disease 
modifying agents. Longitudinal studies are required to assess its potential as a 
biomarker of disease onset or progression though it may be particularly useful as a 
marker of ‘target engagement’ in trials of therapies which interact with microglia, in 
particular, KMO inhibitors. 
Of particular value in tracking progression of HD, would be the development of a 
biomarker from peripheral blood especially because of the ease of obtaining blood 
samples and the availability of sensitive assays.  HD monocytes are hyper-reactive, 
characterised by increased cytokine production upon LPS stimulation.  Despite early 
promise, in this cohort, monocyte stimulation in the periphery did not reflect central 
microglial activation and it does not seem that plasma or monocyte derived cytokines 
would not be a suitable alternative to PK-PET imaging as a biomarker. The variability 
of peripheral immune markers is disappointing but not unexpected as smoking, diet and 
exercise are all factors known to alter peripheral cytokine levels.  Preliminary data 
investigating measurement of total and mHTT levels in immune cells has revealed that 
mHTT levels in monocytes, T cells and B cells differ significantly between HD patients 
and controls, as well as between premanifest and manifest patients and may provide a 
more robust marker of progression (Weiss A et al., 2012).  Peripheral immune 
activation does seem to be an early and sustained phenomenon in HD, however, and 
study of the mechanisms involved may still provide novel therapeutic targets.  Further 
study has revealed the increased cytokine production to be caused by dysregulation of 
the NFκB pathway (Träger et al 2013).  Work from this group has also demonstrated 
that by lowering HTT levels in primary human HD monoctyes and macrophages, HD-
specific phenotypes such as increased cytokine production and transcriptional 
dysregulation can be, at least, partially reversed 
 
The peripheral immune activation described in HD prompted the study of variability in 
genes related to the immune system dysfunction and linked to Alzheimer’s Disease 
pathogenesis that I have presented here.  I have not been successful in identifying 
potential genetic modifiers of age on onset in this thesis.  I am not alone and the hunt for 
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genetic modifiers in HD has not, to date, yielded strong and reproducible candidates.  
GWAS data analysis is ongoing and may prove more fruitful.  However, this thesis has 
highlighted the importance of accurate and rigorous data acquisition in observational 
studies which will contribute to future large-scale modifier studies.  The collection of 
age of onset data through existing studies, such as REGISTRY, is retrospective and 
subject to biases on the part of both the rater and the subject.  Data collected 
prospectively within these studies are likely to be more robust and for this reason, 
genetic modifers of rate of progression rather than age of onset may be more readily 
identifiable. It is still possible that such studies will identify genes which lie within 
immune pathways as potential modifiers. In addition, further study of epigenetic 
phenomena in HD, such as the investigation of histone modification and chromatin 
remodelling is warrented given the relevance of epigenetics to the interaction between 
genes, the environment and the immune system. 
“…I have never known a recovery or even an amelioration of 
symptoms in this form of chorea; when once it begins it clings to the 
bitter end.  No treatment seems to be of any avail…It seems at least 
to be one of the incurables….I know nothing of it’s pathology. I have 
drawn your attention to this form of chorea gentlemen, not that I 
considered it of any great practical importance to you, but merely as 
a medical curiosity, and as such it may have some interest.” 
(Huntington 1872) 
 
These are the final words from George Huntington’s article on chorea.  Though HD 
remains ‘incurable’ there are now interventions which significantly improve the lives of 
those affected and we have accumulated a considerable knowledge of it’s pathology.   
Most importantly, the HD community is edging closer to trials of disease modifying 
therapies and studies like TRACK-HD and REGISTRY have been instrumental in this.   
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APPENDICES 
 Appendix A: UHDRS-99 
 
REGISTRY V3
UNIFIED HUNTINGTON'S DISEASE RATING SCALE '99 - MOTOR ASSESSMENT
Study Site: Subject:
Examiner: Date info obtained:
D D
.
M M
.
Y Y Y Y
All items must be completed. Use U if information is unavailable. Use N if information is not applicable.
General
Motor score:
Motor Assessment
Ocular pursuit:
0 = complete (normal)
1 = jerky movement
2 = interrupted pursuits/full range
3 = incomplete range
4 = cannot pursue
Horizontal Vertical
Saccade initiation:
0 = normal
1 = increased latency only
2 = suppressible blinks or head movements to initiate
3 = unsupressable head movements
4 = cannot initiate saccades
Horizontal Vertical
Saccade velocity:
0 = normal
1 = mild slowing
2 = moderate slowing
3 = severely slow, full range
4 = incomplete range
Horizontal Vertical
Dysarthria:
0 = normal
1 = unclear, no need to repeat
2 = must repeat to be understood
3 = mostly incomprehensible
4 = anarthria
Tongue protrusion:
0 = can hold tongue fully protruded for 10 sec
1 = cannot keep fully protruded for 10 sec
2 = cannot keep fully protruded for 5 sec
3 = cannot fully protrude tongue
4 = cannot protrude tongue beyond lips
Finger taps:
0 = normal (≥15/5 sec.)
1 = mild slowing, reduction in amplitude (11-14/5 sec.)
2 = moderately impaired (7-10/5 sec.)
3 = severely impaired (3-6/5 sec.)
4 = can barely perform task (0-2/5 sec.)
Right Left
Pronate/supinate-hands:
0 = normal
1 = mild slowing and/or irregular
2 = moderate slowing and irregular
3 = severe slowing and irregular
4 = cannot perform
Right Left
1 / 3
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REGISTRY V3
UNIFIED HUNTINGTON'S DISEASE RATING SCALE '99 - MOTOR ASSESSMENT
Study Site: Subject:
Examiner: Date info obtained:
D D
.
M M
.
Y Y Y Y
All items must be completed. Use U if information is unavailable. Use N if information is not applicable.
Luria:
0 = ≥4 in 10 sec, no cue
1 = <4 in 10 sec, no cue
2 = ≥4 in 10 sec with cues
3 = <4 in 10 sec with cues
4 = cannot perform
Rigidity-arms:
0 = absent
1 = slight or present only with activation
2 = mild to moderate
3 = severe, full range of motion
4 = severe with limited range
Right Left
Bradykinesia-body:
0 = normal
1 = minimally slow (?normal)
2 = mildly but clearly slow
3 = moderately slow, some hesitation
4 = markedly slow, long delays in initiation
Maximal dystonia:
0 = absent
1 = slight/intermittent
2 = mild/common or moderate/intermittent
3 = moderate/common
4 = marked/prolonged
Trunk
RUE
LUE
RLE
LLE
Maximal chorea:
0 = absent
1 = slight/intermittent
2 = mild/common or moderate/intermittent
3 = moderate/common
4 = marked/prolonged
Face
BOL
Trunk
RUE
LUE
RLE
LLE
Gait:
0 = normal gait, narrow base
1 = wide base and/or slow
2 = wide base and walks with difficulty
3 = walks only with assistance
4 = cannot attempt
2 / 3
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REGISTRY V3
UNIFIED HUNTINGTON'S DISEASE RATING SCALE '99 - MOTOR ASSESSMENT
Study Site: Subject:
Examiner: Date info obtained:
D D
.
M M
.
Y Y Y Y
All items must be completed. Use U if information is unavailable. Use N if information is not applicable.
Tandem walking:
0 = normal for 10 steps
1 = 1 to 3 deviations from straight line
2 = >3 deviations
3 = cannot complete
4 = cannot attempt
Retropulsion pull test:
0 = normal
1 = recovers spontaneously
2 = would fall if not caught
3 = tends to fall spontaneously
4 = cannot stand
Diagnostic Confidence
Diagnostic confidence level:
0 = Normal (no abnormalities)
1 = non-specific motor abnormalities (less than 50 % confidence)
2 = motor abnormalities that may be signs of HD (50 - 89 % confidence)
3 = motor abnormalities that are likely signs of HD (90 - 98 % confidence)
4 = motor abnormalities that are unequivocal signs of HD ≥ 99 % confidence)
3 / 3
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REGISTRY V3
UNIFIEDHUNTINGTON'SDISEASERATINGSCALE '99 - TOTALFUNCTIONALCAPACITY
Study Site: Subject:
Examiner: Date info obtained:
D D
.
M M
.
Y Y Y Y
All items must be completed. Use U if information is unavailable. Use N if information is not applicable.
General
Functional score:
Functional Capacity
Occupation:
0 = unable
1 = marginal work only
2 = reduced capacity for usual job
3 = normal
Finances:
0 = unable
1 = major assistance
2 = slight assistance
3 = normal
Domestic chores:
0 = unable
1 = impaired
2 = normal
ADL:
0 = total care
1 = gross tasks only
2 = minimal impairment
3 = normal
Care level:
0 = full time skilled nursing
1 = home or chronic care
2 = home
Information Sources:
Was the information obtained from:
1 = participant only
2 = participant and family/companion
Adopted from 1999 Huntington Study Group. 1 / 1
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REGISTRY V3
HUNTINGTON'S DISEASE RATING SCALE '99 - FUNCTIONAL ASSESSMENT
Study Site: Subject:
Examiner: Date info obtained:
D D
.
M M
.
Y Y Y Y
All items must be completed. Use U if information is unavailable. Use N if information is not applicable.
General
Functional Assessment Score:
Functional Assessment
For the next 25 questions, please use:
1 = yes
0 = no
Could subject engage in gainful employment in his/her accustomed work:
Could subject engage in any kind of gainful employment?
Could subject engage in any kind of volunteer or non-gainful work?
Could subject manage his/her finances (monthly) without any help?
Could subject shop for groceries without help?
Could subject handle money as a purchaser in a simple cash (shop) transaction?
Could subject supervise children without help?
Could subject operate an automobile safely and independently?
Could subject do his/her own housework without help?
Could subject do his/her own laundry (wash/dry) without help?
Could participant prepare his/her own meals without help?
Could subject use the telephone without help?
Could subject take his/her own medications without help?
Could subject feed himself/herself without help?
Could subject dress himself/herself without help?
Could subject bathe himself/herself without help?
Could subject use public transportation to get places without help?
Could subject walk to places in his/her neighbourhood without help?
Could subject walk without falling?
Could subject walk without help?
Could subject comb hair without help?
Could subject transfer between chairs without help?
Could subject get in and out of bed without help?
Could subject use toilet/commode without help?
Adopted from 1999 Huntington Study Group. 1 / 2
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REGISTRY V3
HUNTINGTON'S DISEASE RATING SCALE '99 - FUNCTIONAL ASSESSMENT
Study Site: Subject:
Examiner: Date info obtained:
D D
.
M M
.
Y Y Y Y
All items must be completed. Use U if information is unavailable. Use N if information is not applicable.
Could subject's care still be provided at home?
Information sources:
Was the functional assessment information obtained from:
1 = subject only
2 = subject and family/companion
Independence Scale
Subject's independence in %:
100 = no special care needed
95
90 = no physical care needed if difficult tasks are avoided
85
80 = pre-disease level of employment changes or ends; cannot perform household chores to pre-disease
level, may need help with finances
75
70 = self-care maintained for bathing, limited household duties, e.g. cooking and use of knives, driving
terminates; unable to manage finances
65
60 = needs minor assistance in dressing, toileting, bathing; food must be cut for subject
55
50 = 24-hour supervision appropriate; assistance required for bathing, eating, toileting
45
40 = chronic care facility needed; limited self feeding, liquified diet
35
30 = subject provides minimal assistance in own feeding, bathing, toileting
25
20 = no speech, must be fed
15
10 = tube fed, total bed care
5
Adopted from 1999 Huntington Study Group. 2 / 2
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 Appendix B: TRACK-HD co-investigators 
 Last name First name Location 
1.  Axelson Eric Iowa 
2.  Bechtel Natalie Muenster 
3.  van den Bogaard Simon J.A.  LUMC, Leiden  
4.  Callaghan Jenny Manchester 
5.  Bohlen Stefan Muenster 
6.  Campbell Colin Indiana/Monash 
7.  Campbell Melissa Monash 
8.  Cash David M. IXICO 
9.  Coleman Allison  UBC, Vancouver  
10.  Dar Santos Rachelle UBC, Vancouver  
11.  Decolongon Joji UBC, Vancouver 
12.  Dumas Eve M. LUMC, Leiden  
13.  Fox Nick C UCL 
14.  van der Grond   Jeroen  LUMC, Leiden 
15.  ‘t Hart Ellen P. LUMC, Leiden 
16.  Hobbs Nicola Z UCL 
17.  Jauffret Celine  Paris  
18.  Justo Damian  Paris  
19.  Lahiri Nayana  UCL 
20.  Lehericy Stéphane Paris 
21.  Malone Ian UCL 
22.  Marelli Cecilia Paris  
23.  Milchman Cassie Monash 
24.  Nigaud Kevin Paris 
25.  Pepple Tracey UCL 
26.  Queller Sarah Indiana 
27.  Read Joy  UCL  
28.  Say Miranda J UCL  
29.  Sturrock Aaron UBC, Vancouver  
30.  Valabrègue  Romain Paris 
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31.  Wild Edward UCL 
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 Appendix C: REGISTRY co-investigators 2004-2010  
 
Registry Steering committee:  A-C Bachoud-Lévi, AR Bentivoglio, I Biunno, RM 
Bonelli, J-M Burgunder, SB Dunnett, JJ Ferreira, OJ Handley, A Heiberg, T Illmann, 
GB Landwehrmeyer, J Levey, Maria Dolores Martinez-Jaurrieta, JE Nielsen, S Pro 
Koivisto, M Päivärinta, RAC Roos, A Rojo Sebastián, SJ Tabrizi, W Vandenberghe, C 
Verellen-Dumoulin, J Zaremba, T Uhrova, J Wahlström 
 
Language coordinators: Katrin Barth, Leonor Correia-Guedes, Ana Maria Finisterra, 
Monica Bascuñana Garde, Reineke Bos, Sabrina Betz; Daniel Ecker, Olivia J Handley, 
Christine Held, Kerstin Koppers; Matilde Laurà, Asunción Martínez Descals, Tiago 
Mestre, Sara Minster, Daniela Monza, Jenny Townhill, Helene Padieu, Laurent 
Paterski; Nadia Peppa, Susana Pro Koivisto, Amandine Rialland, Niini Røren (formerly 
Heinonen) Pavla Šašinková, Patricia Trigo Cubillo, Marleen R van Walsem, Marie-
Noelle Witjes-Ané, Elizaveta Yudina, Daniel Zielonka, Eugeniusz Zielonka; Paola 
Zinzi 
 
AUSTRIA 
 
Graz (LKH Graz, Abteilung für Psychiatrie): Raphael M. Bonelli; Brigitte Herranhof;  
Anna Holl (formerly Hödl); Hans-Peter Kapfhammer; Michael Koppitz; Markus 
Magnet; Daniela Otti; Annamaria Painold; Karin Reisinger; Monika Scheibl; Karen 
Hecht; Sabine Lilek; Nicole Müller; Helmut Schöggl; Jasmin Ullah 
 
Innsbruck (Universitätsklinik Innsbruck, Neurologie): Florian Brugger; Caroline 
Hepperger; Anna Hotter; Klaus Seppi; Gregor Wenning; Lisa Buratti; Eva-Maria 
Hametner; Christiane Holas; Eva-Maria Hametner; Anna Hussl; Werner Poewe; Eva-
Maria Braunwarth; Fabienne Sprenger; Christoph Müller 
 
BELGIUM 
 
Charleroi (Institut de Pathologie et de Génétique (IPG): Pascale Ribaï; Christine 
Verellen-Dumoulin 
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Leuven: (Universitair Ziekenhuis Gasthuisberg,): Andrea Boogaerts; Wim 
Vandenberghe;  Dimphna van Reijen 
 
CZECH REPUBLIC 
 
Prague (Extrapyramidové centrum, Neurologická klinika, 1. LF UK a VFN):  Jiří 
Klempíř; Veronika Majerová; Jan Roth 
 
DENMARK 
 
Copenhagen University Hospital (Rigshospitalet, Memory clinic): Jørgen Nielsen; Lena 
Hjermind, Oda Jacobsen, Tua Vinthev-Jensen; Ida Unmack Larsen, Jette Stockholm 
FINLAND 
 
Turku-Suvituuli (Rehabilitation Centre Suvituuli): Heli Hiivola; Kirsti Martikainen; 
Katri Tuuha 
 
Oulu (Dep. of Neurology): Jaakko Ignatius; Mikko Kärppä; Jaana Åman 
 
Oulu (Dep. of Medicak Genetics): Aki Mustonen, Outi Kajula 
 
Tampere (Terveystalo Healthcare Service Centre); Maire Santala 
 
FRANCE 
 
Angers (Centre de référence des maladies neurogénétique- CHU d’Angers): Philippe 
Allain ; Dominique Bonneau, Marie-Anne Guérid ; Bénédicte Gohier ; Audrey Olivier ; 
Adriana Prundean ; Clarisse Scherer-Gagou ; Christophe Verny ; Marie Bost,  
 
Marseille (Hôpital La Timone): Jean-Philippe Azulay; Christelle Chabot ; Marie Delfini 
; Alexandre Eusebio ; Hélène Grosjean ; Laura Mundler ; Marielle Nowak 
 
GERMANY 
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Aachen (Universitätsklinikum Aachen, Neurologische Klinik): Christoph Michael 
Kosinski; Eva Milkereit ; Daniela Probst; Kathrin Reetz, Christian Sass; Johannes  
Schiefer; Christiane Schlangen; Cornelius J. Werner 
 
Bochum (Huntington-Zentrum (NRW) Bochum im St. Josef-Hospital): Jürgen Andrich;  
Gisa Ellrichmann, Rainer Hoffmann; Barbara Kaminski, Carsten Saft; Christiane 
Stamm;  
 
Dinslaken (Reha Zentrum in Dinslaken im Gesundheitszentrums Lang): Herwig Lange 
 
Dresden (Universitätsklinikum Carl Gustav Carus an der Technischen Universität 
Dresden, Klinik und Poliklinik für Neurologie): Matthias Löhle; Simone Schmidt;  
Alexander Storch; Annett Wolz; Martin Wolz 
 
Freiburg (Universitätsklinik Freiburg, Neurologie): Philipp Capetian, Johann Lambeck, 
Birgit Zucker 
 
Hamburg (Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für 
Neurologie): Kai Boelmans; Christos Ganos; Ute Hidding; Jan Lewerenz; Alexander 
Münchau; Michael Orth; Jenny Schmalfeld; Lars Stubbe; Simone Zittel 
 
Hannover (Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische 
Hochschule Hannover): Gabriele Diercks; Dirk Dressler, Heike Gorzolla; Christoph 
Schrader, Pawel Tacik 
 
Heiligenhafen (Psychatrium Heiligenhafen): Walburgis Heinicke 
 
Marburg KPP (Klinik für Psychiatrie und Psychotherapie Marburg-Süd): Bernhard 
Longinus 
 
München (Huntington-Ambulanz im Neuro-Kopfzentrum - Klinikum rechts der Isar der 
Neurologischen Klinik und Poliklinik der Technischen Universität München): Mark 
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Mühlau, Alexander Peinemann; Michael Städtler; Adolf Weindl, Juliane Winkelmann, 
Cornelia Ziegler 
 
Münster (Universitätsklinikum Münster, Klinik und Poliklinik für Neurologie): Natalie 
Bechtel; Heike Beckmann; Stefan Bohlen; Eva Hölzner; Herwig Lange; Ralf Reilmann; 
Stefanie Rohm, Silke Rumpf ; Sigrun Schepers  
 
Taufkirchen (Isar-Amper-Klinikum - Klinik Taufkirchen (Vils): Matthias Dose; 
Gabriele Leythaeuser; Ralf Marquard; Tina Raab; Caroline Schrenk; Michele Schuierer; 
 
Ulm (Universitätsklinikum Ulm, Neurologie): Katrin Barth; Andrea Buck; Daniel 
Ecker; Carolin Eschenbach; Christine Held; Bernhard Landwehrmeyer; Franziska 
Lezius; Solveig Nepper; Anke Niess; Michael Orth, Daniela Schwenk, Sigurd 
Süssmuth, Sonja Trautmann; Patrick Weydt 
 
ITALY 
 
Bari Clinica Neurologica - Neurophysiopatology of Pain Unit UNIVERSITA' DI 
BARI):  Claudia Cormio; Vittorio Sciruicchio; Claudia Serpino; Marina de Tommaso 
 
Bologna (Dipartimento di Scienze Neurologiche - Clinica Neurologica, Università di 
Bologna): Sabina Capellari; Pietro Cortelli; Roberto Gallassi; Roberto Poda; Giovanni 
Rizzo; Cesa Scaglione 
 
Florence (Dipartimento di Scienze Neurologiche e Psichiatriche Universita' degli Studi 
di Firenze-Azienda Ospedaliera Universitaria Careggi): Elisabetta Bertini; Elena Ghelli, 
Andrea Ginestroni, Francesca Massaro, Claudia Mechi; Marco Paganini; Silvia 
Piacentini; Silvia Pradella; Anna Maria Romoli; Sandro Sorbi 
 
Genoa (Dipartimento di Neuroscienze, Oftalmologia e Genetica (DiNOG) Università di 
Genova): Giovanni Abbruzzese; Monica Bandettini di Poggio; Emilio Di Maria, 
Giovanna Ferrandes; Paola Mandich; Roberta Marchese 
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Milan (Fondazione IRCCS Istituto Neurologico Carlo Besta): Alberto Albanese; 
Daniela Di Bella;  Stefano Di Donato; Cinzia Gellera; Silvia Genitrini; Caterina 
Mariotti; Daniela Monza; Lorenzo Nanetti; Dominga Paridi; Paola Soliveri; Chiara 
Tomasello 
 
Naples (Dipartimento di Scienze Neurologiche,  Università Federico II): 
Giuseppe De Michele; Luigi Di Maio; Carlo Rinaldi; Fabiana Rossi, Marco 
Massarelli; Pierpaolo Sorrentino; Cinzia Valeria Russo; Elena Salvatore; 
Tecla Tucci; Alessandro Roca 
 
Pozzilli (IS) (Centro di Neurogenetica e Malattie Rare - IRCCS Neuromed): Francesca 
Elifani, Martina Petrollini, Annunziata De Nicola, Tiziana Martino, Francesca Lovo, 
Ferdinando Squitieri 
 
Rome (Istituto di Neurobiologia e Medicina Molecolare & Istituto di Scienze e 
Tecnologie della Cognizione /CNR;  Istituto di Neurologia Università Cattolica del 
Sacro Cuore): Anna Rita Bentivoglio;  Claudio Catalli; Raffaella Di Giacopo; Alfonso 
Fasano; Marina Frontali; Arianna Guidubaldi; Tamara Ialongo; Gioia Jacopini; 
Giovanna Loria, Carla Piano; Piccininni Chiara; Davide Quaranta; Silvia Romano; 
Francesco Soleti; Maria Spadaro; Paola Zinzi 
 
NETHERLANDS 
 
Enschede (Medisch Spectrum Twente): Monique S.E. van Hout; Jeroen P.P. van Vugt; 
A. Marit de Weert 
 
Groningen (Polikliniek Neurologie): J.J.W. Bolwijn; M. Dekker; K.L. Leenders;  J.C.H. 
van Oostrom 
 
Leiden (Leiden University Medical Centre (LUMC): Reineke Bos; Eve M. Dumas;; 
Simon J. A. van den Bogaard;  Raymund A.C. Roos; Ellen P. ‘t Hart;  
 
Nijmegen (Universitair Medisch Centrum St. Radboud, Neurology): Berry Kremer; 
C.C.P. Verstappen 
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NORWAY 
 
Bergen (Haukeland University Hospital): Ellen Økland Blinkenberg. (NKS Olaviken`s 
HD clinic): Erik Hauge, Hilde Tyvoll 
 
Oslo University Hospital (Rikshospitalet, Dept. of Medical Genetics and Dep. of 
Neurology): Arvid Heiberg; Marleen R van Walsem; Jan Frich; Olaf Aaserud; Raghild 
Wehus  
 
Oslo University Hospital (Ulleval, Dept of Medical Genetics and Department): Kathrine 
Bjørgo; Madelein Fannemel; Per Gørvell; Eirin Lorentzen; Susana Pro Koivisto; Lars 
Retterstøl; Bodil Stokke 
 
Trondheim (St. Olavs Hospital): Inga Bjørnevoll; Sigrid Botne Sando 
 
POLAND 
 
Gdansk (St. Adalbert Hospital, Gdansk; Medical University of Gdansk, Neurological 
and Psychiatric Nursing Dpt.): Artur Dziadkiewicz, Malgorzata Nowak, Piotr 
Robowski, Emilia Sitek; Jaroslaw Slawek; Witold Soltan, Michal Szinwelski,  
 
Katowice (Medical University of Silesia, Katowice): Magdalena Blaszcyk, Magdalena 
Boczarska-Jedynak; Ewelina Ciach-Wysocka, Agnieszka Gorzkowska, Barbara 
Jasinska-Myga; Gregorz Opala; Gabriela Kłodowska – Duda, Magdalena Błaszczyk, 
Daniel Stompel , Ewelina Ciach-Wysocka,  
 
Krakow (Krakowska Akademia Neurologii): Krzysztof Banaszkiewicz; Dorota 
Boćwińska, Andrzej Szczudlik; Monika Rudzińska; Magdalena Wójcik; Małgorzata 
Dec; Malgorzata Krawczyk, Dorota Boćwińska, Kamila Bojakowska-Jaremek, Elżbieta 
Szczygieł, Anna Wasielewska. 
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Poznan (Poznan University of Medical Sciences, Poland): Anna Bryl; Anna Ciesielska; 
Aneta Klimberg; Jerzy Marcinkowski; Justyna Sempołowicz; Daniel Zielonka; Husam 
Samara. 
 
Warsaw-MU (Medical University of Warsaw, Neurology): Piotr Janik; Anna Gogol 
(formerly Kalbarczyk); Hubert Kwiecinski; Zygmunt Jamrozik. 
 
Warsaw-IPiN (Institute of Psychiatry and Neurology Dep. of Genetics, First Dep. of 
Neurology): Jakub Antczak; Katarzyna Jachinska; Maryla Rakowicz; Przemyslaw 
Richter; Rafal Rola, Danuta Ryglewicz; Halina Sienkiewicz-Jarosz , Iwona Stępniak , 
Grzegorz Witkowski; Elzbieta Zdzienicka; Jacek Zaremba; Anna Sułek, Wioletta 
Krysa; Iwona Stępniak; Karolina Zieora-Jakutowicz. 
 
PORTUGAL 
 
Coimbra – (Hospital Universitário de Coimbra): Filipa Júlio; Cristina Januário. 
 
Lisbon- (Hospital de Santa Maria; Neurological Clinical Research Unit, Instituto de 
Medicina Molecular): Leonor Correia-Guedes, Tiago Mestre;; Miguel Coelho; Tiago 
Mendes; Anabela Valadas; Joaquim J Ferreira 
 
Porto- (Hospital de São João, (Faculdade de Medicina da Universidade do Porto): 
Carlos Andrade, Miguel Gago; Carolina Garrett; Maria Rosália Guerra. 
 
SPAIN 
 
Badajoz (Hospital Infanta Cristina): Carmen Durán Herrera; Patrocinio Moreno Garcia 
 
Granada (Hospital Universitario San Cecilio, Neurología): Francisco Barrero; Blas 
Morales  
 
Burgos (Servicio de Neurología Hospital General Yagüe): Esther Cubo; Natividad 
Mariscal; Jesús Sánchez 
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Fuenlabrada (Hospital Universitario de Fuenlabrada): Fernando Alonso-Frech; Maria 
Rabasa Perez 
 
Madrid-Clinico (Hospital Clínico Universitario San Carlos): María Fenollar; Rocío 
García-Ramos García; Purificacion Pin Quiroga; Susana Vázquez Rivera; Clara 
Villanueva  
 
Madrid RYC (Hospital Ramón y Cajal, Neurología): Javier Alegre ,Mónica Bascuñana; 
Juan Garcia Caldentey,Marta Fatás Ventura; Guillermo García Ribas; Justo García de 
Yébenes; José Luis López – Sendón Moreno, Patricia Trigo Cubillo  
 
Madrid FJD (Madrid-Fundación Jiménez Díaz): Pedro J García Ruíz, Asunción 
Martínez-Descals, María José Saiz Artiga; Vicenta Sánchez, Rosa Guerrero, Fernando 
Alonso Frech 
 
Murcia (Hospital Universitario Virgen de la Arrixaca): María Fuensanta Noguera Perea; 
Lorenza Fortuna; María Martirio Antequera Torres; Gema Reinante ; Laura Vivancos 
Moreau 
Salvadora Manzanares 
 
Barcelona-Hospital Mútua de Terrassa: Miquel Aguilar Barbera; Dolors Badenes Guia; 
Laura Casas Hernanz ; Judit López Catena; Ana Rojo Sebastián, Pilar Quiléz Ferrer; 
Gemma Tome Carruesco 
 
Barcelona-Bellvitge (Hospital Universitari de Bellvitge): Jordi Bas; Núria Busquets 
Matilde Calopa 
  
Barcelona-Merced (Hospital Mare de Deu de La Merced): Marina Dalmau Elorza; 
Cristóbal Díez-Aja López; Santiago Durán-Sindreu Terol; Misericordia Floriach 
Robert; Belén Garzón Ruíz; Ana González Casado; Isabel Haro Martínez; Celia Mareca 
Viladrich; Regina Pons i Càrdenas; Elvira Roca; Joan Roig Llesoy; Jesús Miguel Ruiz 
Idiago; Mar Ruíz Vergara; Socorro Soriano García; Antonio Villa Riballo 
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Oviedo (Hospital Central de Asturias): Sonia González González; Luis Menéndez 
Guisasola; Carlos Salvador; Esther Suaréz San Martín 
 
Palma de Mallorca (Hospital Universitario Son Espases): Inés Legarda, Aranzazú 
Gorospe, Mónica González, Penelope Navas Arques, María José Torres Rodríguez, 
Barbara Vives 
 
Sevilla ("Hospital Universitario Virgen Macarena"): Jose Manuel Garcia Moreno; José 
Chacón Peña; Luminita Dinca Avarvarei; Antonio Martín Bastida; Maria Fernández 
Recio; Luis Redondo Vergé; Violeta Sánchez Sánchez 
 
Sevilla (Hospital Universitario Virgen del Rocío): Fátima Carrillo; María Teresa 
Cáceres; Pablo Mir; María José Lama Suarez  
 
SWEDEN 
 
Umeå (Umeå University Hospital): Ghada Loutfi; Carina Olofsson; Eva-Lena Stattin; 
Laila Westman; Birgitta Wikström  
 
Stockholm (Karolinska University Hospital): Sven E Pålhagen; Martin Paucar; Per 
Svenningsson; Tina Walldén Reza-Soltani; Arja Höglund; Britta Sandström  
 
Göteborg (Sahlgrenska University Hospital): Jan Wahlström; Ulrika Høsterey-Ugander; 
Gunnel Fredlund; Radu Constantinescu; Liselotte Neleborn-Lingefjärd   
 
SWITZERLAND 
 
Bern (Swiss HD Zentrum);  Jean-Marc Burgunder;  
Bern (Zentrum für Bewegungsstörungen, Neurologische Klinik und Poliklinik, 
Universität Bern); Yanik Stebler Alain Kaelin; Irene Romero; Michael Schüpbach; 
Sabine Weber Zaugg  
 
United Kingdom 
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Aberdeen (NHS Grampian Clinical Genetics Centre & University of Aberdeen): 
Zosia Miedzybrodzka; Daniela Rae; Sheila A Simpson; Fiona Summers; Alexandra 
Ure; Roisin Jack; Kirsty Matheson 
 
Birmingham (The Barberry Centre, Dept of Psychiatry): Shahbana Akhtar,Jenny 
Crooks; Adrienne Curtis; Jenny de Souza (Keylock); Hugh Rickards; Jan Wright 
 
Bristol (Frenchay Hospital): Beverley Hayward; Kasia Sieradzan; Abigail Wright  
 
Cambridge (Cambridge Centre for Brain Repair, Forvie Site): Roger A. Barker; Deidre 
O’Keefe, Anna Di Pietro; Kate Fisher; Anna Goodman; Susan Hill; Sarah Mason; 
Rachel Swain, Natalie Valle Guzman 
 
Cardiff (Schools of Medicine and Biosciences, Cardiff University): Monica Busse, 
Cynthia Butcher, Stephen Dunnett, Catherine Clenaghan, Ruth Fullam, Sarah Hunt, 
Lesley Jones, Una Jones, Hanan Khalil, Sara Minster,  Michael Owen, Kathleen Price, 
Jenny Townhill,  Anne Rosser 
 
Edinburgh (SE Scotland Genetic Service, Western General Hospital): Mary Porteous; 
Maureen Edwards; Carrie Ho  
Edinburgh (Scottish Huntington´s Association); Marie McGill; Pauline Pearson 
 
Fife (Scottish Huntington's Association Whyteman's Brae Hospital): Peter Brockie; 
Jillian Foster; Nicola Johns; Sue McKenzie, Jean Rothery, Gareth Thomas, Shona Yates 
 
Glasgow (Abercromby Center): Joanne Miller; Stuart Ritchie 
 
Gloucester (Department of Neurology Gloucestershire Royal Hospital): Liz Burrows; 
Amy Fletcher; Alison Harding, Fiona Laver; Mark Silva; Aileen Thomson 
 
Hull (Castle Hill Hospital): Peter Burns; Carol Chu; Carole Evans; Stephanie Hamer; 
Ivana Markova; Julie Miller; Ashok Raman 
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Leeds (Chapel Allerton Hospital, Department of Clinical Genetics): Sue Wild; Pam 
Yardumian; Hannah Musgrave; Liz Rowett, Jean Toscano; Stuart Jamieson; Emma 
Hobson 
 
Leicester (Leicestershire Partnership Trust, Mill Lodge): Carole Clayton; Heather 
Dipple, Julia Middleton;  Dawn Freire- Patino 
 
 
London (Guy's Hospital): Thomasin Andrews; Andrew Dougherty; Fred Kavalier; 
Charlotte Golding; Hana Laing, Alison Lashwood; Dene Robertson; Deborah Ruddy; 
Anna Whaite, Alastair Santhouse 
 
London (St. Georges-Hospital): Michael Patton, Maria Peterson; Sarah Rose 
 
London (The National Hospital for Neurology and Neurosurgery): Thomasin Andrews; 
Stefania Bruno; Karen Doherty; Charlotte Golding; Nayana 
Lahiri; Marianne Novak; Aakta Patel; Elisabeth Rosser; Sarah Tabrizi; Rachel 
Taylor; Thomas Warner; Edward Wild 
 
Manchester (Genetic Medicine, University of Manchester, Manchester Academic 
Health Sciences Centre and Central Manchester University Hospitals NHS Foundation 
Trust): David Craufurd, Ruth Fullam, Liz Howard, Andrea Sollom, Julie Snowden, 
Jennifer Thompson, Jenny Callaghan, Mary Jones, Helen Murphy, Iris Trender-
Gerhard, Dawn Rogers, Judith Bek, Emma Oughton, Liz Johnson, Marianne Hare, 
Natalie Arran, Nichola Verstraelen (formerly Ritchie), Lucy Partington-Jones, Susan 
Huson, Cheryl Stopford, Leann Westmoreland 
 
Oxford (Oxford University Hospitals NHS Trust, Dept. of Neurosciences, University of 
Oxford): Andrea H Nemeth; Gill Siuda 
 
Plymouth (Plymouth Huntington Disease Service, Mount Gould Hospital): David 
Harrison; Max Hughes; Andrew Parkinson; Beverley Soltysiak 
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Sheffield (The Royal Hallamshire Hospital– Sheffield Children’s Hospital): Oliver 
Bandmann; Alyson Bradbury, Paul Gill, Helen Fairtlough, Kay Fillingham, Isabella 
Foustanos; Mbombe Kazoka, Kirsty O’Donovan; Nadia Peppa, Cat Taylor, Katherine 
Tidswell, Oliver Quarrell 
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